Amedeo Smart

Free Medical Literature Service

 

Amedeo

Vaccines
  Free Subscription

Articles published in
Vaccine
    March 2026
  1. MWALE M
    Persistent measles immunization gaps in LMICs: Insights from the 2024 revision of the WHO/UNICEF estimates of National Immunization Coverage.
    Vaccine. 2026;75:128298.
    >> Share

  2. MISHRA PM, Chaudhary S, Manhas RS, Lokwani SR, et al
    A novel hypothetical protein (SAUSA300_1684) confers excellent protection against multi-drug-resistant Staphylococcus aureus infection in the murine model.
    Vaccine. 2026;75:128220.
    >> Share

    February 2026
  3. CHOI Y, Choi IJ, Shim DH, Cha HR, et al
    Microneedle array patch delivery of Shigella flexneri 2a GMMA.
    Vaccine. 2026;74:128221.
    >> Share

  4. HOBBS M, Marek L, Wiki J, Paynter J, et al
    Examining spatial variation and inequity in COVID-19 immunisation coverage in Aotearoa New Zealand: a nationwide geospatial study.
    Vaccine. 2026;74:128165.
    >> Share

  5. SANO K, Kato H, Ryo A, Hasegawa H, et al
    Immune response and IgG subclass dynamics following repeated SARS-CoV-2 mRNA vaccination in Japanese healthcare workers.
    Vaccine. 2026;77:128396.
    >> Share

  6. SOPHIAN A, Sulanjari D, Harumanto A
    Global implications of recent changes in U.S. vaccine policy: ethical and trust challenges for immunization programs.
    Vaccine. 2026;77:128393.
    >> Share

  7. WILSON M, Althouse BM, Lucas A, Tort MJ, et al
    A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13.
    Vaccine. 2026;77:128350.
    >> Share

  8. MILES S, Mourglia-Ettlin G, Chabalgoity JA
    Applied immunoinformatics in modern vaccine design: a comprehensive review of available computational tools.
    Vaccine. 2026;77:128392.
    >> Share

  9. WHITAKER JA, Rebolledo PA, Abate G, Babu TM, et al
    The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults.
    Vaccine. 2026;77:128358.
    >> Share

  10. BOETTIGER DC, Carlson SJ, Adams SR, Tse V, et al
    Unequal access: Respiratory syncytial virus vaccine uptake by socioeconomic status among older adults in Australia.
    Vaccine. 2026;77:128395.
    >> Share

  11. SOHN WY, Goody SMG, Reid DW, Edwards DK, et al
    Evidence-based assessment of safety and mechanistic questions Related to mRNA COVID-19 Vaccines.
    Vaccine. 2026;77:128394.
    >> Share

  12. HUDSON A, Borgetti S, Rick AM, Laurens MB, et al
    Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials.
    Vaccine. 2026;77:128380.
    >> Share

  13. FIREIZEN SM, Finkelstein A, Benisti L, Tenenbaum A, et al
    Vaccination decision-making in children with intellectual and developmental disabilities- it's a matter of trust.
    Vaccine. 2026;77:128382.
    >> Share

  14. LI R, Vafeiadis M, Shen F, Hou Z, et al
    The role of health beliefs in COVID-19 vaccination acceptance: A Meta-analysis.
    Vaccine. 2026;77:128379.
    >> Share

  15. PEREDO R, Savard N, Separovic L, Zhan Y, et al
    Influenza vaccination status ascertainment and vaccine effectiveness estimation: Validity of self-report for current and prior season.
    Vaccine. 2026;77:128368.
    >> Share

  16. DERAZ N, Payne M, See E, Ragavapuram V, et al
    XBB 1.5 monovalent booster vaccination stimulates oral mucosal and systemic immune responses in healthy adults.
    Vaccine. 2026;77:128346.
    >> Share

  17. LIANG G, Song Y, Liu Q
    Adverse events following dengue vaccine (Dengvaxia) reported to the Vaccine Adverse Event Reporting System (VAERS), 2019-2025.
    Vaccine. 2026 Feb 20:128376. doi: 10.1016/j.vaccine.2026.128376.
    >> Share

  18. TAL-SINGER R, McCreary G, Luttmann M, Williams S, et al
    Attitudes toward vaccines and antivirals for viral respiratory infections in a survey of US adults with chronic health conditions.
    Vaccine. 2026;77:128384.
    >> Share

  19. ANWER K, Musso L, Lasrado N, Barouch DH, et al
    Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.
    Vaccine. 2026;77:128357.
    >> Share

  20. MANDARIC S, Friberg H, Gottardo R, Messer W, et al
    Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial.
    Vaccine. 2026;77:128373.
    >> Share

  21. MORENO MZ, Martin JJP
    Evaluation of the impact of different notification methods for unvaccinated individuals in a ACWY meningococcal vaccination campaign.
    Vaccine. 2026;77:128383.
    >> Share

  22. CHANDRA LA, Nugroho DB, Thobari JA, Dimaguila GL, et al
    Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review.
    Vaccine. 2026;77:128341.
    >> Share

  23. LOEHR J, Moser CA, Asturias EJ, Shaw AC, et al
    Science for vaccine policy: Lack of transparency, misinformation, and poor decision processes at the December 2025 ACIP meeting.
    Vaccine. 2026;76:128338.
    >> Share

  24. PERCIO J, Silva RMA, Lopez AM, Cabral CM, et al
    What is the impact of the safety signal on dengue vaccination coverage among adolescents in Brazil?
    Vaccine. 2026;77:128355.
    >> Share

  25. AL-ABBOODI A, Falih IQ, Al-Asadi M, Hussein BA, et al
    Iron-oxide nanoparticles (SPIONs) enhance malaria vaccine antibody response.
    Vaccine. 2026;77:128353.
    >> Share

  26. KASONGA JN, Hoff NA, Merritt S, Fandema E, et al
    Comparing sampling approaches for assessing sub-national vaccination coverage: a pilot study in Central African Republic and the Democratic Republic of Congo.
    Vaccine. 2026;76:128313.
    >> Share

  27. MADNI SA, Olson CK, Zauche LH, Machefsky A, et al
    Risk of spontaneous abortion after mRNA COVID-19 vaccination received just prior to or during pregnancy: Complete data from CDC COVID-19 vaccine pregnancy registry.
    Vaccine. 2026;76:128340.
    >> Share

  28. MADLEY-DOWD P, Horne EMF, Hulme WJ, Palmer TM, et al
    Effectiveness of bivalent BA.1 mRNA booster vaccines during the autumn 2022 COVID-19 booster programme in adults aged 50+ in England: observational matched cohort study using OpenSAFELY.
    Vaccine. 2026 Feb 18:128276. doi: 10.1016/j.vaccine.2026.128276.
    >> Share

  29. AMOAKO N, Cohuet S, Adjei MR, Gurry C, et al
    COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
    Vaccine. 2026 Feb 17:128310. doi: 10.1016/j.vaccine.2026.128310.
    >> Share

  30. SOBLE A, Koh M, Taaffe J, Procter SR, et al
    Evaluating the broader impact of improved influenza vaccines: A full value of vaccine assessment approach.
    Vaccine. 2026;60 Suppl 2:128166.
    >> Share

  31. CONTARINO F, Fiorilla C, Bella F, Leonforte F, et al
    Missed opportunities and co-administration patterns for influenza vaccination in older adults in Italy: a retrospective cohort study.
    Vaccine. 2026;77:128366.
    >> Share

  32. GREEN MA, Jeffery C, Cheyne C, Bonnett L, et al
    Learning from the outliers: A longitudinal ecological study of social and spatial inequalities in older adult influenza vaccination and hospitalisation (Cheshire and Merseyside, UK, 2018-19 to 2023-24).
    Vaccine. 2026;77:128356.
    >> Share

  33. MAK TS, Chan KS, Yu OY, Lee VH, et al
    HPV vaccine discussion and administration in dental primary healthcare settings for oropharyngeal cancer prevention: A systematic review from dental patients' perspectives.
    Vaccine. 2026;76:128335.
    >> Share

  34. TRUONG HC, Pham QD, Phan TV, Vo DTT, et al
    Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease in Vietnamese children prior to national introduction: A matched case-control study.
    Vaccine. 2026;77:128349.
    >> Share

  35. REVIE NM, Guo MY, Mullin AE, Excler JL, et al
    The invasive non-typhoidal Salmonella vaccine landscape: Innovations and challenges ahead.
    Vaccine. 2026;76:128339.
    >> Share

  36. SETHNA V, Apte A, Sanghavi S, Tang Y, et al
    Nasopharyngeal pneumococcal carriage in Indian children following 10-valent PCV (PNEUMOSIL(R)) introduction through India's universal immunization program: A post licensure cross-sectional study.
    Vaccine. 2026;73:128129.
    >> Share

  37. TYAGI P, Ganguly M, Manney S, Wadkar K, et al
    Plaque reduction neutralization test (PRNT(50)) for the detection of anti-yellow fever antibodies from clinical samples.
    Vaccine. 2026;73:128151.
    >> Share

  38. DAS S, Begum F, Ghora S, Ray U, et al
    Engineered dengue virus NS1 mRNA-lipid nanoparticle induces therapeutic IgG production that lacks autoantibody activity and neutralizes NS1 entry in liver cells.
    Vaccine. 2026;73:128147.
    >> Share

  39. DE OLIVEIRA NR, Maia MAC, Bunde TT, Pedra ACK, et al
    A self-assembled Pirococcus abyssi exosome complex displaying outer membrane proteins of Leptospira interrogans elicits protective immunity against leptospirosis.
    Vaccine. 2026;73:128159.
    >> Share

  40. HELBLE M, Nannei C, Friede M, Nicholson MW, et al
    Pathways to economically viable and sustainable vaccine manufacturing in LMICs.
    Vaccine. 2026 Feb 14:128273. doi: 10.1016/j.vaccine.2026.128273.
    >> Share

  41. ABBAD A, Lerman B, Ehrenhaus J, Ojeda DS, et al
    Corrigendum to "Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naive and convalescent populations" [Vaccine 70 (2026) 128018].
    Vaccine. 2026;77:128333.
    >> Share

  42. IMANISHI Y, Iorini M, Wada I, Jwa S, et al
    Child sexual abuse and adult vaccination: Opposing patterns between routine and pandemic vaccines in a Nationwide survey.
    Vaccine. 2026;76:128299.
    >> Share

  43. BROGAN D, Prabhu PS, Deng L, Sharma K, et al
    Vaccination under sedation in children with needle phobia or behavioural difficulties: A retrospective study.
    Vaccine. 2026;76:128352.
    >> Share

  44. RADIA K, Sapuan S, Grassly N, Andrews N, et al
    An observational, cohort, multi-centre, open label phase IV extension study comparing IPV immune responses to preschool dTaP-IPV booster vaccines in children whose mothers received or did not receive an IPV-containing pertussis vaccine during pregnanc
    Vaccine. 2026;76:128306.
    >> Share

  45. MAKI W, Ishitsuka K, Morisaki N, Machida M, et al
    Association of parental vaccination readiness and descriptive norms with childhood vaccination status.
    Vaccine. 2026;76:128337.
    >> Share

  46. STICCHI L, Di Biagio A, Domnich A, Inglese M, et al
    Immunogenicity and safety of two doses of the four-component recombinant meningococcal B (4CMenB) vaccine in adults with immunodeficiency.
    Vaccine. 2026;76:128295.
    >> Share

  47. OGAWA T, Sunyi J, Kawachi K, Murakami J, et al
    Regulatory approaches for platform-based vaccine development in Japan: Insights from PMDA's experience with COVID-19 and RSV vaccines.
    Vaccine. 2026;76:128315.
    >> Share

  48. ALMEIDA GG, Pinto JA, Pinto PM, da Silva LB, et al
    Corrigendum to "Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19" [Vaccine 64 (2025) 127756].
    Vaccine. 2026;76:128316.
    >> Share

  49. BOYCE MR, Sell TK
    Support for vaccine-related priorities included in the Make Our Children Healthy Again Assessment and impacts on trust in vaccine safety: a national survey of parents in the United States.
    Vaccine. 2026;76:128336.
    >> Share

  50. STEFKOVICS A, Ligeti AS, Koltai J
    Willingness to vaccinate in a future pandemic. Evidence from a vignette experiment.
    Vaccine. 2026;76:128284.
    >> Share

  51. DUFOUR L, Drouin J, Dray-Spira R, Le Vu S, et al
    Uptake of HPV vaccination and associated factors in France: a nationwide study from 2007 to 2023.
    Vaccine. 2026;76:128308.
    >> Share

  52. TIWANA MH, Smith J
    Structural determinants of vaccine access: an integrated review of the Canadian literature.
    Vaccine. 2026;76:128324.
    >> Share

  53. SEMPRINI J, Brandt H
    Exploring rural-urban disparities in HPV vaccine initiation: new insights from the 2022 national health interview survey.
    Vaccine. 2026;76:128334.
    >> Share

  54. THUMAR R, Shekh SL, Chauhan A, Kapoor K, et al
    Immunoinformatics design and in vivo evaluation of a multiepitope vaccine targeting OMPL1, Lipl32, Lipl41, and Lipl46 for leptospirosis in a male ICR mouse model.
    Vaccine. 2026;76:128331.
    >> Share

  55. SIDEBOTHAM E, Caldwell DM, Davies SR, Thornton ZA, et al
    Interventions to increase vaccine uptake among socially excluded groups: A systematic review.
    Vaccine. 2026;76:128314.
    >> Share

  56. LU Y, Tang C, Xu S, Hussain I, et al
    Understanding parental HPV vaccination decision in China through the lens of vaccine hesitancy and preference heterogeneity: a discrete choice experiment.
    Vaccine. 2026;76:128307.
    >> Share

  57. URIU K, Kaku Y, Kosugi Y, Chen L, et al
    Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2.
    Vaccine. 2026;76:128311.
    >> Share

  58. CAO Q, Du S, Yang K, Liu M, et al
    Assessing the impact of SARS-CoV-2 infection and vaccination on fertility and assisted reproductive techniques outcomes: an umbrella review.
    Vaccine. 2026;76:128293.
    >> Share

  59. GREWAL R, Alessandrini J, Wilson SE, Hernandez A, et al
    Human papillomavirus (HPV) vaccine coverage and associated sociodemographic factors among individuals eligible for publicly funded vaccine in Ontario, Canada from 2007 to 2023: A Canadian immunization research network study.
    Vaccine. 2026;76:128303.
    >> Share

  60. OYEDELE T, Park R, Morales K, Jain M, et al
    A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.
    Vaccine. 2026;76:128304.
    >> Share

  61. TIPTON T, Laidlaw S, Nguyen D, Longet S, et al
    ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation.
    Vaccine. 2026;72:128123.
    >> Share

  62. ZINTGRAFF J, Gagetti P, Eluchans NS, Marchetti P, et al
    Serotype distribution and antimicrobial resistance in pediatric invasive pneumococcal pneumonia: A Laboratory Surveillance Study from Argentina, 2022-2024.
    Vaccine. 2026;72:128128.
    >> Share

  63. JABBAR F, Kadhim KA, Alhilfi RA, Al Khafaji IS, et al
    Advancements in monitoring adverse events following immunization in Iraq: Insights from the CIVIE project 2022-2023.
    Vaccine. 2026;72:128121.
    >> Share

  64. SINCLAIR JE, Mayfield HJ, Lu H, Brown SJ, et al
    Estimating risk of long COVID using a Bayesian network-based decision support tool.
    Vaccine. 2026;72:128127.
    >> Share

  65. DRISLANE S, Moore H, Attwell K
    Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024.
    Vaccine. 2026;72:128133.
    >> Share

  66. CATA-PRETA BO, Arroyave L, Costa FS, Mengistu T, et al
    Monitoring the SDG immunization indicator: Approaches and challenges.
    Vaccine. 2026;72:128118.
    >> Share

  67. FAY MJ, Howe AS, Wilson E, Sinclair O, et al
    Impact of a single-dose program on varicella hospitalizations and infectious disease inequity in New Zealand: A retrospective cohort study.
    Vaccine. 2026;72:128082.
    >> Share

  68. KRISTOFFERSEN AB, Boas H, Meijerink H, LeBlanc M, et al
    Increasing incidence of pertussis before scheduled primary school booster vaccinations in Norway, 1998-2019.
    Vaccine. 2026;76:128309.
    >> Share

  69. STEFFENS M, Bolsewicz K, Prokopovich K, Beard F, et al
    Immunisation program managers' experiences of implementing the change from a two dose to a single dose course of HPV vaccination in Australia's school-based program.
    Vaccine. 2026;76:128300.
    >> Share

  70. YAN X, Hu X, Xu Y, Zhang X, et al
    Herpes zoster vaccination coverage and associated factors among individuals aged >/=50 years in Zhejiang, China: A population-based cross-sectional study.
    Vaccine. 2026;76:128301.
    >> Share

  71. MA X, Jin L, Li J, Jin P, et al
    Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study.
    Vaccine. 2026;76:128286.
    >> Share

  72. SMITH EA, Malhame M, Malvolti S, Voss G, et al
    Use cases for pan-sarbecovirus vaccines: a workshop report.
    Vaccine. 2026;76:128312.
    >> Share

  73. KIM DH, Kim JC, Lee SH, Kim J, et al
    Efficacy of dual administration vaccine of recombinant Newcastle disease virus expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza and viscerotropic Velogenic Newcastle disease virus in broilers.
    Vaccine. 2026;76:128288.
    >> Share

  74. MADSEN AMR, Schaltz-Buchholzer F, Trebbien R, Roring R, et al
    Evaluating the non-specific effects of BCG vaccination on the immune system and serological response to influenza vaccination in the elderly: A randomised controlled trial.
    Vaccine. 2026;76:128305.
    >> Share

  75. KHAN S, McWhorter AR, Andrews DM, Underwood GJ, et al
    Corrigendum to "An enhanced vaccination regime reduces the shedding of Salmonella Typhimurium from layer chickens" [Vaccine 72 (2026) 128115].
    Vaccine. 2026;76:128260.
    >> Share

  76. ANDERSON SA, Smith ER, Wan Z, Amend KL, et al
    Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.
    Vaccine. 2026;75:128225.
    >> Share

  77. SAUVAGEAU C, Ionescu IG, Ouakki M, Panicker G, et al
    Long-term immunogenicity of alternative HPV vaccine schedules and the effect of an additional dose given three to five years post-primary vaccination.
    Vaccine. 2026;75:128287.
    >> Share

  78. ALMEIDA ST, Paulo AC, Simoes AS, Handem S, et al
    Pneumococcal carriage and serotype distribution in Portuguese children six months after the lifting of COVID-19 restrictions: rise in serotype 3 amid stable non-vaccine serotypes.
    Vaccine. 2026;76:128294.
    >> Share

  79. SHARMA AJ, Smoots AN, Madni SA, Zauche LH, et al
    COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.
    Vaccine. 2026;75:128268.
    >> Share

  80. TONDEL C, Jenum S, Tonby K, Christensen EE, et al
    SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial.
    Vaccine. 2026;75:128290.
    >> Share

  81. WANG K, Jordan T, Suzuki-Williams L, Qin J, et al
    Direct comparison of three herpes simplex virus-2 vaccine candidates using peripheral or mucosal routes of vaccination.
    Vaccine. 2026;75:128107.
    >> Share

    January 2026
  82. KENEALY T, Aguirre-Duarte N, Roxburgh RH, Royle G, et al
    Accuracy of ICD and SNOMED search strategies for adverse events following COVID-19 vaccination: Analysis of hospital administrative data.
    Vaccine. 2026;75:128275.
    >> Share

  83. POLAND GA, Ratishvili T, Pitts PJ
    COVID-19 vaccine policy: a response and way forward.
    Vaccine. 2026;75:128292.
    >> Share

  84. PARK IY, Cantu-Aldana A, Grafft N, Lo BK, et al
    Fathers' reports of within-household vaccine decision making and young children's COVID-19 vaccination status.
    Vaccine. 2026;75:128282.
    >> Share

  85. CASSIE D, Komlenovic V, Parrera G, Drobic B, et al
    A phase 4, open-label, single arm, multi-center study to evaluate the safety of a smallpox vaccine in previously vaccinated individuals.
    Vaccine. 2026;75:128289.
    >> Share

  86. CHELIOTIS KS, Gonzalez-Dias P, German EL, Goncalves ANA, et al
    Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies.
    Vaccine. 2026;75:128280.
    >> Share

  87. PASIK K, Iwan E, Bomba A, Blicharz KD, et al
    HTS-based control of Salmonella Enteritidis vaccines for chickens - pilot study.
    Vaccine. 2026;75:128297.
    >> Share

  88. WITTENAUER R, Shah PD, Bacci JL, Mooney SJ, et al
    Pharmacy access and shingles vaccinations in the US: a propensity score matching analysis.
    Vaccine. 2026;75:128256.
    >> Share

  89. THAKKAR K, Kefalogianni R, Zhang J, Yung CF, et al
    Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore.
    Vaccine. 2026;75:128285.
    >> Share

  90. SAITO T, Couzinet A, Suzuki T, Shimomura M, et al
    Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms" [Vaccine 68 (2025) 127942].
    Vaccine. 2026;75:128267.
    >> Share

  91. BHUIYAN MU, Hernandez-Suarez G, Pilishvili T, Mayer B, et al
    Incidence and bacterial etiology of acute otitis media in children in the pneumococcal conjugate vaccine era: A systematic literature review and meta-analysis.
    Vaccine. 2026;75:128270.
    >> Share

  92. HONG H, Eom TH, Lee E, Lee E, et al
    Immunological response of using emulsifying elongation factor 1 alpha of Plasmodium falciparum-based vaccines in complete Freund's adjuvant.
    Vaccine. 2026;75:128279.
    >> Share

  93. CAI L, Fu Y, Li J, Wang X, et al
    Preliminary safety evaluation of a diphtheria, tetanus, acellular component pertussis, Sabin inactivated poliovirus and Haemophilus influenzae type b combination vaccine (DTacP-sIPV/Hib).
    Vaccine. 2026;75:128277.
    >> Share

  94. LIAO Z, Wu M, Chen Y, Zhu Z, et al
    Single-dose mSEB-mi3 nanoparticle vaccine elicits robust humoral immunity and protects mice against SEB intoxication and MRSA infection.
    Vaccine. 2026;75:128245.
    >> Share

  95. EMBERS ME, Hasenkampf NR, Tardo AC, Timofeyeva Y, et al
    Protective properties of a candidate C-terminal domain OspA vaccine for prevention of Lyme disease.
    Vaccine. 2026;75:128231.
    >> Share

  96. LOTSPEICH-COLE L, Jha MK, Parvathaneni S, Lee RC, et al
    Neonatal mice immune response to COVID-19 mRNA vaccine.
    Vaccine. 2026;75:128271.
    >> Share

  97. NAGY EZ, Szeredi L, Foldi D, Belecz N, et al
    Development and efficacy test of a live, attenuated Mycoplasma hyorhinis vaccine candidate strain.
    Vaccine. 2026;75:128278.
    >> Share

  98. HAHM HC, Tang M, Lupaczyk L, Lee J, et al
    Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis.
    Vaccine. 2026;75:128283.
    >> Share

  99. CHANG TY, Jacobson M, Shah M, Pramanik R, et al
    Impact of reminder messages, with and without financial incentives, on influenza vaccination: A randomized trial in a California health system.
    Vaccine. 2026;75:128263.
    >> Share

  100. KOEKEN VACM, Nissen TN, Birk NM, Boahen CK, et al
    The effect of BCG vaccination on systemic inflammation in neonates.
    Vaccine. 2026;75:128241.
    >> Share

  101. JAMISON AM, Gardner LM
    What happens when the CDC stops posting about measles on social media? An exploratory analysis of social media coverage during the 2025 measles outbreak.
    Vaccine. 2026;71:128074.
    >> Share

  102. BARBER C, Barber M, Lee JSW, Ting J, et al
    Vaccination policies, practices, and procedures in level-III neonatal intensive care units across Canada: An environmental scan.
    Vaccine. 2026;75:128261.
    >> Share

  103. PAXITZIS AN, Oyebanji OA, Olagunju OJ, Keresztesy D, et al
    Antibody responses to SARS-CoV-2 vaccine in nursing home residents support a Bi-annual update schedule.
    Vaccine. 2026;75:128240.
    >> Share

  104. WOO EJ
    Adjuvanted recombinant zoster vaccine and live attenuated zoster vaccine are vastly different.
    Vaccine. 2026 Jan 23:128272. doi: 10.1016/j.vaccine.2026.128272.
    >> Share

  105. MANSFIELD ME, Okui L, Simon S, Hosangadi D, et al
    Understanding COVID-19 vaccination choices and development of a toolkit and training for Botswana, 2022-2023.
    Vaccine. 2026;75:128274.
    >> Share

  106. HAUSDORFF WP, Cavaleri M, Gruber MF, Nyarko KA, et al
    Report of a one-day convening on regulatory science, practices, and innovative approaches to facilitate approval of novel combination vaccines.
    Vaccine. 2026;75:128257.
    >> Share

  107. OKOLI GN, Kwan MYW, Chan ELY, Murphy C, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study.
    Vaccine. 2026;75:128262.
    >> Share

  108. STUART R, Theopold N, Miall N, Kobayashi E, et al
    The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraints.
    Vaccine. 2026;75:128187.
    >> Share

  109. ADAM A, Lee C, Jones MC, Harrington BR, et al
    VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.
    Vaccine. 2026;75:128255.
    >> Share

  110. LI J, Kyaw PE, Tan C, Wen K, et al
    Development of duck hepatitis A virus type 1 attenuated vaccine E23-SP80 and its protective efficacy evaluation against DHAV-1 infection in ducks.
    Vaccine. 2026;75:128258.
    >> Share

  111. LANGLEY JM, Sadarangani M, Ockenhouse C, Barreto L, et al
    Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.
    Vaccine. 2026;75:128236.
    >> Share

  112. CONTARINO F, Fiorilla C, Bella F, Orsi A, et al
    Exploring regional variations in the provision of influenza vaccination in Italy.
    Vaccine. 2026;75:128266.
    >> Share

  113. TEMBO G, Hoving D, de Kroon AC, Chimgoneko L, et al
    13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.
    Vaccine. 2026;75:128269.
    >> Share

  114. BARBEY FA, Otth M, Kroiss S, Drozdov D, et al
    Adherence to national vaccination guidelines among pediatric cancer patients: a retrospective study from two tertiary care centers in Switzerland.
    Vaccine. 2026;75:128265.
    >> Share

  115. MVUNDURA M, Slavkovsky R, Dagnew B, Hunduma A, et al
    Evaluating the delivery costs and operational context of a single-dose human papillomavirus (HPV) vaccine regimen administered to a multi-age cohort of adolescent girls in Ethiopia.
    Vaccine. 2026;75:128248.
    >> Share

  116. LISTER H, Farquharson K, Seale H, Smith LE, et al
    Erratum to "A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults" [Vaccine 74 (2026) 128195].
    Vaccine. 2026;75:128252.
    >> Share

  117. FLOROS L, Johnson KD, Tsoumani E
    Serotype-specific incidence and comparative vaccine coverage of invasive pneumococcal disease among adults >/=65 years of age in European countries from 2011 to 2023.
    Vaccine. 2026;75:128181.
    >> Share

  118. FAIJUE DD, Bouaddi O, Mackey K, Deal A, et al
    Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.
    Vaccine. 2026;75:128249.
    >> Share

  119. SHUAI W, Sun Q, Li J, Shen W, et al
    Needle-free intradermal delivery of a recombinant PRRSV-vectored CSFV E2 vaccine enhances humoral immunity and growth performance in piglets.
    Vaccine. 2026;75:128247.
    >> Share

  120. KLING K, Falman A, Branke L, Ramharter M, et al
    Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya.
    Vaccine. 2026;75:128251.
    >> Share

  121. AYABINA D, Stoecker C, Cho BH, Prasad N, et al
    Public health impact and cost-effectiveness of 20-valent pneumococcal conjugate vaccine use among children in the United States.
    Vaccine. 2026;74:128212.
    >> Share

  122. CHANGALUCHA J, Ferguson E, Luka MM, Lushasi K, et al
    Comparative effectiveness and cost-effectiveness of policies for provisioning rabies post-exposure vaccines.
    Vaccine. 2026;74:128178.
    >> Share

  123. WU B, Cheng T, Zhang Y, Kezhong A, et al
    Adult and maternal pertussis vaccination in China: intention, preferences, and pricing implications from a discrete choice experiment.
    Vaccine. 2026;75:128243.
    >> Share

  124. SIGAUQUE B, Vilanculos L, Chauque A, Moiane B, et al
    Effectiveness of 10-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia and invasive pneumococcal disease among young children in Mozambique.
    Vaccine. 2026;75:128237.
    >> Share

  125. CHELLAPPAN G, Seal F, Balasundaram WU, Zhao Y, et al
    Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine.
    Vaccine. 2026;75:128242.
    >> Share

  126. SIM SY, Silal S, Hutubessy RC, Bar-Zeev N, et al
    Advancing the use of vaccine impact modeling for immunization decisions in low- and middle-income countries.
    Vaccine. 2026;75:128239.
    >> Share

  127. HANDY AB, Ren B, Seidman LC, Granger SW, et al
    Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination in adolescents.
    Vaccine. 2026;75:128226.
    >> Share

  128. NIKHAB A, Patel T, Rooney G, Wasti S, et al
    Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in England.
    Vaccine. 2026;75:128246.
    >> Share

  129. SHI L, Chen J, Li H, Yan X, et al
    Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study.
    Vaccine. 2026;75:128244.
    >> Share

  130. YIGIT I, Stoner MCD, Muessig KE, Hightow-Weidman LB, et al
    Pathways to COVID-19 vaccine initiation: The roles of medical mistrust, conspiracy beliefs, hesitancy, and confidence among black young adults.
    Vaccine. 2026;75:128253.
    >> Share

  131. YESENIA RODRIGUEZ-TANTA L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, et al
    Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
    Vaccine. 2026;75:128227.
    >> Share

  132. JEONG O, Choi W, Ahn H, Lee S, et al
    Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay.
    Vaccine. 2026;75:128235.
    >> Share

  133. VATTOTH AL, Hayney MS, Forati AM, Warren B, et al
    Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.
    Vaccine. 2026;75:128208.
    >> Share

  134. MALLET A, Jaunay LB, Jaury P, Partouche H, et al
    Vaccine refusal during the COVID-19 pandemic: A qualitative study.
    Vaccine. 2026;74:128206.
    >> Share

  135. HEBERT LS, Pickens W, Satterwhite E, Soto GB, et al
    Erratum to "Gene discovery and expression analysis of the B cell receptor repertoire in the domestic ferret model" [Vaccine 64 (2025) 127725].
    Vaccine. 2026;74:128161.
    >> Share

  136. DE WALS P, Papenburg J, Gilca R, Brousseau N, et al
    Are hemagglutinin-only influenza vaccines as effective as conventional influenza vaccines against severe infection?
    Vaccine. 2026;74:128234.
    >> Share

  137. PATERNINA-DE LA OSSA R, Oliveira MC, Achcar JA, Zanin-Silva DC, et al
    Immunological responses to tetanus, diphtheria, pertussis (Tdap) vaccine in Brazilian hematopoietic stem cell transplant recipients.
    Vaccine. 2026;75:128250.
    >> Share

  138. VEERARAGHAVAN B, Varghese R, Gurumoorthy M
    Beyond serotypes: Why GPSC10 redefines vaccine escape in the pneumococcal vaccine era.
    Vaccine. 2026;74:128238.
    >> Share

  139. CHENG K, Pullenayegum E, Singh P, Loeb M, et al
    Use of composite outcomes in cluster randomized control trials of influenza vaccines.
    Vaccine. 2026;74:128224.
    >> Share

  140. LU Y, Zhao W, Xu S, Tang C, et al
    Effectiveness of information interventions in reducing HPV vaccine hesitancy: a randomized survey experiment in China.
    Vaccine. 2026;74:128205.
    >> Share

  141. COBLENTZ EG, Packee CR, Ky SL, Brubaker AG, et al
    Prioritization of HPV vaccine preventable diseases among emerging adults - Implications for health education and communication.
    Vaccine. 2026;74:128223.
    >> Share

  142. DE MORAES JC, Ribeiro KB, Vargas-Zambrano JC, Rujula MJP, et al
    Parental perceptions of adverse events associated with the whole-cell pertussis vaccine in Brazil.
    Vaccine. 2026;74:128184.
    >> Share

  143. PAGE CL, Holbrook BC, Miller LD, Grayson JM, et al
    TLR5 versus TLR7/8 agonist-dependent modulation of the early gene expression response to inactivated influenza virus vaccine in newborn nonhuman primates.
    Vaccine. 2026;74:128163.
    >> Share

  144. SHENG S, Sun Y, Qin J, Zhao J, et al
    Hepatitis B core antigen-based trivalent VLP vaccine against porcine viral diarrhea.
    Vaccine. 2026;74:128210.
    >> Share

  145. SABIR R, Liu M, Saeed HA, Deng Z, et al
    Next-generation live vector vaccine targeting Mycoplasma synoviae and Mycoplasma gallisepticum via recombinant Salmonella.
    Vaccine. 2026;74:128211.
    >> Share

  146. HARKER EJ, Lewis NM, Johnson CA, Zhu Y, et al
    Differences in influenza vaccine effectiveness by sex among adults hospitalized with acute respiratory illness-IVY network, January 24, 2022-September 1, 2024.
    Vaccine. 2026;74:128192.
    >> Share

  147. GIDUTHURI JG, Vengiau G, Vutliu V, Manineng C, et al
    Behavioural and social drivers of COVID-19 vaccination in Papua New Guinea: A cross-sectional study.
    Vaccine. 2026;74:128207.
    >> Share

  148. KATSUTA T, Sato S, Kawazoe Y, Fukuda H, et al
    Active vaccine safety monitoring system using health insurance claims data in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Vaccine. 2026;74:128209.
    >> Share

  149. QIAO X, Du L, Qin Z, Zhang Y, et al
    Robust immunoreaction induced by a subunit vaccine of PEDV spike protein based on GEM surface-display system.
    Vaccine. 2026;74:128204.
    >> Share

  150. LEE SE, Najjengo M, Shaum A, Sekiziyivu AB, et al
    Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report.
    Vaccine. 2026;74:128131.
    >> Share

  151. YOKOYAMA Y, Yao S, Cozza R, Gil F, et al
    A novel calcium influx inducer and a TLR7 agonist are synergistic co-adjuvants that enhance cross-reactive immunity against influenza in young and aged mice.
    Vaccine. 2026;74:128189.
    >> Share

  152. ALBY-LAURENT F, Ouedrani A, Jateau P, Strullu M, et al
    Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study.
    Vaccine. 2026 Jan 7:128130. doi: 10.1016/j.vaccine.2025.128130.
    >> Share

  153. GRANADE C, Lindley M, Nelson J, Asif A, et al
    Bridging the gap: a review of the factors contributing to differences in vaccination coverage among rural and urban adults.
    Vaccine. 2026;74:128148.
    >> Share

  154. RENNER TM, Agbayani G, Azizi H, Deschatelets L, et al
    Heterologous vs. homologous vaccine regimens: Sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted SARS-CoV-2 spike protein boost following an mRNA/LNP prime induces robust and balanced immune responses.
    Vaccine. 2026;74:128182.
    >> Share

  155. LISTER H, Farquharson K, Seale H, Smith LE, et al
    A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults.
    Vaccine. 2026;74:128195.
    >> Share

  156. WILLEMIN T, Guinchard F, Marmey J, Chareyre A, et al
    Comprehensive characterization of multivalent mRNA vaccines functionality by flow cytometry and mass spectrometry.
    Vaccine. 2026;74:128180.
    >> Share

  157. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    Corrigendum to "A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme" [Vaccine 42(20) (2024) 125988.
    Vaccine. 2026;74:128162.
    >> Share

  158. DE BRABANDERE L, Herzog SA, Desombere I, Arien KK, et al
    Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness.
    Vaccine. 2026;73:128153.
    >> Share

  159. YAO X, Su D, Ma Z, Jin Z, et al
    Adjuvant comprising nano-aluminum hydroxide pickering emulsion with polysialic acid for enhanced vaccination.
    Vaccine. 2026;74:128188.
    >> Share

  160. ZHANG M, Huang S, Ruan C, Jiang Y, et al
    Anti-vaccination attitudes and behavioral intentions towards three recommended vaccinations among Chinese older adults with chronic diseases: A multicenter cross-sectional study.
    Vaccine. 2026;74:128191.
    >> Share

  161. MARTINEZ-DE-ALBENIZ I, Bottomley C, Lucinde R, Kaniu MW, et al
    Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial.
    Vaccine. 2026;73:128186.
    >> Share

  162. GRACE A, Schick V, Quan FT, Troisi C, et al
    Hepatitis B vaccination series completion among residents of low-income housing in Texas: An exploratory analysis of demographic and clinical factors.
    Vaccine. 2026;70:128037.
    >> Share

  163. CARDOSO TL, Hartwig DD
    Recombinant chimeric proteins offer new hope to control of leptospirosis.
    Vaccine. 2026;70:128012.
    >> Share

  164. HUANG O, Tan BF, Lu CY
    Taiwanese parental perspectives on RSV: knowledge, risks, and acceptance toward immunization.
    Vaccine. 2026;70:128005.
    >> Share

  165. ORELLANA-MANZANO A, Garcia-Angulo A, Quinto F, Munizaga MG, et al
    COVID-19 vaccination campaign, knowledge, and trust in Duran, Ecuador: a cross-sectional study.
    Vaccine. 2026;72:127867.
    >> Share

  166. CORREIRA JW, Morrison KT, Doll MK
    Homeschooling trends before and after the New York state repeal of nonmedical vaccine exemptions.
    Vaccine. 2026;73:128169.
    >> Share

  167. YE G, Qu C, Liao Z, Wu R, et al
    Engineered flagellin-based adjuvant boosts mucosal immunity in recombinant RSV vaccine.
    Vaccine. 2026;73:128190.
    >> Share

  168. ZHU Z, Chen Z, Gao Y, Xie Z, et al
    Genetic distance predicts neutralizing antibody titers for monovalent and bivalent SARS-CoV-2 vaccines.
    Vaccine. 2026;73:128185.
    >> Share

  169. CRAMER EY, Dada AO, Onofrey S, Pearlman J, et al
    Population-based serosurveys for SARS-CoV-2 transmission 2021-2022, Massachusetts USA.
    Vaccine. 2026;69:127952.
    >> Share

  170. MARTINEZ-PEREZ A, Galvez RI, Grifoni A, Sette A, et al
    Impact of the bivalent COVID-19 booster on spike-specific t cell responses.
    Vaccine. 2026;69:127995.
    >> Share

  171. SHI C, Li Q, Wang S, Li R, et al
    Brucella secreted effector BspH stimulates intracellular ion flux and confers anti-Brucella immunity.
    Vaccine. 2026;69:127992.
    >> Share

  172. KHAN MY, Aljehani ND, Abdulal RH, Ghazwani A, et al
    Intranasal CD40-targeted recombinant MERS-CoV S1 protein is superior to intramuscular immunization in eliciting systemic and mucosal immune responses in mice.
    Vaccine. 2026;69:127975.
    >> Share

    December 2025
  173. BREZNIK JA, Ang JC, Bhakta H, Liu LM, et al
    Humoral and cellular immunogenicity of sequential heterogeneous bivalent SARS-CoV-2 vaccinations in long-term care and retirement home residents.
    Vaccine. 2025;73:128160.
    >> Share

  174. OKABE H, Hashimoto K, Asano Y, Sato M, et al
    Adverse events post-BNT162b2 vaccination in Japanese children.
    Vaccine. 2025;73:128167.
    >> Share

  175. JANG AY, Ji HJ, Kang EH, Choi YJ, et al
    Cross-reactive immunity within pneumococcal serogroups: Implications for next-generation vaccine development.
    Vaccine. 2025;73:128179.
    >> Share

  176. DANIEL N, Smith C, Miah N, Akroyd C, et al
    Enablers and barriers to participation in vaccine trials: a narrative synthesis.
    Vaccine. 2025;73:128183.
    >> Share

  177. ZHANG G, Li W, Sui X, Guo Y, et al
    Characterization and vaccine-induced immunogenicity of a re-emerging Neisseria meningitidis serogroup Y in Tianjin, China.
    Vaccine. 2025;73:128156.
    >> Share

  178. PAL SS, Kim KH, Bhatnagar N, Grovenstein P, et al
    A combination of new prefusion mRNA and protein vaccines enhances neutralizing antibodies and protection against respiratory syncytial virus.
    Vaccine. 2025;73:128154.
    >> Share

  179. STOUT NL, Rudisill TM, Halbritter K, Ahmed H, et al
    Developing an implementation plan to improve vaccine uptake in pulmonary medicine: An institutional approach through the American Thoracic Society vaccine initiative.
    Vaccine. 2025;73:128138.
    >> Share

  180. SALLOUM M, Vandermosten L, Maseko T, Milolo S, et al
    Assessing vaccination coverage and antibody levels for measles, pertussis, and tetanus in Boende, DR Congo: Implications for maternal and child health.
    Vaccine. 2025;73:128083.
    >> Share

  181. ALVES K, Kouassi A, Nelson J, Plested JS, et al
    Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2025;73:128164.
    >> Share

  182. ZHAO D, Chen G, Wang S, Suo Y, et al
    A single ultra-low dose self-amplifying RNA rabies vaccine confers rapid and complete protection in mice.
    Vaccine. 2025;73:128150.
    >> Share

  183. TECHAWIWATTANABOON T, Leekitcharoenphon R, Alameh MG, Boonkea S, et al
    mRNA vaccines targeting Leptospira immunoglobulin-like proteins confer partial protection in a hamster model of leptospirosis.
    Vaccine. 2025;73:128099.
    >> Share

  184. FEBRIANI Y, Ursu MM, Sauvageau C, Kegbevi KB, et al
    Immune memory assessment three years following a single dose of hepatitis a vaccine at 12, 13 or 19 months of age.
    Vaccine. 2025;73:128144.
    >> Share

  185. HUNT AR, Regan AK, Perkins RB, Wise LA, et al
    The effect of human papillomavirus vaccination during adolescence or early adulthood on incidence of spontaneous abortion in adulthood.
    Vaccine. 2025;72:128152.
    >> Share

  186. DROBIC B, Akintunde G, Kim J, Mirceta M, et al
    Effect of Co-administration of the anthrax vaccine adsorbed, adjuvanted with ciprofloxacin or doxycycline on antibiotic pharmacokinetics and the vaccine immunogenicity: A phase 2 drug-vaccine interaction study.
    Vaccine. 2025;73:128135.
    >> Share

  187. MIRON E, Sauvageau C, Dube E, Vivion M, et al
    Vaccine hesitancy among older adults, urban indigenous and newcomers in Canada: A qualitative comparative study.
    Vaccine. 2025;73:128143.
    >> Share

  188. PINANDYO SH, Ali S, Aurelio B, Amoah AS, et al
    The association of helminth infection against antimalarial antibody responses in malaria infection and vaccination: a systematic review and meta-analysis.
    Vaccine. 2025;73:128125.
    >> Share

  189. STRENG BMM, Hensen LCM, Delemarre EM, Binnendijk RS, et al
    Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome.
    Vaccine. 2025;73:128079.
    >> Share

  190. PIJPERS J, van Roon A, van den Hof S, van Gaalen R, et al
    Large differences in MMR and DTaP-IPV vaccination coverage among primary schools by denomination, the Netherlands, 2024.
    Vaccine. 2025;72:128137.
    >> Share

  191. NONBOE MH, Napolitano G, Schroll JB, Andersen B, et al
    Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study.
    Vaccine. 2025;73:128142.
    >> Share

  192. BOUM Y, Ibeneme CU, Nsasiirwe S, Nakame R, et al
    Mpox vaccines: an urgent equity imperative.
    Vaccine. 2025;73:128158.
    >> Share

  193. LARSEN FD, Juhl AK, Dietz LL, Nielsen H, et al
    Immunogenicity of SARS-CoV-2 primary vaccination and boosters in patients with immune-mediated inflammatory diseases: Impact of immunosuppressive therapy.
    Vaccine. 2025;73:128155.
    >> Share

  194. SEESKIN ZH, Steffan M, Geistwhite B, Yarbrough M, et al
    Using latent class analysis of survey data to explore parent behaviors and attitudes regarding children's COVID vaccinations.
    Vaccine. 2025;73:128149.
    >> Share

  195. RAMAKRISHNAN SM, Ganaie FA, Govindan V, Mavupadi AM, et al
    Pneumococcal baseline IgG antibody levels and immune response to 23-valent pneumococcal polysaccharide vaccine among Indian adults.
    Vaccine. 2025;73:128157.
    >> Share

  196. BARRY EVH, Suffel AM, Walker J, Andrews N, et al
    Disparities in uptake of Shingrix(R) vaccine in immunosuppressed individuals in England: a population-based cohort study.
    Vaccine. 2025;72:128078.
    >> Share

  197. MA W, Yu Y, Zhu N, Zhang F, et al
    Ensuring structural integrity of Hib capsular polysaccharide in conjugate vaccine manufacturing by (1)H NMR and HPSEC-MALLS/RI.
    Vaccine. 2025;72:128145.
    >> Share

  198. KOVACS D, Brar G, Anthony SJ, Wang LF, et al
    Initiation of a coronavirus vaccine library.
    Vaccine. 2025;72:128140.
    >> Share

  199. PHADKE VK, Bednarczyk RA, Maldonado H, McCracken JP, et al
    Impact of pregnancy on longitudinal pertussis antibody responses to Tdap vaccine in Guatemala.
    Vaccine. 2025;72:128134.
    >> Share

  200. HARO SLY MJ, Zubeldia L
    COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil.
    Vaccine. 2025;72:128141.
    >> Share

  201. MUKHERJEE A, Das S, Mandal S, Roy N, et al
    Safety, immunogenicity and preliminary protective efficacy of a bivalent bacterial ghost vaccine against typhoidal Salmonella in rabbits: a pilot study.
    Vaccine. 2025;72:128126.
    >> Share

  202. KHAN S, McWhorter AR, Andrews DM, Underwood GJ, et al
    An enhanced vaccination regime reduces the shedding of Salmonella Typhimurium from layer chickens.
    Vaccine. 2025;72:128115.
    >> Share

  203. CHEN Y, Liu Q, Wang C, Chen S, et al
    Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models.
    Vaccine. 2025;72:128136.
    >> Share

  204. KAYESH MEH, Kohara M, Tsukiyama-Kohara K
    Carboxy-vinyl polymer: A promising immunostimulant for vaccines targeting respiratory and internal organ viruses.
    Vaccine. 2025;72:128146.
    >> Share

  205. NAGUIB M, Comfort SO, Renukaradhya GJ, Sharma S, et al
    Mucosal delivery (in ovo and oral) of chitosan nanoparticle-based subunit vaccine enhances resistance against Campylobacter jejuni colonization in broiler chickens.
    Vaccine. 2025;72:128116.
    >> Share

  206. TOMOI H, Hanley SJB, Larson HJ, Tomoi H, et al
    Determinants of human papillomavirus vaccination decision-making in Japan: a scoping review exploring contextual, social, and adolescent-specific influences.
    Vaccine. 2025;72:128111.
    >> Share

  207. MADIA JE, Nicodemo C, Petrou S, de Lusignan S, et al
    Primary healthcare costs associated with the AstraZeneca COVID-19 vaccine in England.
    Vaccine. 2025;72:128067.
    >> Share

  208. GSCHWEND MH, Faust E, Rousculp MD, Toback S, et al
    The shadow of reactogenicity: Parental hesitancy due to prior vaccine experiences.
    Vaccine. 2025;72:128120.
    >> Share

  209. BOCQUIER A, Cadoret S, Fall E, Bonnay S, et al
    Process evaluation of a school-based vaccination intervention to improve HPV vaccine coverage: A mixed-method study embedded in the French PrevHPV cluster randomized controlled trial.
    Vaccine. 2025;72:128122.
    >> Share

  210. DE OLIVEIRA NR, Maia MAC, Kremer FS, Moreira ADL, et al
    Whole-genome sequencing as a regulatory tool for quality control of Leptospira strains for vaccines and diagnostics.
    Vaccine. 2025;71:128110.
    >> Share

  211. RAHMAN L, Gao T, Nam J, Zeng Y, et al
    The effect of digital interventions on the uptake of HPV vaccination in the United States: A systematic review and meta-analysis.
    Vaccine. 2025;71:128117.
    >> Share

  212. ZHANG X, Chen S, Tang S
    Closing the immunization gap: Overcoming barriers for new vaccine introduction in Southeast and South Asia.
    Vaccine. 2025;72:128119.
    >> Share

  213. CARRICO J, McGuiness C, Yasuda M, Chen CC, et al
    Herpes zoster vaccination among immunocompromised adults in the United States.
    Vaccine. 2025;72:128124.
    >> Share

  214. YU S, Zheng B, Zhao J, Jiang L, et al
    Vaccine fatigue, perceived risk and trust: Unraveling the motivational drivers of influenza vaccination in Chinese adults using the COM-B model.
    Vaccine. 2025;72:128112.
    >> Share

  215. DROBIC B, Akintunde G, Kim J, Mirceta M, et al
    Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial.
    Vaccine. 2025;72:128068.
    >> Share

  216. NOGUCHI S, Ishimaru T, Yatera K, Machida M, et al
    Factors associated with respiratory syncytial virus vaccination among Japanese adults aged 60 years and older: an internet-based cross-sectional study.
    Vaccine. 2025;71:128114.
    >> Share

  217. HAYASHI K, Hashimoto N, Hashimoto C, Takeuchi Y, et al
    Effect of completed COVID-19 vaccination on serum interferon lambda3: a single-center retrospective study.
    Vaccine. 2025;72:128108.
    >> Share

  218. COAD S, Liebermann EJ, Lim E, Matsunaga M, et al
    Does changing the routinely recommended age for HPV vaccination change parental thoughts about vaccinating their adolescent: A mixed-methods analysis.
    Vaccine. 2025;71:128080.
    >> Share

  219. NKEREUWEM O, Jallow AO, Jallow DN, Owolabi J, et al
    Acceptance of a newly introduced COVID-19 vaccine among pregnant women and their decision influencers: a qualitative study in The Gambia.
    Vaccine. 2025;71:128070.
    >> Share

  220. WANG L, Li L, Yang W, Pang X, et al
    Immunogenicity and safety of inactivated quadrivalent influenza vaccines in children aged 6-35 months: A multi-center, randomized, double-blind, active-controlled clinical trial.
    Vaccine. 2025;71:128113.
    >> Share

  221. CASWELL C, Pullenayegum E, Singh P, Ward BJ, et al
    Sex-differences in influenza vaccine efficacy and immunogenicity among Canadian Hutterite children.
    Vaccine. 2025;72:128102.
    >> Share

  222. ZADE JK, Pisal SS, Tyagi P, Menon R, et al
    Immunogenicity and non-inferiority evaluation of dose-sparing adjuvanted inactivated polio vaccine in Wistar rats.
    Vaccine. 2025;72:128109.
    >> Share

  223. PARIDANS M, Gillain N, Husson E, Darcis G, et al
    COVID-19 vaccination: Does knowledge of higher immunity influence first and second COVID-19 booster uptake? A study carried out in a university population.
    Vaccine. 2025;72:128057.
    >> Share

  224. GROMIS A, Faherty LJ
    School-entry vaccine exemptions in Maine before and after public law 154, 2018-2023.
    Vaccine. 2025;71:128103.
    >> Share

  225. ZELKOSKI AE, Mitre E, Alameh MG, Malloy AMW, et al
    Distinct innate immune activation profiles of an mRNA-lipid nanoparticle vaccine compared to the empty lipid nanoparticle.
    Vaccine. 2025;71:128061.
    >> Share

  226. WOLFF E, Schollin Ask L, Larsson S
    Cost-effectiveness analyses of catch-up vaccination against human papillomavirus (HPV) related cancers of boys and young men in Sweden.
    Vaccine. 2025;72:128077.
    >> Share

  227. WALTER EB, Schlaudecker EP, Talaat KR, Rountree W, et al
    Immunogenicity of mRNA COVID-19 vaccine with either simultaneous or sequentially administered inactivated influenza vaccines: a randomized clinical trial.
    Vaccine. 2025;72:128072.
    >> Share

  228. BALLOUT S, Darwish SA, Kelly PJ, Keller T, et al
    The use of storytelling in COVID-19 vaccine promotion: A scoping review of interventions and campaigns.
    Vaccine. 2025;72:128098.
    >> Share

  229. SONG JY, Cheong HJ
    Understanding the low effectiveness of influenza vaccines in older adults of South Korea: an exploration of contributing factors.
    Vaccine. 2025;71:128076.
    >> Share

  230. HURLEY LP, Crane LA, Daley MF, Beaty B, et al
    Accuracy of self-reported vaccination status using surveys in safety-net, integrated and rural health systems in Colorado.
    Vaccine. 2025;72:128101.
    >> Share

  231. PALPHRAMAND KL, Anderson P, Bellamy F, Birch C, et al
    Immune response to co-administration of Bacillus Calmette-Guerin (BCG) and contraceptive vaccines in badgers (Meles meles).
    Vaccine. 2025;71:128069.
    >> Share

  232. BHATTACHARYA M, Chatterjee S, Das A, Lee SS, et al
    Machine learning (ML) and deep learning (DL) in vaccine target selection, design, development and characterization.
    Vaccine. 2025;71:128051.
    >> Share

  233. BJORK J, Dietler D, Bonander C, Moghaddassi M, et al
    Vaccine protection against COVID-19 mortality in relation to time since last booster dose among nursing home residents in Sweden - A case-control study over 35 months.
    Vaccine. 2025;71:128043.
    >> Share

  234. KULAPPU ARACHCHIGE SN, Abeykoon AMH, Stevenson MA, Kanci Condello A, et al
    Assessment of tracheal mucosal thicknesses is a preferable method for evaluation of the immunogenicity of Mycoplasma gallisepticum vaccines in poultry.
    Vaccine. 2025;72:128063.
    >> Share

  235. MEYER AC, Braegelmann K, Orozco-Ruiz X, Kruppert S, et al
    Comparing uptake of high-dose and standard-dose influenza vaccination at the practice and patient level in Germany.
    Vaccine. 2025;71:128075.
    >> Share

  236. HERNANDEZ-FRANCO JF, Abdelkhalek A, Zhang L, Ibrahium OM, et al
    Role of adjuvants in the efficacy of an IZUMO1-based immunocontraceptive vaccine in mice.
    Vaccine. 2025;72:128071.
    >> Share

  237. GATWOOD J, Gomez-Espinosa E, Fusco N, Stempniewicz N, et al
    Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States.
    Vaccine. 2025;71:128015.
    >> Share

  238. TALESHI J, Paramo MV, Watts A, Chilvers M, et al
    Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, Canada.
    Vaccine. 2025;68:127936.
    >> Share

  239. HUANG Y, Li T, Zhang Y, Wang H, et al
    Comparable protective efficacy of Brucella melitensis outer membrane vesicles via intramuscular, subcutaneous, and intranasal immunization routes in mice.
    Vaccine. 2025;68:127963.
    >> Share

  240. COUTO P, Campbell H, Li Y, Rondy M, et al
    Implications of respiratory syncytial virus seasonality for the timing of passive immunisation scenarios in Latin America and the caribbean - a cross-sectional modelling study.
    Vaccine. 2025;68:127934.
    >> Share

  241. SAHA S, van Binnendijk R, Ussher J, Ten Hulscher H, et al
    Limitations of serological screening for measles immunity in young health care workers in New Zealand.
    Vaccine. 2025;68:127931.
    >> Share

  242. SONG X, Peng Q, Zhang X, Zhao Y, et al
    Enhanced immunogenicity of swine coronavirus PEDV by engineering transcriptional regulatory sequences.
    Vaccine. 2025;68:127914.
    >> Share

  243. KOU G, Cheng Y, Zhang G, Wang Y, et al
    A live-attenuated human-lamb rotavirus reassortant confers robust protective immunity in mice.
    Vaccine. 2025;68:127898.
    >> Share

  244. ABEL ZDV, Roope LSJ, Violato M, Clarke PM, et al
    Corrigendum to "Accuracy of online surveys in predicting COVID-19 vaccine uptake and demand: A cohort study investigating vaccine sentiments and switching in 13 countries from 2020 to 2022" [Vaccines 62 (2025) 127450].
    Vaccine. 2025;71:128050.
    >> Share

  245. NOWZARI F, Nowzari F, Kian M, Zahedi M, et al
    Evolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025.
    Vaccine. 2025;71:128059.
    >> Share

  246. ASKAR M, Adel K, Batke M, Chi Y, et al
    Population effects of influenza vaccination in children and adolescents: Systematic review.
    Vaccine. 2025;71:128040.
    >> Share

  247. RICHARDSON RA, Moon C, Sands CM, Nelson R, et al
    Generation of a shelf-stable, broadly-reactive influenza vaccine formulated with TLR4, TLR7/8, or TLR9 stimulating adjuvants.
    Vaccine. 2025;72:128028.
    >> Share

  248. DAMBRE C, Cornelissen L, Cuypers L, Desmet S, et al
    Pneumococcal vaccines: A dose of change. Vaccine failures and breakthrough infections in Belgian children during the PCV13 era (2019-2024).
    Vaccine. 2025;72:128065.
    >> Share

  249. WAND H, Naidoo S, Moodley J, Govender V, et al
    Geospatial inequalities in zero-dose vaccination and structural determinants: Insights from sub-Saharan Africa (2015-2023).
    Vaccine. 2025;71:128062.
    >> Share

  250. BUDD EL, De Anda S, Chaovalit P, Vu AH, et al
    Psychometric testing of two measures of vaccination attitudes among U.S. Latine respondents.
    Vaccine. 2025;71:128044.
    >> Share

  251. TOWACHIRAPORN S, Thongwitokomarn H, Salee P
    The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19.
    Vaccine. 2025;71:128060.
    >> Share

  252. CHILDS L, Zoma RL, Ouedraogo I, Sawadogo G, et al
    Pneumococcal carriage among children and adults before and after a change from a three-dose 13-valent pneumococcal conjugate vaccine schedule without a booster to a two-dose schedule with a booster in Burkina Faso.
    Vaccine. 2025;72:128064.
    >> Share

  253. SUN Z, Liu Y, Zhang H, Ge T, et al
    A novel alphavirus-based saRNA platform for enhanced vaccination efficacy and organ-specific targeting.
    Vaccine. 2025;72:128055.
    >> Share

  254. SABSABI MA, Kheimar A, von La Roche D, Hartle S, et al
    B cells play an important role in HVT vaccine-mediated protection against Marek's disease virus.
    Vaccine. 2025;72:128048.
    >> Share

  255. REITER PL, Katz ML
    Vaccine hesitancy among midlife and older adults in the United States.
    Vaccine. 2025;72:128054.
    >> Share

  256. JIANG J, Lam KF, Lau EHY, Yin G, et al
    Learning from the omicron BA.4/5 dominance: Strategies for future vaccination preparedness.
    Vaccine. 2025;71:128058.
    >> Share

  257. CHANG CY, Nasreen S, Sadarangani M, Cragg JJ, et al
    Effect of pneumococcal conjugate vaccine booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018.
    Vaccine. 2025;71:128066.
    >> Share

  258. WANG XL, Xu JQ, Ye BL, Liu F, et al
    Estimating diphtheria, acellular pertussis, tetanus vaccine (DTaP) effectiveness in preventing pertussis in children aged three months to six years old in Shenzhen area, China, case control study.
    Vaccine. 2025;71:128024.
    >> Share

  259. REEVES C, Miura SST, Chappell AR, Banaag A, et al
    Trends in influenza vaccination uptake in a universally insured population in the united states, 2017-2023.
    Vaccine. 2025;71:128052.
    >> Share

  260. SEN BK, Ghosh RR, Rahman M, Ahmed I, et al
    Vaccines as a strategic approach to combat Vibrio parahaemolyticus and control of early mortality syndrome sin shrimp aquaculture: A comprehensive review.
    Vaccine. 2025;71:128049.
    >> Share

  261. ABBAD A, Lerman B, Ehrenhaus J, Ojeda DS, et al
    Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naive and convalescent populations.
    Vaccine. 2025;70:128018.
    >> Share

  262. GENSOROWSKY D, Surmann B, Meyer AC, Poshtiban A, et al
    Outpatient care intensity and influenza vaccination: evidence from Germany.
    Vaccine. 2025;70:128038.
    >> Share

  263. PEI C, Zeng D, He C, Sun W, et al
    A national survey on HPV vaccination status among 42,800 female physicians and nurses in China, 2021.
    Vaccine. 2025;70:128025.
    >> Share

  264. MESSINA NL, Pittet LF, Forbes EK, Francis KL, et al
    Neonatal BCG vaccination to prevent respiratory infections in the first 5 years of life: results from the MIS BAIR randomised controlled trial.
    Vaccine. 2025;69:127958.
    >> Share

  265. MIKAS J, Zibolenova J, Litvova S, Baska T, et al
    Seroprevalence of measles, mumps and rubella specific antibodies in the population of Slovakia: One vaccine, three different patterns.
    Vaccine. 2025;70:128039.
    >> Share

  266. KIM SH, Kang MG, Jang JG, Kim Y, et al
    Severe COVID-19, vaccination, and mortality among individuals with asthma: A Nationwide population-based cohort study.
    Vaccine. 2025;70:128017.
    >> Share

  267. HAMMOUD M, Smith AKJ, Sachs O, Bavinton BR, et al
    Drivers, barriers, and implications of mpox vaccine uptake in Australia among gay, bisexual, and other men who have sex with men: results from a prospective observational mixed-methods study (2022-2024).
    Vaccine. 2025;70:128041.
    >> Share

    November 2025
  268. RHYNE PW, Sunshine J, Hogrefe W, Roscia G, et al
    Corrigendum to "Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines" [Vaccine 68 (2025) 127896].
    Vaccine. 2025;70:128014.
    >> Share

  269. ZHANG X, Xu T, Xian J, Liu J, et al
    Development of a recombinant fusion protein subunit vaccine comprising two truncated proteins effectively protects largemouth bass against infectious spleen and kidney necrosis virus infection.
    Vaccine. 2025;70:128007.
    >> Share

  270. LE TOURNEAU N, Sharma A, Pry JM, Haambokoma M, et al
    Drivers of decision-making for future adult vaccines: a best-worst scaling among community members and health care workers in Zambia.
    Vaccine. 2025;70:128003.
    >> Share

  271. KAWAZOE Y, Katsuta T, Tanaka T, Nakamura Y, et al
    Prevalence of HPV vaccine-associated symptoms in unvaccinated Japanese adolescents: A descriptive study from the VENUS study database.
    Vaccine. 2025;70:128020.
    >> Share

  272. DEV AS, Broos HC, Llabre MM, Saab PG, et al
    Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent.
    Vaccine. 2025;70:128008.
    >> Share

  273. LADOMENOU F, Gorla E, Matalliotakis M, Serbis A, et al
    Determinants of human papillomavirus (HPV) vaccine uptake and health literacy regarding HPV infection and vaccine among undergraduate university students in Greece.
    Vaccine. 2025;70:128042.
    >> Share

  274. TEWARI T, Armah G, Cunliffe NA, Chisenga CC, et al
    Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants.
    Vaccine. 2025;70:128019.
    >> Share

  275. FREY SE, Baden LR, El Sahly HM, Davey RT, et al
    Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination.
    Vaccine. 2025;69:127959.
    >> Share

  276. BIAN H, Zhang S, Zhu Z, Cao Y, et al
    Preparation and evaluation of genetically engineered recombinant subunit vaccines containing serine metalloprotease, anchor M domain-containing protein, and pyolysin against Trueperella pyogenes infection in a mouse model.
    Vaccine. 2025;69:128009.
    >> Share

  277. PICHE-RENAUD PP, Buchan CA, Burton C, Chapdelaine H, et al
    Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study.
    Vaccine. 2025;70:128016.
    >> Share

  278. KELLY SA, Changalucha J, Malibwa D, Ewing VL, et al
    Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial.
    Vaccine. 2025;69:128002.
    >> Share

  279. CHAVES SS, Castells VB, Wague S, Tian Z, et al
    Chlamydia vaccine willingness among young adults in Australia.
    Vaccine. 2025;70:128027.
    >> Share

  280. WAHEED DE, Bolio A, Burdier R, Guillaume D, et al
    Barriers to HPV vaccine introduction and revitalization in sub-Saharan francophone African countries - A qualitative descriptive study.
    Vaccine. 2025;70:128030.
    >> Share

  281. CHAU SL, Hung IFN, Luk TT, Chan SSC, et al
    The impacts of long COVID and booster doses of post-infection vaccination among hospital-discharged COVID-19 survivors in Hong Kong: A retrospective observational study.
    Vaccine. 2025;70:128022.
    >> Share

  282. CHAZARIN B, Bhat AS, Sundararaman N, Liu Y, et al
    Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals.
    Vaccine. 2025;70:127888.
    >> Share

  283. SHAHEEN MNF, Clark A, Zaghlol A, Rashed MK, et al
    An impact and cost-effectiveness analysis of rotavirus vaccine introduction in Egypt.
    Vaccine. 2025;69:128010.
    >> Share

  284. DOULOU K, Bacopoulou F, Michos A, Tsolakidis A, et al
    HPV vaccination coverage among children and adolescents in Greece using national prescription data.
    Vaccine. 2025;70:128026.
    >> Share

  285. VAHABI MM, Ketentzi S, Kahraman U, Erdem HA, et al
    A single center's 25-year experience with hepatitis B and pneumoccocal vaccines in heart transplant patients: the impact of the COVID-19 pandemic.
    Vaccine. 2025;70:128023.
    >> Share

  286. HUANG F, Deng Z, Huang Y, Lv Q, et al
    COVID-19 as a catalyst? Uptake and drivers of seasonal influenza and pneumococcal vaccination among older adults in post-pandemic Shenzhen, China.
    Vaccine. 2025;69:128013.
    >> Share

  287. SPEDICATO M, Profeta F, Li Y, Celani P, et al
    Vaccine candidate based on a baculovirus expressed VP2 provides full protection from epizootic hemorrhagic disease virus serotype 8 in calves.
    Vaccine. 2025;69:128000.
    >> Share

  288. CHILVER M, Ahsani Z, Sullivan SG, Edwards J, et al
    Evaluating the role of self-collected home swab data in enhancing influenza vaccine effectiveness estimates in general practice.
    Vaccine. 2025;69:127994.
    >> Share

  289. VANASSE LT, Safdar B, Self WH, Zhu Y, et al
    Comparison of immunization information systems, electronic medical records, and self-report to ascertain RSV vaccination status among US adults aged >/=60 years, 2023-2024.
    Vaccine. 2025;69:127946.
    >> Share

  290. ULRICH AK, Bigalke L, Arpey M, Redepenning S, et al
    Funding the priorities of the influenza vaccines research and development roadmap: an evaluation of global investment.
    Vaccine. 2025;69:127967.
    >> Share

  291. NJOH AA, Bolio A, Venczel L, Libwea JN, et al
    Key players and determinants improving human papillomavirus vaccination coverage in Cameroon: a cross-sectional nationwide health workers survey.
    Vaccine. 2025;69:128006.
    >> Share

  292. BOONE AC, Gaghan C, Fares A, Browning M, et al
    Ability to accelerate innate and cell-mediated immune responses in meat-type chickens by in ovo vaccination with monovalent and bivalent Marek's disease vaccines.
    Vaccine. 2025;69:128001.
    >> Share

  293. STOECKER C, Wang Y, Leidner AJ, Cho BH, et al
    Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults.
    Vaccine. 2025;69:127940.
    >> Share

  294. MCGOWAN CR, van Zandvoort K, Ibrahim SA, Hassan AI, et al
    Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland.
    Vaccine. 2025;69:127991.
    >> Share

  295. STRUWIG VA, Ta A, Thorat AV, Ilic A, et al
    Evaluating the implementation of the 20-valent pneumococcal conjugate vaccine for paediatric immunization in Australia.
    Vaccine. 2025;69:127996.
    >> Share

  296. LASRADO N, Rossler A, McConnell I, Molloy K, et al
    Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants.
    Vaccine. 2025;69:127997.
    >> Share

  297. ZHONG Y, Yang H, Chai W, Chen D, et al
    Development and immunological evaluation of a Streptococcus suis serotype 2 capsular polysaccharide conjugate vaccine.
    Vaccine. 2025;69:128004.
    >> Share

  298. ILBOUDO DP, Simpore A, Sawadogo J, Ouattara AK, et al
    Acceptance, hesitancy, and ethical challenges of the COVID-19 vaccine in sub-Saharan Africa: a systematic review and meta-analysis.
    Vaccine. 2025;69:127966.
    >> Share

  299. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Erratum to "Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1-5 September 2025" [Vaccine 68 (2025) 127903].
    Vaccine. 2025;69:127972.
    >> Share

  300. RAUPACH J, Housria Y, Hein S, Schnierle B, et al
    Comparative analysis of a flexible novel vaccine platform based on cell permeable chimeric HBV capsids for mucosal vaccination.
    Vaccine. 2025;69:127987.
    >> Share

  301. MUKHOPADHYAY ES, Bellamy DG, Tinto H, Hamaluba M, et al
    Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
    Vaccine. 2025;69:127973.
    >> Share

  302. CHAPMAN S, Christodoulaki ME, Davey SA, Gaffiero D, et al
    Understanding vaccine hesitancy: The role of fear and message framing in COVID-19 vaccination intention in adults in the UK.
    Vaccine. 2025;69:127999.
    >> Share

  303. MCLAUGHLIN JM, Wassil J
    Response to Anticipated impact of novel adult-specific pneumococcal conjugate vaccine by Joshi et al.
    Vaccine. 2025 Nov 15:127988. doi: 10.1016/j.vaccine.2025.127988.
    >> Share

  304. BIRKETT AJ, Ansah E, Gordon S, Gyapong M, et al
    Value profile for Malaria vaccines and monoclonal antibodies.
    Vaccine. 2025 Nov 15:127971. doi: 10.1016/j.vaccine.2025.127971.
    >> Share

  305. BATMUNKH T, Neal EFG, Amraa O, Mazarakis N, et al
    Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.
    Vaccine. 2025;66:127840.
    >> Share

  306. JOKAR M, Goddard Q, Nobrega D
    Infodemiology of public sentiment toward the measles vaccine in Canada: A google trends and health belief model-based analysis, 2025.
    Vaccine. 2025;69:127998.
    >> Share

  307. RANA MM, Haydel B, Carrara G, Gleason C, et al
    Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.
    Vaccine. 2025;69:127969.
    >> Share

  308. FANG L
    Gene-deletion attenuated live vaccines for Streptococcus suis: Advances, challenges, and future directions.
    Vaccine. 2025;69:127990.
    >> Share

  309. STOVRING H, Ekstrom CT, Schneider JW, Strom C, et al
    What is actually the emerging evidence about non-specific vaccine effects in randomized trials from the Bandim Health Project?
    Vaccine. 2025 Nov 13:127937. doi: 10.1016/j.vaccine.2025.127937.
    >> Share

  310. NUNO T, Soto S, Sepulveda R, Sierra LA, et al
    The Arizona prevention research center vaccine confidence network: A Mobile health unit intervention and survey results of barriers and facilitators to COVID-19 vaccination.
    Vaccine. 2025;60 Suppl 1:127970.
    >> Share

  311. RUSSO L, Farina S, Macri RA, Pentecost WA, et al
    State-level progress and setbacks in influenza vaccination among adults >/=65: A fifteen-season analysis from 2009/10 to 2023/24.
    Vaccine. 2025;69:127983.
    >> Share

  312. DAS T, Nath BK, Dhar PK, Peters A, et al
    Safety and immunogenicity of a novel psittacine beak and feather disease vaccine and optimisation of a thermostable spray-dried formulation.
    Vaccine. 2025;69:127989.
    >> Share

  313. COOPER SC, Williams IV, Porter A, Presti C, et al
    'They're not going to tell you everything': A qualitative study with HPV vaccine hesitant parents and caregivers in the northeast and southeast U.S.
    Vaccine. 2025;68:127948.
    >> Share

  314. DEVSAM B, Bortolussi K, Tippins J, Vasiliadis S, et al
    The experience of seeking & granting special medical exemptions for mandated vaccines: A scoping review.
    Vaccine. 2025;68:127935.
    >> Share

  315. NAHAR N, Parveen S, Gurley ES, Ghosh PK, et al
    Community interpretation of a consent form and willingness to participate in a Nipah virus vaccine trial in Bangladesh.
    Vaccine. 2025;68:127953.
    >> Share

  316. KUMAR P, Bateson D, Costa T, Ahmed S, et al
    HPV vaccination coverage and determinants in adolescent girls with disability: a scoping review.
    Vaccine. 2025;68:127968.
    >> Share

  317. KANTOR J, Morrison M, Vanderslott S, Pollard AJ, et al
    Public attitudes towards intranasal and ultrasound mediated vaccine delivery: A cross-sectional study in the United Kingdom and United States.
    Vaccine. 2025;69:127950.
    >> Share

  318. GRASSI CM, Feng J, Wahid R, Kandinov B, et al
    Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.
    Vaccine. 2025;69:127960.
    >> Share

  319. LAKSHMANASAMY R, Palaniraja S, Basu P
    "Beyond promises: Why India must act now to deliver HPV vaccination".
    Vaccine. 2025;69:127974.
    >> Share

  320. FIORILLA C, Contarino F, Sorrentino M, Bella F, et al
    Socioeconomic deprivation and human papillomavirus vaccination inequities: evidence from Southern Italy.
    Vaccine. 2025;69:127986.
    >> Share

  321. DO THT, Kent SJ, Whealtey AK, Koutsakos M, et al
    Impact of serum versus anticoagulant-containing plasma on influenza virus neuraminidase-based serological assays.
    Vaccine. 2025;69:127956.
    >> Share

  322. LEDDERER L, Nielsen KH, Skodborg L, Fage-Butler A, et al
    Public trust and mistrust of COVID-19 vaccines: A systematic meta-narrative review.
    Vaccine. 2025;69:127947.
    >> Share

  323. DENG L, Fan X, Li J, Yin D, et al
    Characteristics of neuraminidase-specific immune responses in influenza vaccinated or naturally infected populations in Shenzhen, China.
    Vaccine. 2025;69:127918.
    >> Share

  324. LUHATA LUNGAYO C, Burnett E, Mulumba A, Milabyo A, et al
    Rotasiil vaccine effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo: comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative design.
    Vaccine. 2025;68:127944.
    >> Share

  325. LAM LN, Berges A, Sedra A, Saengpet IS, et al
    A pentavalent vaccine targeting adhesins and metal-binding lipoproteins confers robust protection against enterococcal infections.
    Vaccine. 2025;69:127965.
    >> Share

  326. GARVEY K, Salmon DA, Dudley MZ, Brewer J, et al
    Associations between trust in public health, vaccine confidence, and COVID-19 vaccination among American adults.
    Vaccine. 2025;68:127955.
    >> Share

  327. JEFFERY C, Cheyne CP, Buchan I, Garcia-Finana M, et al
    Effect of influenza vaccination on post-admission outcomes for influenza patients in England: a population-based cohort study.
    Vaccine. 2025;68:127933.
    >> Share

  328. ZHU Y, Si M, Wang L, Zhang Y, et al
    Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial.
    Vaccine. 2025;68:127962.
    >> Share

  329. MCCARTHY K, Silkiss RZ
    Ocular manifestations of vaccine-preventable diseases: A comprehensive review.
    Vaccine. 2025;68:127900.
    >> Share

  330. REINHOLM A, Khan H, Laakso T, Maljanen S, et al
    Corrigendum to "Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1" [Vaccine 68 (2025) 127894].
    Vaccine. 2025;68:127939.
    >> Share

  331. KOUZELI A, Hasan T, Smith K, Metelmann S, et al
    Impact of vaccination on shingles-related hospitalisations in 70-79-year-olds in Scotland between 2000 and 2023: A retrospective cohort study.
    Vaccine. 2025;68:127951.
    >> Share

  332. MIRANDA-LOPEZ A, Castillo CG, Gonzalez-Ortega O, Romero-Maldonado A, et al
    The rpZDIII vaccine triggers vertical protection on newborn mice against zika virus infection.
    Vaccine. 2025;68:127941.
    >> Share

  333. BICEGO A, Wood JG, Newall AT, Hogan AB, et al
    Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies.
    Vaccine. 2025;68:127868.
    >> Share

  334. O'BRIEN TL, Johnson DR
    U.S. state lawmaker support for COVID-19 vaccine policies during the pandemic.
    Vaccine. 2025;68:127930.
    >> Share

  335. CHEN G, Chen G, Wang S, Xing R, et al
    Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B.
    Vaccine. 2025;68:127964.
    >> Share

  336. KAMATHEWATTA KI, Kanci Condello A, Ekanayake D, Noormohammadi AH, et al
    Day-old vaccination with the Vaxsafe MG304 live-attenuated vaccine protects chickens from tracheal transcriptional changes induced by chronic infection with Mycoplasma gallisepticum.
    Vaccine. 2025;68:127915.
    >> Share

  337. CHENG C, Chen X, Ge Y, Sung MH, et al
    Assessing factors associated with one-year antibody waning in participants with repeated influenza vaccinations: A six-year cohort study.
    Vaccine. 2025;68:127904.
    >> Share

  338. ZIDAN M, Trinh NTH, Desalegn A, Smith LH, et al
    BNT162b2 mRNA COVID-19 vaccine effectiveness in pregnancy: Emulating trial NCT04754594 using observational data from Norwegian health registries.
    Vaccine. 2025;68:127908.
    >> Share

  339. ZHANG Q, Lewis KB, Phillips JC, Ma H, et al
    Decisional needs of older adults considering COVID-19 booster vaccinations: A systematic review comparing China with other countries.
    Vaccine. 2025;68:127949.
    >> Share

  340. REEKIE J, Stepien S, Hendry A, Dalton L, et al
    Provider setting for influenza and COVID-19 vaccination among Australian adults in 2023 and 2024.
    Vaccine. 2025;68:127945.
    >> Share

  341. KHUU E, Moussaoui S, Vignier N, Bonello K, et al
    Vaccine hesitancy among migrant populations in Europe: A mixed-methods systematic review.
    Vaccine. 2025;68:127954.
    >> Share

  342. SAITO T, Couzinet A, Suzuki T, Shimomura M, et al
    Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.
    Vaccine. 2025;68:127942.
    >> Share

  343. LIU D, Zhang Y, Lei J, Li J, et al
    Influenza, pneumococcal, COVID-19 vaccine willingness and uptake with influencing factors in 38,184 chinese older adults in 2022: a nationwide cross-sectional study.
    Vaccine. 2025;68:127961.
    >> Share

  344. NETT RJ, Brault AC, Lambert AJ, Agnihothram S, et al
    Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development.
    Vaccine. 2025;68:127938.
    >> Share

  345. SHARFF KA, Haslam A, Nealon J
    COVID-19 vaccine variant target: how should we choose?
    Vaccine. 2025;68:127917.
    >> Share

  346. DE MELO ARAUJO AC, Frugoli AG, de Sena Goncalves JE, Percio J, et al
    Corrigendum to "Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review" [Vaccine 66 (2025) 127850].
    Vaccine. 2025;68:127929.
    >> Share

  347. WU Y, Ren B, Gao X, Li N, et al
    Evaluation of the immunization effects of needle-free injection for four common porcine vaccines.
    Vaccine. 2025;68:127943.
    >> Share

  348. HAMASHIMA Y, Breheny K, Davies SR, Dawson S, et al
    A synthesis of economic data from randomized trials of recipient-focused interventions to increase vaccine uptake.
    Vaccine. 2025;68:127906.
    >> Share

  349. SENDERS S, Korbal P, Kline M, Tamimi N, et al
    Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants.
    Vaccine. 2025;68:127916.
    >> Share

  350. MORRIS SE, O'Halloran A, Sundaresan D, Dawood FS, et al
    Heterogeneity in seasonal influenza vaccination opportunity and disease risk during pregnancy and in infants <6 months.
    Vaccine. 2025;68:127887.
    >> Share

  351. MAHAJAN M, Martin LB, Gaurav K, Suri RK, et al
    Adaptive clinical trial designs for rapid vaccine development: Developing country vaccine manufacturers' perspective.
    Vaccine. 2025;68:127890.
    >> Share

  352. MEMIRIE ST, Teka T, Mekasha A, Alemayehu T, et al
    Prioritization of future new vaccines introduction: The experience of the Ethiopian National Immunization Technical Advisory Group.
    Vaccine. 2025;68:127932.
    >> Share

  353. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC) meeting, virtual gathering, 1-5 September 2025.
    Vaccine. 2025;68:127903.
    >> Share

  354. SALINES M, Andraud M, Scoizec A, Schmitz A, et al
    To what extent may the duck population be protected after vaccination against highly pathogenic avian influenza? Contributions from a modelling approach and French field data.
    Vaccine. 2025;68:127905.
    >> Share

    October 2025
  355. RHYNE PW, Sunshine J, Hogrefe W, Roscia G, et al
    Development and qualification of a multiplexed immunoassay to assess the immunogenicity of Shigella vaccines.
    Vaccine. 2025;68:127896.
    >> Share

  356. THAWEETHAI T, Gross RS, Pant DB, Rhee KE, et al
    Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection.
    Vaccine. 2025;68:127907.
    >> Share

  357. YU SL, Chung NH, Chen YC, Ho HM, et al
    Natural killer T cells play a significant role in preventing Coxsackievirus A10 infection through an adeno-based vaccine expressing enterovirus-like particles.
    Vaccine. 2025;68:127909.
    >> Share

  358. NAKAHIRA A, Iwaoka H, Sato K, Ishizuka S, et al
    NKT cell-dependent PspA-specific IgA production caused by mucosal administration of a novel nanoparticle pneumococcal vaccine.
    Vaccine. 2025;68:127911.
    >> Share

  359. TIAN J, Wang X, Gu L, Ren J, et al
    Optimizing immunization through concurrent vaccination: a safety and cost analysis of PCV13 and rotavirus vaccines co-administration in Shanghai.
    Vaccine. 2025;68:127880.
    >> Share

  360. SAUVAGEAU C, Ionescu IG, Ouakki M, Panicker G, et al
    Long term immunogenicity of two doses of the quadrivalent HPV vaccine and the effect of an additional dose given five years post-primary vaccination.
    Vaccine. 2025;68:127893.
    >> Share

  361. MIRANDA-HERNANDEZ S, Sathkumara HD, Zhao G, Schofield L, et al
    Co-administration of a synthetic saccharide conjugate vaccine with BCG provides synergistic protection against murine tuberculosis.
    Vaccine. 2025;68:127912.
    >> Share

  362. GUO Z, Li J, Luo M, Shuai W, et al
    Development and immunogenicity of a recombinant PRRSV live vector co-expressing CSFV E2 antigen and porcine IL-18 for multivalent swine vaccination.
    Vaccine. 2025;68:127886.
    >> Share

  363. LI V, McClure H, Patel R, Kuchel GA, et al
    Medication count, including statin or metformin use, is not associated with influenza vaccine responses in older adults.
    Vaccine. 2025;68:127913.
    >> Share

  364. SHAO J, Yang B, Feng S, Zhi Q, et al
    Evaluating the impact of different MMR vaccination strategies on mumps incidence in Shapingba, China:An interrupted time series analysis.
    Vaccine. 2025;67:127885.
    >> Share

  365. REINHOLM A, Khan H, Laakso T, Maljanen S, et al
    Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1.
    Vaccine. 2025;68:127894.
    >> Share

  366. ZENG S, Fu Z, Wang Y, Jiang S, et al
    Construction and evaluation of a chimeric vaccine against Clostridium perfringens type a of sika deer.
    Vaccine. 2025;68:127899.
    >> Share

  367. LOPEZ-ZAMBRANO MA, Sanchez-Gomez A, Lasheras Carbajo MD, Gutierrez Rodriguez MA, et al
    Trend and factors associated to pertussis and influenza vaccination in pregnant women in Madrid, Spain, 2018-2023 - a retrospective cohort study.
    Vaccine. 2025;68:127895.
    >> Share

  368. GROMER DJ, Kalash S, Tanios R, Rouphael N, et al
    The relationship between the immunogenicity and reactogenicity of vaccines: A narrative review.
    Vaccine. 2025;68:127892.
    >> Share

  369. NOROOZI A, Esha SM, Ghari M
    Predictors of childhood vaccination uptake in England: an explainable machine learning analysis of regional data (2021-2024).
    Vaccine. 2025;68:127902.
    >> Share

  370. LIU X, Han S, Wang H, Sun L, et al
    Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled
    Vaccine. 2025;67:127891.
    >> Share

  371. LOURENCO KL, Oliveira Paim AA, Hojo-Souza NS, Queiroz-Junior CM, et al
    The LVD/NIAID/NIH MVA1974 clone as an Mpox vaccine - preclinical assessment upon in a model of lethal infection with Orthopoxvirus monkeypox in mice.
    Vaccine. 2025;67:127889.
    >> Share

  372. MATTINGLY TJ 2ND
    Penny wise, pound foolish: The cost of reduced support for measles prevention.
    Vaccine. 2025;65:127830.
    >> Share

  373. OPHIR Y, Wong JH, Haddad KR, Huuskonen A, et al
    Expression and characterization of SARS-CoV-2 spike protein in Thermothelomyces heterothallica C1.
    Vaccine. 2025;65:127784.
    >> Share

  374. DONAHUE JG, Cocoros NM, Kieke BA, Hanson KE, et al
    Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink.
    Vaccine. 2025;67:127873.
    >> Share

  375. ABDUL AZIZ N, Kirsebom FCM, Allen A, Andrews N, et al
    Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England.
    Vaccine. 2025;67:127870.
    >> Share

  376. ACHARYA KP, Phuyal S, Lopes BS
    Overcoming vaccine cold chain challenges in Nepal's animal health sector: innovative strategies for effective immunisation.
    Vaccine. 2025;67:127857.
    >> Share

  377. ASTURIAS EJ, Chen LH, Shaw AC, Moser CA, et al
    Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes.
    Vaccine. 2025;67:127876.
    >> Share

  378. ZHANG X, Li Y, Tian J, Zhang M, et al
    Recombinant truncated gD glycoprotein from E.coli as a thermostable and protective subunit vaccine candidate against ILTV in chickens.
    Vaccine. 2025;67:127882.
    >> Share

  379. PORTER A, Cooper S, King A, Presti C, et al
    Regional voices, different choices: Parents' and caregivers' HPV vaccine attitudes in the northeast and Southeast United States.
    Vaccine. 2025;67:127864.
    >> Share

  380. STEINER A, Settgast A, DeSilva M, Payton C, et al
    Tetanus and diphtheria vaccination coverage and electronic health record alerts for immigrants and refugees at three United States health systems, 2017-2023.
    Vaccine. 2025;67:127881.
    >> Share

  381. BOSETTI P, Peckeu-Abboud L, Andrianasolo RM, Baguelin M, et al
    Modelling the impact of a quadrivalent ACWY meningococcal vaccination and vaccination targeting serogroup B in France.
    Vaccine. 2025;67:127871.
    >> Share

  382. EAGAN RL, Claessens T, Hendrickx G, Larson HJ, et al
    The state of vaccine confidence among the general public in Eastern Europe and Central Asia.
    Vaccine. 2025;67:127849.
    >> Share

  383. CAO BK, Nguyen TPL, Postma MJ, van der Schans J, et al
    Acceptance and willingness to pay for pneumococcal vaccination in Vietnam: insights into adult preferences and influencing factors.
    Vaccine. 2025;67:127884.
    >> Share

  384. YAO N, Liu Y, Zhang YY, Wang Q, et al
    Impacts of two-dose mumps-containing vaccine strategy on mumps incidence using segmented regression models.
    Vaccine. 2025;67:127874.
    >> Share

  385. MALTEZOU HC, Drositis I, Sourri F, Tseroni M, et al
    Understanding the attitudes of unvaccinated COVID-19 patients hospitalized in Greece toward the 2024-2025 booster COVID-19 vaccine.
    Vaccine. 2025;67:127829.
    >> Share

  386. HAPOSAN JH, Icanervilia AV, Watts E, Widyaningsih SA, et al
    Real-world vaccine effectiveness of typhoid conjugate vaccine in children and adolescents: a systematic review and meta-analysis.
    Vaccine. 2025;67:127872.
    >> Share

  387. MERCADANTE E, Minssen T, Shadlen KC, van Zimmeren E, et al
    A global landscape of patenting activity in COVID-19 vaccines.
    Vaccine. 2025;67:127866.
    >> Share

  388. ANOSIKE C, Ojiakor IM, Etiaba EI, Uguru NP, et al
    Cost-effectiveness and budget impact of malaria, measles, and meningitis vaccines in Africa: a scoping review.
    Vaccine. 2025;67:127853.
    >> Share

  389. MOHANTY S, Zurovac J, Barna M, Cossrow N, et al
    Corrigendum to "Changes in pneumococcal vaccination disparities by area-level social vulnerability during the COVID-19 pandemic among Medicare and Medicaid enrollees" [Vaccine 62 (2025) 127452].
    Vaccine. 2025;67:127875.
    >> Share

  390. OIKAWA K, Murakami M, Ochi S, Yamagata M, et al
    Contributing factors to reversed willingness to vaccinate after the COVID-19 pandemic: Insights from a national panel survey.
    Vaccine. 2025;67:127869.
    >> Share

  391. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Corrigendum to "Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort" [Vaccine 62 (2025) 127580].
    Vaccine. 2025;67:127855.
    >> Share

  392. LIU B, Huang N, Liu Y, Zhang X, et al
    Parental perceptions and willingness to pay for childhood vaccination experiences in China: a multi-city comprehensive evaluation study.
    Vaccine. 2025;67:127826.
    >> Share

  393. CARACO Y, Madar-Balakirski N, Ben-Ami E, Zeltser D, et al
    Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults.
    Vaccine. 2025;67:127837.
    >> Share

  394. WILLIAMS LR, Voysey M, Pollard AJ, Grassly NC, et al
    A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.
    Vaccine. 2025;67:127856.
    >> Share

  395. HARA-HUBBARD KK, Beaulieu A, Mendiola A, Gandhi P, et al
    Strategies for addressing COVID-19 vaccine equity with intermediaries, prevention research centers, and the vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127847.
    >> Share

  396. CIMA MJ, Joshua C, Zohoori N, Porter A 3rd, et al
    Hesitancy towards routine childhood vaccinations before and after the COVID-19 pandemic in Arkansas.
    Vaccine. 2025;66:127834.
    >> Share

  397. PEIXOTO DE MIRANDA EJF, de Sousa Moreira JA, da Silva Braga R, Silveira DHR, et al
    Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine.
    Vaccine. 2025;66:127836.
    >> Share

  398. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
    Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
    Vaccine. 2025;66:127843.
    >> Share

  399. CARTER AS, Steele D, John J, Saha S, et al
    Advancing typhoid conjugate vaccine implementation in Asia: Regional policy priorities.
    Vaccine. 2025;66:127848.
    >> Share

  400. BAZZUCCHI M, Rossini E, Cavadini P, Bertasio C, et al
    Genome sequence of the Myxoma virus Borghi vaccine strain.
    Vaccine. 2025;66:127835.
    >> Share

  401. IVERSEN EF, Rahimic AHF, Frattari GS, Rosas-Umbert M, et al
    TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.
    Vaccine. 2025;66:127851.
    >> Share

  402. VAN RIJN PA, Wernery U, Feddema AJ, Maris-Veldhuis MA, et al
    Corrigendum to "Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes" [Vaccine 64 (2025) 127772].
    Vaccine. 2025;66:127839.
    >> Share

  403. HOU Y, Zarodkiewicz P, Cortazar JT, Stoner D, et al
    Protective efficacy of two novel Klebsiella pneumoniae vaccine antigens, LysM/BON and OMPP1, in a murine model.
    Vaccine. 2025;66:127844.
    >> Share

  404. RAMAY BM, Yoder J, Castillo C, Fahsen N, et al
    Assessing effects of pneumococcal vaccination (PCV13) and rotavirus vaccination (RV) on colonization with extended-spectrum cephalosporin-resistant enterobacterales (ESCrE) in guatemalan children.
    Vaccine. 2025;66:127852.
    >> Share

  405. YAMAGUCHI Y, Amiya S, Inokuchi S, Nagao S, et al
    Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis.
    Vaccine. 2025 Oct 12:127771. doi: 10.1016/j.vaccine.2025.127771.
    >> Share

  406. RAFFL S, Springer DN, Aberle SW, Florian DM, et al
    Tick-borne encephalitis: Burden of disease and impact of vaccination, Austria (2000-2024).
    Vaccine. 2025;66:127854.
    >> Share

  407. WANG X, Shang S, Zou T, Hu Y, et al
    Drivers of herpes zoster vaccine hesitancy in adults aged 50 and above: A machine learning approach.
    Vaccine. 2025;66:127838.
    >> Share

  408. BELMONTE M, Kusi KA, Kyei-Baafour E, Ofori EA, et al
    Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology.
    Vaccine. 2025;66:127832.
    >> Share

  409. YEO D, Lee K, Jo Y, Lee S, et al
    Long-term effectiveness of live zoster vaccine against herpes zoster and related complications: a nationwide emulated target trial in South Korea.
    Vaccine. 2025;66:127824.
    >> Share

  410. HANSEN BT, Ostlie IB, Greve-Isdahl M, Gleditsch RN, et al
    Determinants of parental readiness for childhood vaccination: experiences, information, sociodemographics and adherence.
    Vaccine. 2025;66:127809.
    >> Share

  411. KALIAPPAN A, Ramakrishnan S, Panwar K, Naveen D, et al
    Triple-TLR agonists' adjuvanted inactivated Newcastle disease virus vaccine promotes effective Th1/Th2 immune responses and affords protective efficacy in chickens.
    Vaccine. 2025;66:127846.
    >> Share

  412. PIRES C
    Influenza vaccine hesitancy in the elderly: Where do we stand?
    Vaccine. 2025;66:127831.
    >> Share

  413. DE MELO ARAUJO AC, Frugoli AG, de Sena Goncalves JE, Percio J, et al
    Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review.
    Vaccine. 2025;66:127850.
    >> Share

  414. DOMINGO JL
    Differentiating COVID-19 vaccine-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches.
    Vaccine. 2025;66:127842.
    >> Share

  415. NICHOLLS EJ, Onyango D, Kolodin V, Ottaway Z, et al
    The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK.
    Vaccine. 2025;66:127802.
    >> Share

  416. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
    Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
    Vaccine. 2025;66:127825.
    >> Share

  417. GE Y, Zahid A, Kuchur R, Martinez L, et al
    Using machine learning models to predict vaccine hesitancy: a showcase of COVID-19 vaccine hesitancy in rural populations during the pandemic.
    Vaccine. 2025;66:127799.
    >> Share

  418. HEINZE N, Martin AF, Tirion ASC, Pae R, et al
    Exploring the effectiveness of interventions to increase uptake of measles vaccination among healthcare workers: a systematic review.
    Vaccine. 2025;66:127808.
    >> Share

  419. LE T, Jia B, Sun C, Zhou Y, et al
    Lipid nanoparticle encapsulated membrane-anchored E2 mRNA vaccine elicits cross-protective immune responses against bovine viral diarrhoea virus infection in calves.
    Vaccine. 2025;66:127841.
    >> Share

  420. HORA R, Ray A, Kumari A, Dutta M, et al
    Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) vaccine under the immunization programme in India.
    Vaccine. 2025;66:127827.
    >> Share

  421. SCHIEFERDECKER R, Menting T, Mankertz A, Santibanez S, et al
    Vaccination versus antibody screening for measles immunity in health care workers.
    Vaccine. 2025;66:127845.
    >> Share

  422. HAYASHI T, Yao S, Sato-Kaneko F, Cozza R, et al
    Enhancing vaccine immunogenicity through heterologous prime-boost regimen with multiple nasal boosting with liposomal TLR7 ligand.
    Vaccine. 2025;65:127778.
    >> Share

  423. KANG CK, Im YJ, Kim DY, Choe PG, et al
    Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.
    Vaccine. 2025;65:127819.
    >> Share

  424. HERNANDEZ M, Caltempa AO, Villalobos N, Elisondo MC, et al
    Novel Oral papaya-based preventive and therapeutic vaccine for controlling different zoonotic Taeniid parasites: Current advances.
    Vaccine. 2025;66:127818.
    >> Share

  425. SHAMSRIZI P, Eitze S, Heinemeier D, Tanzer AS, et al
    Post-pandemic questions in vaccination counseling: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines.
    Vaccine. 2025;66:127823.
    >> Share

  426. ANGELIDOU A, Cotugno N, Sherman AC, Amodio D, et al
    Editorial for the special issue "Vaccines for the vulnerable".
    Vaccine. 2025;65:127783.
    >> Share

  427. EL HINDI T, Anugulruengkitt S, Lapphra K, Limkittikul K, et al
    Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.
    Vaccine. 2025 Oct 6:127786. doi: 10.1016/j.vaccine.2025.127786.
    >> Share

  428. HALLIDAY R, Morais B, Bouaddi O, Deal A, et al
    Vaccine-preventable diseases in migrants in Europe: a systematic review.
    Vaccine. 2025;65:127788.
    >> Share

  429. SCHOENFISCH C, Kauter K, Walz N, Wang T, et al
    Persistence of measles, mumps, and rubella immunity following childhood vaccination in Australian health science students: a cohort study.
    Vaccine. 2025;65:127791.
    >> Share

  430. CLAY PA, Markowitz LE, Gopalani SV, Baxter A, et al
    HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving.
    Vaccine. 2025;65:127798.
    >> Share

  431. LAING KJ, Sholukh AM, MacPhee KJ, McClurkan CL, et al
    Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection.
    Vaccine. 2025;65:127821.
    >> Share

  432. ZOU Z, Hu Y, Yang H, Zhao M, et al
    Preferences and willingness-to-pay for human papillomavirus vaccination among men who have sex with men in China: a discrete choice experiment.
    Vaccine. 2025;65:127806.
    >> Share

  433. JOHANSSON-LINDBOM B, Kitson G, Oostvogels L, Darsley M, et al
    Safety and immunogenicity of a single booster dose of the group B streptococcus AlpN candidate vaccine (GBS-AlpN) in previously vaccinated healthy women compared with a single dose in previously unvaccinated women.
    Vaccine. 2025;65:127820.
    >> Share

  434. HIRAGA K, Momose H, Kuribayashi W, Uemura M, et al
    Development of a novel safety assessment method for quality control of mRNA vaccines based on lung biomarker gene expression.
    Vaccine. 2025;65:127805.
    >> Share

  435. OGATA T, Hattori S, Kawachi K, Ishikane M, et al
    Durability of effectiveness of a booster dose of COVID-19 bivalent (ancestral/BA.4-5) vaccine against all-cause mortality in older adults in Japan, October 2022 to September 2023.
    Vaccine. 2025;65:127796.
    >> Share

  436. BRUCE AA, Gallagher K
    Determinants of measles second-dose vaccine coverage in the Gambia - a secondary analysis of 2019 demographic and health survey data.
    Vaccine. 2025;65:127789.
    >> Share

  437. ROMANOVA J, Krokhin A, Ferko B, Pleimes D, et al
    Protective efficacy of the UniFluVec influenza vaccine vector against the highly pathogenic influenza A/Indonesia/5/2005 (H5N1) strain in ferrets.
    Vaccine. 2025;65:127795.
    >> Share

  438. ASHRAF M, Ghafoor A, Suleman M, Mukhtar M, et al
    Gamma-irradiated Salmonella Gallinarum oral vaccine elicits robust cellular and humoral immune responses in a chicken model.
    Vaccine. 2025;65:127833.
    >> Share

  439. SHI N, Xiu S, Wang J, Shen Y, et al
    Subjective norms and perceived behavior control are more critical than attitudes in HPV vaccination: An investigation in China.
    Vaccine. 2025;65:127800.
    >> Share

  440. JOHN FA, Criollo V, Gaghan C, Armwood AR, et al
    Recombinant Lactococcus lactis-based oral vaccine expressing non-toxic alpha toxin domains of Clostridium septicum can offer protection against Clostridial dermatitis in turkeys.
    Vaccine. 2025;65:127801.
    >> Share

  441. PRAPATTANAKULLAWONG A, Sirisereewan C, Boonprakob R, Kamenkit O, et al
    Comparative evaluation of PRRSV MLV vaccine efficacy administered via intranasal and intramuscular routes in early age of piglets.
    Vaccine. 2025;65:127822.
    >> Share

  442. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
    Corrigendum to "Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa" [Vaccine 64 (2025) 127770].
    Vaccine. 2025;65:127797.
    >> Share

  443. ANDERSON KM, Nowak GJ, Cacciatore MA, Rohani P, et al
    Understanding influenza vaccination attitudes and behaviors: An assessment of health decision-making preferences.
    Vaccine. 2025;65:127804.
    >> Share

  444. LEE YH, Gwak E, Kang HM, Choe YJ, et al
    Safety of intradermal Danish- vs. transcutaneous Tokyo-strain BCG vaccination in Korean children: A nationwide cohort study.
    Vaccine. 2025;65:127828.
    >> Share

  445. CHAKRABORTY S, Dutta P, Pal A, Chakraborty S, et al
    FliC adjuvant augments protective efficacy of recombinant T2544 antigen against SalmonellaTyphiand Paratyphi A by increasing serum antibodies, intestinal secretory immunoglobulin A and T cell memory.
    Vaccine. 2025;64:127767.
    >> Share

  446. ISLAM MD, Kurosu T, Okawa M, Morikoshi N, et al
    Trace amounts of cobalt serve as an adjuvant for unglycosylated JEV-ED3 expressed in E. coli, inducing a potent virus-neutralizing immune response.
    Vaccine. 2025;64:127742.
    >> Share

  447. KIM SH, Lee H, Wi YM, Cho UJ, et al
    Transmission dynamics and risk factors for pertussis during the 2023-2024 outbreak in Korea.
    Vaccine. 2025;64:127726.
    >> Share

  448. SUN Y, Liu Y, Wang H, Guo Q, et al
    Immunogenicity and protection against infectious bursal disease via a transgenic Eimeria acervulina expressing IBDV VP2-2C3d fusion protein.
    Vaccine. 2025;64:127715.
    >> Share

  449. LEAKHENA PC, Awasthi S, Rabilloud M, Daw R, et al
    Pneumococcal colonization rates in children and adults in two developing countries: A prospective cross-sectional hospital-based study.
    Vaccine. 2025;64:127697.
    >> Share

  450. FANG X, Holding AC, Audet EC, Thai H, et al
    Understanding COVID-19 vaccination disparity among Black adults in North America: A two-study motivational approach.
    Vaccine. 2025;65:127803.
    >> Share

  451. WROBLEWSKI M, Meler A
    Vaccine acceptance and refusal in Western and Central and Eastern European countries: An analysis based on the European Social Survey data from 23 countries, using a classification and regression tree.
    Vaccine. 2025;65:127807.
    >> Share

    September 2025
  452. CLARKE M, McMillan M, Giles LC, Riley K, et al
    The impact of obesity on influenza Vaccine immunogenicity: A systematic review.
    Vaccine. 2025;65:127794.
    >> Share

  453. DOMINGUEZ ISLAS CP, Magaret CA, Molitor C, Serebryannyy L, et al
    SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines.
    Vaccine. 2025;65:127738.
    >> Share

  454. ZHANG CX, Quigley MA, Bankhead C, Varughese R, et al
    Ethnic inequities in childhood influenza vaccination coverage in England 2013-2021: An observational cohort study.
    Vaccine. 2025;65:127710.
    >> Share

  455. CAMPBELL PM, Ess GJ, Lale A, Talaat KR, et al
    Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews.
    Vaccine. 2025;65:127781.
    >> Share

  456. NOEL A, Zhang J, Nedumpun T, Sitthicharoenchai P, et al
    T cell-mediated clearance of porcine reproductive and respiratory syndrome virus (PRRSV) from the lung characterized by machine learning analysis in vaccinated and unvaccinated pigs.
    Vaccine. 2025;65:127793.
    >> Share

  457. CHAUDHRY T, Tum P, Morrow F, Hargreaves S, et al
    Facilitators to strengthening vaccine uptake post-pandemic amongst underserved populations considering social norms and health beliefs: a global systematic review.
    Vaccine. 2025;65:127769.
    >> Share

  458. ASHWINI MA, Gupta S, Lodha L, Ramachandran A, et al
    Immunogenicity of the abbreviated one-week intradermal rabies pre-exposure prophylaxis and its boostability in health-care workers: A retrospective observational cohort study.
    Vaccine. 2025;65:127787.
    >> Share

  459. CAO X, Borah P, Lee DKL, Vishnevskaya A, et al
    Beyond the post: The impact of politized anti-vaccine misinformation comments and challenges of correction on social media.
    Vaccine. 2025;65:127760.
    >> Share

  460. ZEEVAT F, Luttjeboer J, Korsten K, van Boven M, et al
    Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands.
    Vaccine. 2025;65:127735.
    >> Share

  461. ROSENBLUM HG, Carpenter CM, Trosclair T, Kaul R, et al
    Time intervals from vaccine administration to reimbursement for an updated Advisory Committee on Immunization Practices (ACIP) recommendation: Evidence from pneumococcal conjugate vaccinations among privately insured adults, 2021-2022.
    Vaccine. 2025;64:127665.
    >> Share

  462. SCHUE JL, Miller ES, Fesshaye B, Singh P, et al
    Corrigendum to "COVID-19 vaccine attitudes, beliefs, intentions and behaviors among pregnant women within the context of dynamic national policy recommendations in Brazil, Ghana, Kenya, and Pakistan" [Vaccine (2025) 127595].
    Vaccine. 2025 Sep 25:127768. doi: 10.1016/j.vaccine.2025.127768.
    >> Share

  463. BREZNIK JA, Miller MS, Bowdish DME
    Rationalizing recommendations for influenza and COVID-19 vaccines.
    Vaccine. 2025;65:127775.
    >> Share

  464. ANWARI P, Sume G, Meshreky W, Maele NV, et al
    Health economics and vaccine financing in the eastern Mediterranean region: A needs assessment.
    Vaccine. 2025;65:127780.
    >> Share

  465. YANG Z, Zhang S, Zhao Y, Ma X, et al
    A mosaic H3 subtype live attenuated influenza vaccine elicits broad immune responses to influenza a viruses.
    Vaccine. 2025;65:127776.
    >> Share

  466. PRZEDPELSKI A, Tepp WH, Gupta S, Barbieri JT, et al
    Nontoxic, multi-domain botulinum neurotoxin-LCHC(N) as vaccines against botulism.
    Vaccine. 2025;65:127779.
    >> Share

  467. VAN RIJN PA, Wernery U, Feddema AJ, Maris-Veldhuis MA, et al
    Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes.
    Vaccine. 2025;64:127772.
    >> Share

  468. HWANG LE, Lin KY, Tseng PH, Ho SY, et al
    Impact of 10-year measles, mumps and rubella booster vaccination program among healthcare personnel: a cross-sectional study.
    Vaccine. 2025;64:127758.
    >> Share

  469. CHO H, Jeong NY, Kim HJ, Lee HE, et al
    Intussusception risk after rotavirus vaccination in Korean infants.
    Vaccine. 2025;64:127782.
    >> Share

  470. SARTORI AL, Buffarini R, Bertoldi AD, da Silveira MF, et al
    Association between maternal influenza vaccination and childhood vaccination among participants of the 2015 Pelotas (Brazil) birth cohort.
    Vaccine. 2025;64:127761.
    >> Share

  471. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
    Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa.
    Vaccine. 2025;64:127770.
    >> Share

  472. PALACHE B, Fyyaz H, Thomson D, Taylor B, et al
    The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination.
    Vaccine. 2025;64:127747.
    >> Share

  473. HUI S, He R, Li H, Li Y, et al
    Revealing dynamic transcriptomic and immune cell signatures underlying heterogeneous responses to influenza vaccination.
    Vaccine. 2025;64:127777.
    >> Share

  474. SAIYED S, Dong E, Gardner LM
    The relationship between state vaccination exemption policies and MMR vaccination trends in the U.S.
    Vaccine. 2025;64:127773.
    >> Share

  475. ESPARZA J, Damaso CR
    The 1904 Rio De Janeiro vaccine revolt: Resistance to compulsory smallpox vaccination.
    Vaccine. 2025;64:127774.
    >> Share

  476. ALMEIDA GG, Pinto JA, Pinto PM, da Silva LB, et al
    Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19.
    Vaccine. 2025;64:127756.
    >> Share

  477. WROBEL-PAWELCZYK I, Golebiewska A, Ronkiewicz P, Kiedrowska M, et al
    Changes in the Streptococcus pneumoniae population responsible for invasive disease of young children after the implementation of conjugated vaccines in the National Immunization Program in Poland.
    Vaccine. 2025;64:127759.
    >> Share

  478. HUMPHREYS J, Blake A, Nicolay N, Braeye T, et al
    Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study.
    Vaccine. 2025;64:127752.
    >> Share

  479. QIAN Y, Phillips M, Eiden AL, Carias C, et al
    Family spillover effects in cost-effectiveness analyses of vaccines.
    Vaccine. 2025;64:127755.
    >> Share

  480. SCHIAVONE A, Edwards JC, Vigneswaran E, De Brito RCF, et al
    Evaluation of a strategy to enhance the efficacy and ease of application of porcine reproductive and respiratory syndrome virus vaccines.
    Vaccine. 2025;64:127757.
    >> Share

  481. HARIT D, Sawant S, Spreng RL, Gurley S, et al
    Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.
    Vaccine. 2025;64:127699.
    >> Share

  482. SCHERM MJ, Holzl R, Gonzalez-Dominguez I, Hjorth R, et al
    Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.
    Vaccine. 2025;64:127671.
    >> Share

  483. KORVES C, Kulldorff M, Balajee AS, Smith J, et al
    Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design.
    Vaccine. 2025;63:127658.
    >> Share

  484. LOUTH J, Holland A, Chum C, Morgan L, et al
    Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
    Vaccine. 2025;63:127647.
    >> Share

  485. GOLLUB EL, Myszkowski N, Xi M, Boyraz G, et al
    Correlates of higher trust in public health officials: results from a representative cohort of private university undergraduates.
    Vaccine. 2025;63:127610.
    >> Share

  486. HODGSON A, Haidara FC, Sow SO, Ansah PO, et al
    Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlers.
    Vaccine. 2025;64:127698.
    >> Share

  487. CUYPERS L, Dambre C, Desmet S
    Exceptional high number of IPD cases in winter season 2024-2025 in Belgium in concomitance with rise in vaccine serotypes.
    Vaccine. 2025;64:127763.
    >> Share

  488. BIZUAYEHU HY, Kebede Y, Deressa M, Solomon E, et al
    Pneumococcal carriage prevalence, serotype distribution, and vaccine coverage in Ethiopia 12 years after pneumococcal vaccine introduction.
    Vaccine. 2025;64:127762.
    >> Share

  489. KAHUSU CM, Peckeu-Abboud L, Goovaerts O, Matungulu E, et al
    Corrigendum to "Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC" [Vaccine 62 (2025) 127537].
    Vaccine. 2025;64:127719.
    >> Share

  490. INOUE S, Fuji K
    The mutual cyclical influence of internet information and vaccination intention on post-dissemination vaccination: A longitudinal study during the availability period of COVID-19 booster shots.
    Vaccine. 2025;64:127741.
    >> Share

  491. PIAL RH, Capeding MR, Tadesse BT, Excler JL, et al
    Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.
    Vaccine. 2025;64:127751.
    >> Share

  492. SHEN Y, Sung MH, Ge Y, Chen Y, et al
    Predicting influenza vaccine-elicited antibody responses with practical point systems.
    Vaccine. 2025;64:127737.
    >> Share

  493. HAMONIC G, Pastural E, Arora S, Lew J, et al
    Safety and immunogenicity of COVAC-2, a Sepivac SWE adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.
    Vaccine. 2025;64:127748.
    >> Share

  494. RAMACHANDRAN V, Tangney S, Gedlinske A, Askelson NM, et al
    Pneumococcal vaccination knowledge, attitudes, and practices among surveyed U.S. adults aged 19-64 years at increased risk for pneumococcal disease.
    Vaccine. 2025;64:127739.
    >> Share

  495. ODAGIRI T, Yoshino N, Sasaki Y, Ishikawa S, et al
    Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine.
    Vaccine. 2025;64:127750.
    >> Share

  496. TURJEMAN A, Shochat T, Drozdinsky G, Leibovici L, et al
    Disparities and temporal trends in pneumococcal vaccination uptake among older adults in the Israeli population: A population-based retrospective cohort study.
    Vaccine. 2025;64:127765.
    >> Share

  497. SEGEL JE, Luan P, Ramos ML, Zaorsky NG, et al
    Drivers of HPV vaccination rates among adolescent dependents in the military health system.
    Vaccine. 2025;64:127753.
    >> Share

  498. VAN BEEK LF, He X, Koks MS, van der Gaast-de Jongh CE, et al
    Comparing the immunogenicity of intradermal and intramuscular vaccination of elderly with BNT162b2 XBB.1.5: An equivalent dose study.
    Vaccine. 2025;64:127749.
    >> Share

  499. MANAQUIN R, Desmoulin A, Luong Nguyen LB, Kornblum D, et al
    Acceptance of chikungunya vaccination: a rapid survey in Reunion island during an epidemic.
    Vaccine. 2025;64:127720.
    >> Share

  500. LANE A, Quach HQ, Ovsyannikova IG, Kennedy RB, et al
    High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons.
    Vaccine. 2025 Sep 12:127677. doi: 10.1016/j.vaccine.2025.127677.
    >> Share

  501. SCHUE JL, Fesshaye B, Miller ES, Singh P, et al
    Examining the role of influence and trust in information sources on the COVID-19 vaccine decision-making process for pregnant and postpartum women in Brazil, Ghana, Kenya, and Pakistan: A mixed methods study.
    Vaccine. 2025 Sep 12:127721. doi: 10.1016/j.vaccine.2025.127721.
    >> Share

  502. HUANG W, Xu M, Diao Z, Chen J, et al
    Vaccination coverage by age 24 months among children born in 2020 and 2021 in China, during the COVID-19 pandemic: A study based on the national immunization information system.
    Vaccine. 2025;64:127717.
    >> Share

  503. KANG W, Wang F, Hao Z, Zhang Z, et al
    A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization.
    Vaccine. 2025;64:127743.
    >> Share

  504. YANG Y, Jin SW, Lee S, Lartey S, et al
    Understanding vaccine willingness in post-COVID America: Key determinants and demographic differences.
    Vaccine. 2025;64:127740.
    >> Share

  505. GARCIA-FOGEDA I, Abrams S, Vanhee S, Salloum M, et al
    Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo.
    Vaccine. 2025;64:127707.
    >> Share

  506. MOHAMED Y, Danchin M, Boyd L, Nightingale C, et al
    A scoping review of multicomponent interventions to improve uptake of routine childhood vaccines in low- and middle-income countries.
    Vaccine. 2025;64:127727.
    >> Share

  507. TIBAVIJA SS, Almario MP, Jaramillo V, Rivera J, et al
    Validation and evaluation of the rapid fluorescent focus inhibition test (RFFIT) for the quantification of neutralizing antibodies as an indirect measure of rabies vaccine relative potency: An alternative to the NIH test.
    Vaccine. 2025;64:127724.
    >> Share

  508. ASIM M, Jessani S, Saleem S, Yasmeen H, et al
    Myths, mandates, and decision-making: A qualitative exploration of COVID-19 vaccine hesitancy among pregnant and postpartum women in Pakistan.
    Vaccine. 2025 Sep 9:127722. doi: 10.1016/j.vaccine.2025.127722.
    >> Share

  509. SANFTENBERG L, Kraeker L, Walter F, Tsiligianni I, et al
    Associations between common mental disorders and vaccination readiness against seasonal influenza and Covid-19 of chronically ill adult patients in primary care - a systematic review.
    Vaccine. 2025;64:127682.
    >> Share

  510. ARSUFFI S, Rossi L, Colombo FR, Inverardi M, et al
    Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine.
    Vaccine. 2025;64:127723.
    >> Share

  511. DIEMERT DJ, Graciaa DS, Zhang B, Rouphael NG, et al
    Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial.
    Vaccine. 2025;64:127718.
    >> Share

  512. BARBERIA LG, Seelaender ICR, Carvalho RJ, de Moraes JC, et al
    Caregivers' attitudes toward school-based vaccination programs: A comparison of COVID-19, HPV, influenza, and dengue vaccines in Brazil.
    Vaccine. 2025;64:127709.
    >> Share

  513. CHAN YL, Chao YP, Li TL, Liao KW, et al
    Chitosan-based Oral DNA vaccine elicits mucosal immunity and reduces Helicobacter pylori colonization in mice.
    Vaccine. 2025;64:127692.
    >> Share

  514. BALMUTH A, Brennan T, Ashebir S, D'Ambrosio L, et al
    Examining the contributions of demographic variables to vaccination uptake among the U.S. aged 50.
    Vaccine. 2025;64:127711.
    >> Share

  515. WANG Y, Ni Y, Leung CMC, Ning K, et al
    Longitudinal patterns and predictors of COVID-19 vaccine confidence from pre-vaccine rollout to mass vaccination: A population-based cohort study.
    Vaccine. 2025;64:127736.
    >> Share

  516. ZHAO Y, Zhao Z, Cheng C, Tian M, et al
    A bivalent SARS-CoV-2 subunit vaccine for cats neutralizes both the original ancestral strain and BA.1 Pseudovirus carrying the 453F and 501 T mutation.
    Vaccine. 2025;64:127685.
    >> Share

  517. TINESSIA A, Sabahelzain MM, King C, Khalatbari-Soltani S, et al
    Systematic review of pro-equity strategies to improve vaccination among priority populations.
    Vaccine. 2025;64:127694.
    >> Share

  518. KISHINO H, Inoue S, Matsuoka O, Yagi M, et al
    Corrigendum to "A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naive Japanese adults >/=65 years of age" [Vaccine 62
    Vaccine. 2025;64:127688.
    >> Share

  519. HAMAD SAIED M, El Bied N, Khoury L, Vastert SJ, et al
    Safety, immunogenicity and efficacy of the Shingrix vaccine in immunocompromised varicella zoster virus naive pediatric patients.
    Vaccine. 2025;64:127708.
    >> Share

  520. MUES KE, Zhou CK, Gerber JE, van Hunsel F, et al
    A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic.
    Vaccine. 2025;64:127691.
    >> Share

  521. BOGA DJ, Robinson M, Tirupathi M, Juste RS, et al
    Latent class and time-to-event analyses of social determinants of health and COVID-19 vaccine uptake among Black women living with HIV.
    Vaccine. 2025;64:127649.
    >> Share

  522. HUANG YT, Tsou TP, Kuo SH, Huang YT, et al
    Assessment of influenza vaccine effectiveness among the elderly in Taiwan using population-based registry data for the 2023-2024 season.
    Vaccine. 2025;64:127690.
    >> Share

  523. ROY DN, Rashid M, Aktar A, Parvin MS, et al
    Potential predictors of COVID-19 booster vaccine confidence among adult people: a cross-sectional analysis amid the Omicron surge in Southern Bangladesh.
    Vaccine. 2025;64:127693.
    >> Share

  524. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2025;64:127667.
    >> Share

  525. BECKERS F, Karkada N, Yang Y, Scott J, et al
    Adopting the estimand framework in prophylactic vaccine trials.
    Vaccine. 2025;64:127645.
    >> Share

  526. NOSAN G, Cerkvenik Skafar A
    Screen first, vaccinate later: Enhancing tuberculosis vaccination safety through newborn immunodeficiency screening.
    Vaccine. 2025;64:127679.
    >> Share

  527. ZHOU Y, Wang H, Chu L, Chen K, et al
    Influenza vaccination hesitancy and decision between parental and grandparental caregivers of preschoolers: a comparative study.
    Vaccine. 2025;64:127696.
    >> Share

  528. ZHAO Z, Ma X, Milligan P, Cheung YB, et al
    Robust evaluation of vaccine effects based on estimation of vaccine efficacy curve.
    Vaccine. 2025;63:127673.
    >> Share

  529. OKOLI GN, Murphy C, Mak L, Cheng SMS, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study.
    Vaccine. 2025;63:127687.
    >> Share

  530. O'LEARY ST, Skenadore A, Mosley BS, Severson R, et al
    Boot camp translation: A novel method to increase human papillomavirus (HPV) vaccination uptake.
    Vaccine. 2025;63:127683.
    >> Share

  531. MAYERLEN LI, Wong TAS, To A, Smith O, et al
    Thermostable bivalent & trivalent filovirus vaccines from insect cells: potency demonstrated after 3 months and 2 years.
    Vaccine. 2025;64:127684.
    >> Share

  532. BALAM S, Kane F, Traore B, Konate D, et al
    Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
    Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680.
    >> Share

  533. HERNANDEZ NIETO A, Delgado D, Moreno VA, Lucero D, et al
    Factors influencing HPV vaccine initiation and intentions among Central American immigrant fathers in the United States: An exploratory cross-sectional study.
    Vaccine. 2025;63:127672.
    >> Share

  534. DAIGLE D, Morales G, Hayford K, Haridy H, et al
    Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).
    Vaccine. 2025;63:127669.
    >> Share

  535. HASAN Z, Masood KI, Qaiser S, Kanji A, et al
    Corrigendum to "Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains" [Vaccine 59 (2025) 127270].
    Vaccine. 2025;63:127686.
    >> Share

    August 2025
  536. DEBELLUT F, Jit M, Portnoy A, Mvundura M, et al
    Valuing combination vaccines: an incomplete picture and a pathway to a broader view.
    Vaccine. 2025;63:127675.
    >> Share

  537. NALUBEGA P, Namugumya R, Kyohere M, Seeley J, et al
    A mix of views: Perspectives on pregnant women's participation in maternal vaccine trials.
    Vaccine. 2025;63:127627.
    >> Share

  538. CHEON K, Buchwald UK, Hammitt LL, LeBlanc JJ, et al
    The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.
    Vaccine. 2025;62:127453.
    >> Share

  539. ZHAO Y, Li G, Li Q, Shi H, et al
    Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis.
    Vaccine. 2025;62:127622.
    >> Share

  540. STIMPSON JP, Tamirisa K, Morenz AM, Adhikari EH, et al
    Trust typologies and HPV awareness in the U.S.: a latent class analysis.
    Vaccine. 2025;62:127606.
    >> Share

  541. WU X, Xing J, Tang X, Sheng X, et al
    Temporal transcriptome analysis of head kidney revealed protective cellular immunity in flounder (Paralichthys olivaceus) immunized with inactivated Edwardsiella piscicida.
    Vaccine. 2025;62:127613.
    >> Share

  542. SSALI A, Nalubega P, Namugumya R, Kyohere M, et al
    Pregnant and breastfeeding women concerns during a group B Streptococcus phase ll clinical trial: A qualitative study in Kampala, Uganda.
    Vaccine. 2025;62:127592.
    >> Share

  543. PROCIANOY GS, Silveira RC, Procianoy RS
    Impact of the May 2024 floods on childhood immunization coverage in Rio Grande do Sul, Brazil.
    Vaccine. 2025;62:127573.
    >> Share

  544. SALOMAO MDG, de Almeida Leitao Curimbaba C, Braga PE, Franca JID, et al
    Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.
    Vaccine. 2025;62:127527.
    >> Share

  545. VAN DER WEG W, von Kreijfelt G, Davidson L, Zwaveling J, et al
    Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool.
    Vaccine. 2025;62:127549.
    >> Share

  546. SHIBUYA Y
    Culture filtrate proteins from Bacillus Calmette-Guerin.
    Vaccine. 2025;62:127486.
    >> Share

  547. RICHARDSON M, Daneman N, Miller FA, Sander B, et al
    Moving from intervention management to disease management for Clostridioides difficile infection: an economic evaluation exploring the impact of a systems approach to health technology assessment.
    Vaccine. 2025;62:127512.
    >> Share

  548. BROAD J, Letley L, Adair G, Walker J, et al
    An England-wide survey on attitudes towards antenatal and infant immunisation against respiratory syncytial virus amongst pregnant and post-partum women.
    Vaccine. 2025;62:127482.
    >> Share

  549. ARIYARAJAH A, Crowcroft NS, Brown KA, Wang J, et al
    Measles seroprevalence among individuals serologically tested in Ontario, Canada.
    Vaccine. 2025;62:127446.
    >> Share

  550. WAGNER SB, Rincon M, Keen KE, Hawk GS, et al
    SARS-CoV-2 breakthrough infection during pregnancy preferentially elicits IgG4 response and enhanced placental-transfer.
    Vaccine. 2025;62:127476.
    >> Share

  551. SANO K, Miyakawa K, Kato H, Kimura Y, et al
    Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
    Vaccine. 2025;62:127472.
    >> Share

  552. BAUSSANO I, Tenet V, Baghdasarova K, Harutyunyan Z, et al
    HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys.
    Vaccine. 2025;62:127405.
    >> Share

  553. WANG J, Zhao W, Bai S, Zhang A, et al
    Different patterns of antimicrobial non-susceptibility of the nasopharyngeal carriage of Streptococcus pneumoniae in areas with high and low levels of PCV13 coverage.
    Vaccine. 2025;62:127455.
    >> Share

  554. SCHMITT MM, Rossler A, Netzl A, Knabl L, et al
    Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns.
    Vaccine. 2025;62:127459.
    >> Share

  555. DEGIUSEPPE JI
    Comprehensive assessment of the impact of universal rotavirus vaccination program on the burden of diarrheal disease in children after 10 years of implementation in Argentina.
    Vaccine. 2025;63:127681.
    >> Share

  556. MORGAN JC, Kornides ML, Lee J, Fishman J, et al
    Different vaccination debunking interventions: a randomized, controlled experiment estimating "backfiring" and positive effects.
    Vaccine. 2025;62:127463.
    >> Share

  557. AKSUCU G, Caglar S
    Effects of telehealth during pregnancy on childhood vaccine attitudes and timeliness: A randomized controlled trial.
    Vaccine. 2025;63:127678.
    >> Share

  558. HATZL S, Posch F, Schulz E, Uhl B, et al
    Altered immune responses to mRNA vaccination against SARS-COV-2 are characterized by an impaired cross-talk between humoral and T-cellular immune compartments in patients with hematologic diseases.
    Vaccine. 2025;63:127666.
    >> Share

  559. CHEONG C, Choi WS, An JE, Cho J, et al
    Cost-effectiveness of including herpes zoster vaccines into the national immunization program in the Republic of Korea.
    Vaccine. 2025;63:127648.
    >> Share

  560. KITAMURA N, Tomo Y, Okuyama M, Ueda K, et al
    COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
    Vaccine. 2025;63:127656.
    >> Share

  561. FU JYL, Syed Omar SF, Rajasuriar R, Kukreja A, et al
    Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
    Vaccine. 2025;63:127657.
    >> Share

  562. COSGROVE S, Hider P, Anglemyer A, Walls T, et al
    HPV vaccination in Aotearoa New Zealand: Impact of a school-based program on adolescent vaccine coverage.
    Vaccine. 2025;63:127637.
    >> Share

  563. MARZO E, Guirado E, Taberner E, Castanyer S, et al
    A new method for testing avian metapneumovirus vaccine efficacy: Evaluation of tracheal ciliary activity after a challenge.
    Vaccine. 2025;63:127641.
    >> Share

  564. VASILEV K, Puente-Massaguer E, Hoxie I, Bushfield K, et al
    Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in mice.
    Vaccine. 2025;63:127626.
    >> Share

  565. MUTHURAMAN KR, Boonyakida J, Matsuda M, Suzuki R, et al
    Comparative immunogenicity study of quartet and bifurcated tetravalent dengue virus envelope domain III displayed virus-like particle vaccine candidates in BALB/c mice.
    Vaccine. 2025;63:127670.
    >> Share

  566. HOTEZ PJ
    COVID-19 vaccinations in America: Don't forget long COVID and the post-acute sequelae.
    Vaccine. 2025;63:127676.
    >> Share

  567. WARD JK, Youssef R, Peretti-Watel P
    Different vaccines, different trust issues? Disentangling the effect of trust in various institutions using dominance analysis.
    Vaccine. 2025;63:127668.
    >> Share

  568. ALMUKHTAR S, McWhirter N, Mendiola A, Samuel S, et al
    Exploring lingering COVID-19 vaccine hesitancy in three diverse U.S. states: Alabama, Illinois, and Texas.
    Vaccine. 2025;60 Suppl 1:127664.
    >> Share

  569. BARLOW M, Flanagan S, Ghosh I, Carter J, et al
    Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
    Vaccine. 2025;63:127639.
    >> Share

  570. BREWER SK, Lewis RM, Querec TD, Unger ER, et al
    Evaluation of possible human papillomavirus (HPV) type replacement after vaccine introduction, overall and by race/ethnicity, United States.
    Vaccine. 2025;62:127576.
    >> Share

  571. BEAULIEU A, LaMonaca K, Higginbottom J, Foster J, et al
    Utilizing the Program Impact Pathways framework for improving COVID-19 vaccine confidence and uptake: demonstrations of multi-sector collaboration from two geographies in Connecticut.
    Vaccine. 2025;60 Suppl 1:127623.
    >> Share

  572. PATEL C, Wang X, Giles M, Burns P, et al
    The role of serological testing for vaccination with a focus on immunocompromised patients: a synthesis of current evidence.
    Vaccine. 2025;63:127659.
    >> Share

  573. LI G, Marchevsky NG, Macaulay G, Aley P, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
    Vaccine. 2025;62:127597.
    >> Share

  574. MCDANIELS-DAVIDSON C, Parada H Jr, Martinez ME, Martinez LS, et al
    Validation of a parent HPV vaccine misperceptions scale and its association with children's HPV vaccination status.
    Vaccine. 2025;63:127616.
    >> Share

  575. GROOM HC, Kuntz JL, Varga AM, Smith N, et al
    Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine.
    Vaccine. 2025;63:127618.
    >> Share

  576. MARTORELL S, Ligda P, Rai S, Alward L, et al
    Efficacy of a candidate vaccine against Leishmania infantum on naturally exposed dogs to sand flies.
    Vaccine. 2025;63:127646.
    >> Share

  577. KASSAM P, Laurie C, El-Zein M, Tota JE, et al
    Impact of HPV vaccination on the incidence and clearance of HPV infections in sexually active young women.
    Vaccine. 2025;63:127632.
    >> Share

  578. CIESLA AA, Mak J, Godoshian A, Smith ZR, et al
    Symptom reporting and vaccination status among SARS-CoV-2-positive encounters - Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023-August 2024.
    Vaccine. 2025;63:127635.
    >> Share

  579. JEFFERS A, Kuiper NM, Ramakrishnan A, Swarna H, et al
    Building trust in community-academic partnerships: Strategies for enhancing vaccine confidence and demand - Lessons from Prevention Research Centers.
    Vaccine. 2025;60 Suppl 1:127624.
    >> Share

  580. DE SOUZA KSS, Lopes JM, Ribeiro RMR, Lescano CH, et al
    Genetic and molecular basis for low efficacy of vaccine strains against canine distemper virus in Brazil.
    Vaccine. 2025;62:127621.
    >> Share

  581. BRUCKER A, Hurst JH, O'Brien EC, Anderson D, et al
    An analytic approach considering two temporal mechanisms driving breakthrough viral infections after vaccination.
    Vaccine. 2025;63:127638.
    >> Share

  582. YOU D, Quan J, Bishai D, Lam WWT, et al
    Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong.
    Vaccine. 2025;63:127625.
    >> Share

  583. TSCHERNE A, Sun W, Liu STH, Krammer F, et al
    Mucosal COVID-19 vaccines in clinical development.
    Vaccine. 2025;63:127602.
    >> Share

  584. MACDONALD NE, Dube E, Graham JE
    Political vaccine hesitancy: not new but growing problem.
    Vaccine. 2025;63:127643.
    >> Share

  585. LUONG NGUYEN LB, Magloire L, Francois A, Billard D, et al
    Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
    Vaccine. 2025;63:127633.
    >> Share

  586. EDAO B, Upadhyay I, Zhang W
    Effect of 5 % lactose and 0.1 % polysorbate 80 buffer on protein-based multivalent ETEC vaccine candidate MecVax stabilization and immunogenicity.
    Vaccine. 2025;63:127634.
    >> Share

  587. CHAN MXJ, Khoo YK, Stona AC, Joarder T, et al
    Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.
    Vaccine. 2025;63:127607.
    >> Share

  588. ITO T, Yamaji Y, Sawada A, Nakayama T, et al
    Evaluation of immunogenicity of mumps vaccine strains in cotton rat (Sigmodon hispidus) model.
    Vaccine. 2025;63:127640.
    >> Share

  589. ZHANG X, Zhang X, Lu J, Yang P, et al
    The mRNA vaccine encoding Gc protein confers complete protection against severe fever with thrombocytopaenia syndrome virus.
    Vaccine. 2025;63:127631.
    >> Share

  590. LLOYD PC, Acharya G, Zhao H, Chen B, et al
    Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series analyses.
    Vaccine. 2025;63:127614.
    >> Share

  591. CHUVILEVA YE, Kuiper NM, Ramakrishnan A, Goodman K, et al
    Weaving a public health network: Process and results from an evaluation of CDC's Prevention Research Centers Vaccine Confidence Network.
    Vaccine. 2025;60 Suppl 1:127636.
    >> Share

  592. SHAW CA, Stewart-Jones GBE, Jorquera P, Narayanan E, et al
    Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus.
    Vaccine. 2025;63:127589.
    >> Share

  593. CAI H, Jia B, Song Z, Wang L, et al
    Real-world safety of herpes zoster vaccines: A pharmacovigilance study based on the vaccine adverse event reporting system (may 2006-december 2024).
    Vaccine. 2025;63:127628.
    >> Share

  594. KARRAS J, Harrison M, Danchin M, Kaufman J, et al
    Supporting dialogue amongst multicultural communities: Exploring the role of vaccine champions.
    Vaccine. 2025;63:127629.
    >> Share

  595. KOCER AT, Durasi E, Kuscu E, Amasya H, et al
    Piercing the future of vaccination: the revolutionary role of microneedle-based systems in healthcare advancements.
    Vaccine. 2025;63:127612.
    >> Share

  596. MORSTEAD T, Loo N, Sin NL, DeLongis A, et al
    COVID-19 hoax belief endorsement and its implications for vaccine uptake: Investigating the role of perceived threat.
    Vaccine. 2025;63:127630.
    >> Share

  597. ALBERS AN, Fox ER, Michels SY, Daley MF, et al
    Late initiation of pneumococcal and Haemophilus influenzae type b vaccinations.
    Vaccine. 2025;62:127611.
    >> Share

  598. BUHL C, Jacobsen R, Traulsen JM, Andersen A, et al
    Validation of the Danish translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2025;62:127620.
    >> Share

  599. VARISKALLIO S, Moustgaard H, Remes H, Martikainen P, et al
    Association of parental education with adolescents' COVID-19 vaccine uptake: A nationwide register-based study in Finland.
    Vaccine. 2025;63:127615.
    >> Share

  600. LANKIEWICZ E, Mpemba JKN, Dikassa PSL, Masiala VM, et al
    Trends in vaccination coverage and equity in the Democratic Republic of the Congo from 2017 to 2023.
    Vaccine. 2025;62:127609.
    >> Share

  601. ROEL E, Henderson E, Valmayor S, Porthe V, et al
    Effectiveness of CONFIVAC, an intervention to enhance paediatric nurses and paediatricians skills to promote vaccination: A mixed-methods cluster randomized trial.
    Vaccine. 2025;62:127603.
    >> Share

  602. JEONG NY, Cho S, Lim E, Lee JR, et al
    COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
    Vaccine. 2025;63:127619.
    >> Share

  603. COSTELLO LM, Kerns EK, McCulloh RJ, Roberts JR, et al
    Corrigendum to "Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children" [Vaccine 61 (2025) 127245].
    Vaccine. 2025;62:127584.
    >> Share

  604. ASHRAF M, Stein AN, Youhanna J, Rockman S, et al
    The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness.
    Vaccine. 2025;62:127393.
    >> Share

  605. BAUR C, Saperstein SL, Griffis RL, Vazquez C, et al
    Implementing a co-design approach to facilitate a COVID-19 vaccination rapid response.
    Vaccine. 2025;62:127585.
    >> Share

  606. LINDSEY KM, Farrell Z, Tutino R, Kowalski-Dobson T, et al
    From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.
    Vaccine. 2025;62:127593.
    >> Share

  607. ARAKAWA T, Uefuji H, Tamaki Y, Oogai S, et al
    Corrigendum to "B subunit of the type 2 Shiga toxin e variant (Stx2e) bundled by a five-stranded alpha-helical coiled coil protects piglets from porcine edema disease" [Vaccine 61 (2025) 127140].
    Vaccine. 2025;62:127582.
    >> Share

  608. VARMA A, Andrews NJ, Carazo S, Walter K, et al
    Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: Report from a meeting of the World Health Organization.
    Vaccine. 2025;62:127567.
    >> Share

  609. GIACANI L, Romeis E, Haynes A, Molini BJ, et al
    Immunization with full-length TprC variants induces a broad response to surface-exposed epitopes of the Treponema pallidum repeat protein family and is partially protective in the rabbit model of syphilis.
    Vaccine. 2025;61:127406.
    >> Share

  610. KORHONEN MJ, Polkki M, Anttila VJ, Klemets P, et al
    Healthcare resource use and costs associated with episodes of laboratory confirmed invasive pneumococcal disease in adults in Finland 2016-2022.
    Vaccine. 2025;61:127398.
    >> Share

  611. ZHOU L, Yang Y, Mo C, Zhu Y, et al
    Human adenovirus penton dodecahedron nanoparticles induce an enhanced neutralizing antibody response in mouse model.
    Vaccine. 2025;61:127380.
    >> Share

  612. MARQUEZ AC, Beitari S, Valadbeigy T, Sbihi H, et al
    COVID-19 serological survey utilizing antenatal serum samples in British Columbia.
    Vaccine. 2025;61:127310.
    >> Share

  613. KURTZ SL, Gould V, Flores-Valdez MA, Elkins KL, et al
    Recombinant BCGDeltaBCG1419c protects outbred mice against M. tuberculosis challenge.
    Vaccine. 2025;61:127347.
    >> Share

  614. XIANG W, Pan B, Hao Y, Wang F, et al
    Chimeric virus-like particles replacing the loop on the surface of VP60 from rabbit hemorrhagic disease virus (RHDV) provide protection against two serotypes of RHDV.
    Vaccine. 2025;61:127427.
    >> Share

  615. ARAKAWA T, Uefuji H, Tamaki Y, Oogai S, et al
    B subunit of the type 2 Shiga toxin e variant (Stx2e) bundled by a five-stranded alpha-helical coiled coil protects piglets from porcine edema disease.
    Vaccine. 2025;61:127140.
    >> Share

  616. MCDONALD JU, Hosken NA, Engelhardt OG
    Assessing commutability of the first WHO International Standard for antiserum to respiratory syncytial virus.
    Vaccine. 2025;61:127430.
    >> Share

  617. REYBURN R, Russell FM, Munywoki PK, Franzel L, et al
    Designing effectiveness and impact studies for respiratory syncytial virus immunisation in low- and middle-income countries.
    Vaccine. 2025;61:127397.
    >> Share

  618. SCHUTT CR, Birol D, Lu X, Yamasaki S, et al
    The presenting HLA determines fidelity of SARS-CoV-2 spike protein epitope prediction.
    Vaccine. 2025;61:127381.
    >> Share

  619. WANG Y, Lu G
    Global, regional, and national epidemiology of pertussis in children from 1990 to 2021.
    Vaccine. 2025;61:127378.
    >> Share

  620. ANEZ G, McGarry A, Woo W, Kotloff KL, et al
    Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).
    Vaccine. 2025;61:127362.
    >> Share

  621. GAO RY, Hu T, Taylor AW, Lacey R, et al
    Assay for rapid quantification of capped and tailed intact mRNA.
    Vaccine. 2025;61:127339.
    >> Share

  622. NGOCHO JS, van der Gaast-de Jongh CE, Sebba J, Mtei M, et al
    Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under five years of age in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication.
    Vaccine. 2025;61:127336.
    >> Share

  623. NGOCHO JS, van der Gaast de Jongh CE, Sebba J, Mtei M, et al
    Corrigendum to "Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication" [Vaccine 48 (2025) 1
    Vaccine. 2025;61:127335.
    >> Share

  624. ROBERTS C, Top KA, Henaff L, Tunis M, et al
    Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network.
    Vaccine. 2025;62:127581.
    >> Share

  625. BHAT S, Basak P, Verma S, Siddiqui K, et al
    Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination.
    Vaccine. 2025;62:127604.
    >> Share

  626. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Corrigendum to "Social processes, practical issues, and COVID-19 vaccination among hesitant adults" [Vaccine 41(35) (2023) 5150-5158].
    Vaccine. 2025;62:127583.
    >> Share

  627. YAMEY G, Beyrer C
    The dismantling of the U.S. vaccine regulatory framework.
    Vaccine. 2025;62:127557.
    >> Share

  628. GAO L, Zhang X, Mo X, Sun Y, et al
    Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.
    Vaccine. 2025;62:127596.
    >> Share

  629. HUNTER OF, McClymont E, Lau O, Bettinger JA, et al
    Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortium.
    Vaccine. 2025;62:127594.
    >> Share

  630. LUVIRA V, Lawpoolsri S, Phumratanaprapin W, Jongkaewwattana A, et al
    Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).
    Vaccine. 2025;62:127601.
    >> Share

  631. WEI H, Wang Y, Jiang S, Zhang X, et al
    The roles of tissue-resident memory T cells (TRMs) in diseases and vaccine development: A comprehensive review.
    Vaccine. 2025;62:127605.
    >> Share

  632. HURLEY F, Balanuta MS, Flanagan P
    Barriers and facilitators associated with migrant parents' decisions regarding childhood vaccinations: A mixed methods systematic review.
    Vaccine. 2025;62:127588.
    >> Share

  633. VASILIADIS S, Cook J, Nissan K, Cook W, et al
    Vaccine misinformation among Arabic-speakers in Australia and the audience and appetite for a game-based intervention.
    Vaccine. 2025;62:127599.
    >> Share

  634. ORTIZ-PRADO E, Kyriakidis NC, Lopez-Cortes A, Vasconez-Gonzalez J, et al
    Current and emerging Mpox vaccine strategies: A comprehensive review.
    Vaccine. 2025;62:127598.
    >> Share

  635. NAHAR N, Parveen S, Gurley ES, Ghosh PK, et al
    Community willingness to participate in a Nipah vaccine trial in Bangladesh.
    Vaccine. 2025;62:127578.
    >> Share

  636. MCGEE RE, Barrett DA, Bednarczyk RA, Grant-Whitlock M, et al
    Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.
    Vaccine. 2025;60 Suppl 1:127587.
    >> Share

  637. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.
    Vaccine. 2025;62:127580.
    >> Share

  638. NUZHATH T, Khobragade N, Regan AK, Pinkney JA, et al
    Pregnant women's perceptions of RSVpreF vaccine and Nirsevimab for infant RSV prevention.
    Vaccine. 2025;62:127590.
    >> Share

  639. IMHOF C, Liu S, Messchendorp AL, Sanders JF, et al
    The phenotype and functionality of spike-specific CD4(+) T cells after COVID-19 vaccination associates with time after transplantation in transplant recipients.
    Vaccine. 2025;62:127600.
    >> Share

  640. HORIKOSHI Y, Toizumi M
    Pediatric tuberculosis and BCG vaccine in Japan.
    Vaccine. 2025;62:127564.
    >> Share

  641. LI J, Zhao D, Zi T, Huang R, et al
    Evolving trends in HPV vaccination coverage among women aged 9-45 in Chengdu, China: insights from 2017 to 2023.
    Vaccine. 2025;62:127579.
    >> Share

  642. JAYARAJ VJ, Husin M, Tok PSK, Ismail MZH, et al
    Assessing the relative vaccine effectiveness of a fourth COVID-19 dose on hospitalization in Malaysia amidst evolving omicron variants: An emulated target trial.
    Vaccine. 2025;62:127569.
    >> Share

  643. BORG A, Goulding M, Minkah P, Perrone D, et al
    Promotion of COVID-19 vaccination for youth and families in Worcester, Massachusetts: a Diffusion of Innovations approach.
    Vaccine. 2025;60 Suppl 1:127586.
    >> Share

  644. SCHUE JL, Miller ES, Fesshaye B, Singh P, et al
    COVID-19 vaccine attitudes, beliefs, intentions and behaviors among pregnant women within the context of dynamic national policy recommendations in Brazil, Ghana, Kenya, and Pakistan.
    Vaccine. 2025 Aug 6:127595. doi: 10.1016/j.vaccine.2025.127595.
    >> Share

  645. CHAN YT, Chair SY, Gao RT, Ng MH, et al
    Retraction notice to "Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis" [Vaccine 56 (2025) 127182].
    Vaccine. 2025 Aug 6:127570. doi: 10.1016/j.vaccine.2025.127570.
    >> Share

  646. SIU JY
    Barriers to COVID-19 vaccinations and moral struggle among nurses in a Chinese community: A critical medical anthropology analysis.
    Vaccine. 2025;62:127574.
    >> Share

  647. JARVI SI, Osuna A, Pitt WC, Farias M, et al
    Efficacy of a PP2A vaccine for Angiostrongylus costaricensis against rat lungworm disease caused by Angiostrongylus cantonensis in wild-caught rats (Rattus rattus) in Hawaii.
    Vaccine. 2025;62:127532.
    >> Share

  648. LIDSTROM AK, Albinsson B, Sund F, Lindback J, et al
    Adverse drug reactions following SARS-CoV-2 vaccination of 3805 healthcare workers cause substantial sick-leave and are correlated to vaccine regimen, age, sex and serological response.
    Vaccine. 2025;62:127553.
    >> Share

  649. THORN N, Karampatsas K, Le Doare K, Heath PT, et al
    Progress towards a Group B streptococcal vaccine - where are we now?
    Vaccine. 2025;62:127575.
    >> Share

  650. CHEN Y, Jiang N, Jiao Y, Chen J, et al
    Analysis of HPV vaccination and influencing factors among 9-14-year-old girls in underdeveloped areas of northwestern China: A cross-sectional survey report on guardians.
    Vaccine. 2025;62:127568.
    >> Share

  651. OSMENAJ T, van Roon A, Labuschagne L, Pijpers J, et al
    Determinants for not keeping up to date with COVID-19 vaccination in the 2023 vaccination round among medical risk groups, the Netherlands.
    Vaccine. 2025;62:127561.
    >> Share

  652. XU S, Sy LS, Contreras R, Powers DA, et al
    Differences in COVID-19 XBB.1.5 vaccination coverage: A decomposition analysis across racial and ethnic groups in a large U.S. healthcare system.
    Vaccine. 2025;62:127577.
    >> Share

  653. KISHINO H, Inoue S, Matsuoka O, Yagi M, et al
    A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naive Japanese adults >/=65 years of age.
    Vaccine. 2025;62:127456.
    >> Share

  654. SAVAS LS, Cuccaro P, Zhang K, Hernandez R, et al
    Factors influencing COVID-19 vaccine uptake among vulnerable communities in Texas: Perceptions of 2-1-1 helpline callers.
    Vaccine. 2025;60 Suppl 1:127554.
    >> Share

  655. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 ope
    Vaccine. 2025;62:127562.
    >> Share

  656. LIU R, Patel A, Liu H, Du X, et al
    Influenza vaccination in patients with heart failure compared to usual practice: A model-based cost-effectiveness analysis.
    Vaccine. 2025;62:127566.
    >> Share

  657. AUTHIE P, Souque P, Moncoq F, Noirat A, et al
    Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses.
    Vaccine. 2025;62:127563.
    >> Share

  658. CHOI WS, Lee J, Ottaviano C, Samson S, et al
    Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study.
    Vaccine. 2025;62:127521.
    >> Share

  659. MORO PL, Getahun A, Romanson B, Marquez P, et al
    Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.
    Vaccine. 2025;62:127497.
    >> Share

  660. CARLTON JG, Pamba D, Ryan N, Olomi W, et al
    Facilitators and barriers to implementation of HPV vaccination in Tanzania: a mixed-methods study exploring perspectives from national, subnational, and community stakeholders, 2018-2023.
    Vaccine. 2025;62:127560.
    >> Share

  661. RONG Z, Jiao M, Tian L, Wang X, et al
    PRRSV vector vaccine based on VEEV-VSVG recombinant replicon elicits efficient immune responses in piglets.
    Vaccine. 2025;62:127572.
    >> Share

    July 2025
  662. TOTZKAY D, Fraustino JD, Costello LM, Jarrett T, et al
    Building on West Virginia's innovative COVID-19 public health communication: associations between vaccination beliefs and vaccination messaging, partisanship, and social vulnerability.
    Vaccine. 2025;60 Suppl 1:127555.
    >> Share

  663. GAO S, Cai M, Su M, Zhao T, et al
    Influencing factors and trends in post-vaccination serologic testing completion rates among infants born to HBsAg-positive mothers in Guangdong Province, 2021-2023.
    Vaccine. 2025;62:127565.
    >> Share

  664. SCAIOLI G, Martella M, Moro GL, Mara A, et al
    Assessing vaccination intentions and perceptions among pregnant women in Italy: A multicenter cross-sectional study in the context of mandatory policies and the COVID-19 pandemic.
    Vaccine. 2025;62:127528.
    >> Share

  665. EL HINDI T, Anugulruengkitt S, Lapphra K, Limkittikul K, et al
    Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.
    Vaccine. 2025;62:127558.
    >> Share

  666. MOREIRA J, Patino EG, Braga PE, Pacheco P, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial.
    Vaccine. 2025;62:127559.
    >> Share

  667. GENOVA P, Phung CF, Dickens BL, Lim JM, et al
    Trust in government, science, and vaccine confidence in Southeast Asia: A latent profile analysis.
    Vaccine. 2025;62:127536.
    >> Share

  668. FEDELE G, Schiavoni I, Trentini F, Leone P, et al
    Six-month follow-up of antibody response to bivalent mRNA SARS-CoV-2 vaccine booster in healthcare workers.
    Vaccine. 2025;62:127524.
    >> Share

  669. O'CONNOR MH, Nyman AL, Ali S, Rothenberg R, et al
    Increasing vaccine uptake in a refugee resettlement community with high social vulnerability.
    Vaccine. 2025;60 Suppl 1:127552.
    >> Share

  670. HUANG Q, Peng W, Liu S, Kuznekoff JH, et al
    Identifying factors associated with intention to recommend HPV vaccination among US parents with vaccinated children.
    Vaccine. 2025;62:127543.
    >> Share

  671. CHUNG H, Krishnasamy M, Joyce T, Dryden T, et al
    Recommendations for innovation in vaccination services for adults with haematological malignancies: an Australian cross-sectional survey study.
    Vaccine. 2025;62:127539.
    >> Share

  672. ZHONG CC, Yang Z, Chen M, Li Z, et al
    Factors associated with willingness among adults to receive pneumococcal vaccine in Hong Kong: a cross-sectional study using HBM constructs.
    Vaccine. 2025;62:127544.
    >> Share

  673. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time.
    Vaccine. 2025;62:127556.
    >> Share

  674. FURUICHI M, Omoto Y, Arimitsu T, Ohnishi T, et al
    Post-vaccination fever in infants: Real-world data analysis using a childcare mobile application.
    Vaccine. 2025;62:127551.
    >> Share

  675. LEITE FL, Arruda P, Ford B, Jordan D, et al
    Oral live bivalent Salmonella vaccine reduces clinical disease, colonization and fecal shedding of multidrug resistant Salmonella enterica serovar I 4,[5],12:i:
    Vaccine. 2025;62:127540.
    >> Share

  676. KANG Y, Zhang F, Vogt TM
    Where do children get vaccinated in the U.S.? Parental experiences, attitudes, and beliefs about place of vaccination with a focus on pharmacies and schools.
    Vaccine. 2025;62:126801.
    >> Share

  677. KANG Y, Zhang F, Vogt TM
    Parental attitudes, beliefs, and experiences related to pediatric COVID-19 vaccination.
    Vaccine. 2025;62:127043.
    >> Share

  678. DIRAY-ARCE J, Chang AC, Moradipoor S, Amodio D, et al
    Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.
    Vaccine. 2025;62:127504.
    >> Share

  679. XU S, Sy LS, Hong V, Qian L, et al
    Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study.
    Vaccine. 2025;62:127548.
    >> Share

  680. CUEVAS FI
    Commentary: Processes of pre-clinical and clinical vaccine development public data sharing within the NIAID collaborative influenza vaccine innovation centers (CIVICs).
    Vaccine. 2025;62:127547.
    >> Share

  681. ENGLISH S, Fedosyuk S, Orliacq F, Tem V, et al
    Rabies glycoprotein engineering for improved stability and expression.
    Vaccine. 2025;62:127541.
    >> Share

  682. XIA Y, Guo X, Fu X, Wang F, et al
    Knowledge, perception, and practice regarding meningococcal vaccination in infants 3-7 months of age: A nationwide cross-sectional study in China.
    Vaccine. 2025;62:127542.
    >> Share

  683. OMOLE T, Weinberg AS, Azizad M, Greenberg D, et al
    A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older.
    Vaccine. 2025;62:127514.
    >> Share

  684. SINGH A, Mahapatra B, Srivastava A, Singh S, et al
    Corrigendum to "Antigens activated SOCS3(+)CD200R(+)CD4(+) T cells are critical to Leishmania pathogenesis and a distinctive target for vaccine development" [Vaccine 62 (2025) 127501].
    Vaccine. 2025;62:127546.
    >> Share

  685. TANG E, Arnold BF, Acharya NR
    Shingles vaccination in Medicare Part D and commercial enrollees after the inflation reduction act.
    Vaccine. 2025;62:127545.
    >> Share

  686. OKUNO H, Arai S, Suzuki M, Kikkawa T, et al
    The importance of spontaneous thought in the willingness to receive the human papillomavirus vaccine.
    Vaccine. 2025;62:127469.
    >> Share

  687. ANDERSEN KM, Ahi T, Mateus JS, Yu T, et al
    2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims.
    Vaccine. 2025;62:127534.
    >> Share

  688. RIZZO KR, Yen CJ, Quint J, Hoover C, et al
    Sociodemographic disparities in COVID-19 and RSV vaccine uptake among California adults >/=60 years old who received influenza vaccination.
    Vaccine. 2025;62:127535.
    >> Share

  689. SAIAG E, Shalit R, Alcalay Y, Hasday I, et al
    Cellular and humoral immune responses to SARS-CoV2, comparing previously infected individuals who received one vaccine dose to uninfected individuals after three vaccine doses: A case-control study.
    Vaccine. 2025;62:127525.
    >> Share

  690. BERGER MN, Mathieu E, Bin YS, Davies C, et al
    Validation of the Microarray Patch for Vaccination (MAPVac) scale to measure the perceptions of safety, usability, and acceptability.
    Vaccine. 2025;62:127538.
    >> Share

  691. PERESON MJ, Badano MN, Sabbione F, Keitelman I, et al
    Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants.
    Vaccine. 2025;62:127526.
    >> Share

  692. ELKINS KL, Mittereder LR, De Pascalis R, Singer AW, et al
    Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection.
    Vaccine. 2025;62:127523.
    >> Share

  693. ZAIDAN AL, Grossi de Oliveira AL, Brito RMM, Bueno LL, et al
    Evaluation of MHC class I-binding peptides from Leishmania spp. for vaccine development against visceral leishmaniasis.
    Vaccine. 2025;62:127531.
    >> Share

  694. KAHUSU CM, Peckeu-Abboud L, Goovaerts O, Matungulu E, et al
    Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC.
    Vaccine. 2025;62:127537.
    >> Share

  695. LIN YC
    Letter to the Editor: Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
    Vaccine. 2025 Jul 23:127533. doi: 10.1016/j.vaccine.2025.127533.
    >> Share

  696. BRANDYS P, Albarino CG, Jain S, Merenkova I, et al
    A mRNA vaccine encoding for a 60-mer Nipah virus G glycoprotein nanoparticle elicits a robust neutralizing antibodies response against the Nipah virus.
    Vaccine. 2025;62:127530.
    >> Share

  697. CHISNALL G, Letley L, Mounier-Jack S, Bedford H, et al
    Corrigendum to "I want to chat with a person": a qualitative longitudinal cohort study in England exploring drivers of sub-optimal childhood vaccination uptake" [Vaccine 62 (2025) 127462].
    Vaccine. 2025;62:127522.
    >> Share

  698. VISKUPIC F, Wiltse DL, Djira G
    RSV vaccine uptake among seniors: A path analysis approach.
    Vaccine. 2025;62:127505.
    >> Share

  699. SHETTY AN, Kattan GS, Javed M, Pearce C, et al
    Validating community concerns of menstrual changes associated with COVID-19 vaccination using a self-controlled case series analysis of real-world data.
    Vaccine. 2025;62:127511.
    >> Share

  700. ALFAQEEH M, Ewart S, Tanoto R, Buenastuti W, et al
    New adult and adolescent tuberculosis vaccines and Indonesia: policy planning and evidence, November 2024.
    Vaccine. 2025;62:127490.
    >> Share

  701. DALEXIS RD, Muray M, Kibret TC, Farahi SMMM, et al
    Factors related to COVID-19 vaccine effectiveness perception in racially diverse adults in Canada.
    Vaccine. 2025;62:127498.
    >> Share

  702. ASKARI MS, Macaraig M, Ternier A, Crouch B, et al
    Racial and ethnic differences among Mpox vaccination recipients by vaccination facility type in New York City-August-December 2022.
    Vaccine. 2025;62:127520.
    >> Share

  703. DIONNE M, Sauvageau C, Ward JK, Sylvain-Morneau J, et al
    COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey.
    Vaccine. 2025;62:127529.
    >> Share

  704. LI J, Wang X, Zhang D, Xie F, et al
    Safety and immunogenicity of thiomersal-free recombinant hepatitis E vaccine: A randomized, double-blind, active-controlled study.
    Vaccine. 2025;62:127510.
    >> Share

  705. EXCLER JL, Saluja T, Wilder-Smith A, Kaminski RW, et al
    Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.
    Vaccine. 2025;62:127515.
    >> Share

  706. CARDENAS-GARZON K, Agudelo MC, Tovar-Aguirre OL, Reuter C, et al
    Understanding the decline in HPV vaccination in Colombia: A population-based analysis of girls and parents in early rollout cohorts.
    Vaccine. 2025;62:127507.
    >> Share

  707. MUNOZ FM, Kampmann B, Stergachis A, Chaudhary M, et al
    A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women.
    Vaccine. 2025;62:127513.
    >> Share

  708. BARRET AS, Francois C, Deghmane AE, Lefrancois R, et al
    Increase in invasive Haemophilus influenzae type b disease in young children despite high vaccination coverage, France, 2018-2024.
    Vaccine. 2025;62:127499.
    >> Share

  709. GWAK E, Choe SA, Kim K, Bolormaa E, et al
    Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea.
    Vaccine. 2025;62:127496.
    >> Share

  710. ABHIRAM A, Krishnan R, Ahalya AK, Shaji S, et al
    Development of oral vaccine using calcium phosphate nanoparticles conjugated with outer membrane protein of Aeromonas hydrophila in Oreochromis niloticus (Tilapia).
    Vaccine. 2025;62:127508.
    >> Share

  711. STIEHL E, Borg A, Cullen JP, Mendiola A, et al
    Engaging trusted messengers in public health response: Key strategies to building community trust among CDC'S prevention research center's vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127474.
    >> Share

  712. TAO T, Ni Y, Shi N, Yang X, et al
    Human papillomavirus vaccination coverage and willingness among women in mainland China: A meta-analysis based on the COM-B model.
    Vaccine. 2025;62:127519.
    >> Share

  713. BOSTIC TD, Hook SA, Marx GE
    Lyme disease vaccine acceptability among healthcare providers - United States, 2018 and 2022.
    Vaccine. 2025;62:127495.
    >> Share

  714. KAMACHI K, Kenri T
    A novel 96-well in vitro assay for assessing pertussis toxin activity in the final products of acellular pertussis combination vaccines.
    Vaccine. 2025;62:127516.
    >> Share

  715. PICKERING H, Valli E, Carlock MA, Cappelletti M, et al
    Influenza strain-specific T cell responses longitudinally post-vaccination with FluZone.
    Vaccine. 2025;62:127506.
    >> Share

  716. GASHTI AB, Patel M, Chahal PS, Hrapovic S, et al
    Purification and functional characterization of gag-spike virus-like particles: Process optimization for efficient vaccine production.
    Vaccine. 2025;62:127500.
    >> Share

  717. MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
    Influenza vaccine effectiveness against absenteeism among healthcare personnel during the 2022-2023 season in Greece.
    Vaccine. 2025;62:127468.
    >> Share

  718. GORDY JT, Zheng JJ, Maxwell AR, Bates RE, et al
    MIP3alpha-Rel(Mtb) intranasal DNA vaccination induces reactive T-cell infiltration into the lungs of mice and macaques.
    Vaccine. 2025;62:127517.
    >> Share

  719. FEDERICI C, Silva SS, Koh M, Malvolti S, et al
    Priority setting for improved influenza vaccines: a multi-criteria decision analysis.
    Vaccine. 2025;60 Suppl 2:127470.
    >> Share

  720. VAN TRUONG L, Thuy LT, Hien LT, Tran TQM, et al
    From controversy to confidence: Strengthening dengue vaccines safety reporting.
    Vaccine. 2025;62:127489.
    >> Share

  721. LIMAYE RJ, Fesshaye B, Miller ES, Singh P, et al
    Exploring COVID-19 vaccination behavior: A cross-country study among pregnant and postpartum women in Brazil, Ghana, Kenya, and Pakistan.
    Vaccine. 2025 Jul 14:127478. doi: 10.1016/j.vaccine.2025.127478.
    >> Share

  722. GUZUN N, Ouakki M, Panicker G, Ionescu IG, et al
    Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years.
    Vaccine. 2025;62:127475.
    >> Share

  723. SINGH A, Mahapatra B, Srivastava A, Singh S, et al
    Antigens activated SOCS3(+)CD200R(+)CD4(+) T cells are critical to Leishmania pathogenesis and a distinctive target for vaccine development.
    Vaccine. 2025;62:127501.
    >> Share

  724. REEVES EL, Dascomb K, Irving SA, Klein NP, et al
    Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age.
    Vaccine. 2025;62:127483.
    >> Share

  725. SCHUE JL, Okwaro F, Gichere I, Cherono D, et al
    COVID-19 vaccine attitudes and behaviors among pregnant women in Nairobi, Kenya with diverse socio-economic and educational backgrounds.
    Vaccine. 2025 Jul 12:127480. doi: 10.1016/j.vaccine.2025.127480.
    >> Share

  726. HARA-HUBBARD KK, Flores Moreno MG, Sanchez M, Abdi N, et al
    The partnership for vaccine confidence: community-academic partnerships to promote COVID-19 vaccines to underserved urban and rural communities using the listen, plan, act, evaluate process.
    Vaccine. 2025;60 Suppl 1:127487.
    >> Share

  727. VERA R, Isabella R, Di Chiara C, Anna C, et al
    Sociodemographic and socioeconomic disparities in pediatric influenza vaccination: A cohort study from the pedianet network.
    Vaccine. 2025;62:127494.
    >> Share

  728. LIU P, Sang Z, Liu K, Zhang M, et al
    Mycobacterium tuberculosis Hsp70 as a cancer vaccine adjuvant: Immunomodulatory mechanisms and tumor microenvironment remodeling.
    Vaccine. 2025;62:127493.
    >> Share

  729. GREENBERG BM, Minna JD, Gerber DE, Hernandez RS, et al
    SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population.
    Vaccine. 2025;62:127473.
    >> Share

  730. DANIEL O, Srikanth S, Clarke P, Le Doare K, et al
    Pertussis antibody responses in infants born to mothers vaccinated at different time points in pregnancy.
    Vaccine. 2025;62:127481.
    >> Share

  731. RYDLOVA A, Smith E, Stuart A, Shattock R, et al
    Development of a live-attenuated vaccine challenge model of Yersinia pestis in humans: Expert consultation on clinical trial considerations, January 2025.
    Vaccine. 2025;62:127492.
    >> Share

  732. MOHANTY S, Zurovac J, Barna M, Cossrow N, et al
    Changes in pneumococcal vaccination disparities by area-level social vulnerability during the COVID-19 pandemic among Medicare and Medicaid enrollees.
    Vaccine. 2025;62:127452.
    >> Share

  733. LIN J, Dai Z, Li C, He WQ, et al
    Change in herpes zoster vaccination uptake before and during the COVID-19 pandemic in the United States older adults.
    Vaccine. 2025;62:127503.
    >> Share

  734. MARANGOU J, Beaton A, Fulurija A, Carapetis J, et al
    Cardiac monitoring safety assessment framework for early phase group a streptococcal vaccine trials.
    Vaccine. 2025;60:127334.
    >> Share

  735. NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
    Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
    Vaccine. 2025;60:127323.
    >> Share

  736. STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al
    Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
    Vaccine. 2025;60:127290.
    >> Share

  737. PIAL RH, Capeding MR, Song KR, Park EL, et al
    Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study.
    Vaccine. 2025;60:127304.
    >> Share

  738. LI H, Zhang J, Guo R, Li J, et al
    Immunogenicity evaluation of a recombinant pseudorabies virus co-expressing PCV2 and PCV3 capsid proteins in mice and piglets.
    Vaccine. 2025;60:127307.
    >> Share

  739. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Corrigendum to "Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey" [Vaccine 41(41) (2023) 6120-6126].
    Vaccine. 2025;62:127485.
    >> Share

  740. JESSANI S, Asim M, Saleem S, Nausheen S, et al
    Analyzing attitudes toward COVID-19 vaccine decision making among pregnant women in Pakistan.
    Vaccine. 2025 Jul 11:127479. doi: 10.1016/j.vaccine.2025.127479.
    >> Share

  741. DE MATHIA F, Kargl T, Muller M, Erdem I, et al
    Purification and characterization of recombinant neuraminidase as a potentially broadly protective influenza virus vaccine candidate.
    Vaccine. 2025;62:127471.
    >> Share

  742. ZLOTNICK C, Castel OC
    The predictors of full, partial and no COVID-19 vaccination among immigrants and non-immigrants.
    Vaccine. 2025;62:127484.
    >> Share

  743. MURATA M, Matsumoto Y, Shimono N
    Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1.
    Vaccine. 2025;62:127457.
    >> Share

  744. CHISNALL G, Letley L, Mounier-Jack S, Bedford H, et al
    "I want to chat with a person": a qualitative longitudinal cohort study in England exploring drivers of sub-optimal childhood vaccination uptake.
    Vaccine. 2025;62:127462.
    >> Share

  745. ODZIEMCZYK-STAWARZ I, Perek-Bialas J
    What may influence older Europeans' decision about the seasonal influenza vaccine? A literature review of socio-cultural and psycho-social factors related to seasonal influenza vaccination uptake.
    Vaccine. 2025;61:127265.
    >> Share

  746. ANDRAWEERA PH, Wang B, Danchin M, Blyth CC, et al
    Randomised controlled trials of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccine uptake among pregnant women (EPIC study) in Australia.
    Vaccine. 2025;62:127477.
    >> Share

  747. MALLICK K, Handunge VL, Emmons KM, Blondet L, et al
    Engaging a community health ambassador model to promote COVID-19 vaccine in three Massachusetts communities.
    Vaccine. 2025;60 Suppl 1:127464.
    >> Share

  748. ABE M, Kuzuhara S, Kino Y
    Corrigendum to "Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells" [Vaccine 21(17-18) (2003) 1989-1994].
    Vaccine. 2025;61:127426.
    >> Share

  749. ABEL ZDV, Roope LSJ, Violato M, Clarke PM, et al
    Accuracy of online surveys in predicting COVID-19 uptake and demand: A cohort study investigating vaccine sentiments and switching in 13 countries from 2020 to 2022.
    Vaccine. 2025;62:127450.
    >> Share

  750. EDDY AC, Speaks S, Roth M, Roettger JE, et al
    IFITM3-deficient mice as a model for testing influenza virus vaccines via the intramuscular route.
    Vaccine. 2025;62:127458.
    >> Share

  751. JIA M, Cao Y, Mu X, Ren D, et al
    School-based interventions to increase influenza vaccination in primary school students.
    Vaccine. 2025;62:127442.
    >> Share

  752. MARTINS RM, Marques CMC, Noronha TG, Engstrom EM, et al
    Immunogenicity, safety and immunological memory of a Brazilian meningococcal C conjugate vaccine on a phase II clinical trial.
    Vaccine. 2025;62:127419.
    >> Share

  753. SPRACKLEN TF, Day J, Van Der Ross H, Butters C, et al
    Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.
    Vaccine. 2025;62:127461.
    >> Share

  754. LAZARUS R, Kasstan-Dabush B, Ali I, Mounier-Jack S, et al
    Influenza vaccine delivery models in secondary care (hospital) settings: What approaches are used to enhance access for clinical risk groups in England?
    Vaccine. 2025;62:127445.
    >> Share

  755. WAGNER AL, Floyd C
    Impact of shingles vaccine tolerability on initiation and completion of the two-dose series in adults 50 years and older.
    Vaccine. 2025;62:127465.
    >> Share

  756. LI H, Dekker A, Zhang Y, Zhang Y, et al
    Novel liquid-phase blocking ELISA using single-domain antibody M8 and virus-like particles for in-vitro potency assessment of foot-and-mouth disease virus-like particle vaccine.
    Vaccine. 2025;62:127466.
    >> Share

  757. GILROY J, O'Leary M, Domegan L, O'Connor L, et al
    Increasing the uptake of Live Attenuated Influenza Vaccine through a new school-based vaccination programme in Ireland.
    Vaccine. 2025;62:127467.
    >> Share

  758. MIHIN HUSKIC I, Bensic M, Kretonic K, Miskulin I, et al
    Duration of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after primary homologous vaccination or first infection.
    Vaccine. 2025;62:127440.
    >> Share

  759. CUTLAND CL, Gutu K, Yun JA, Izu A, et al
    Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries.
    Vaccine. 2025;62:127441.
    >> Share

  760. PLATE A, Jager L, Di Gangi S, Pichierri G, et al
    A multifaceted, targeted intervention to improve human papillomavirus vaccination rates in general practice: A pragmatic cluster-randomized controlled trial.
    Vaccine. 2025;62:127444.
    >> Share

  761. PIERCE SR, Shi H, Caetano C, Prots DA, et al
    Self-amplifying mRNA expressing COBRA hemagglutinin elicits long-lasting, broadly reactive antibodies against seasonal influenza A viruses.
    Vaccine. 2025;62:127449.
    >> Share

  762. WANG L, Han W, Li D, Wang S, et al
    Immunogenicity and safety of sequential Sabin strain inactivated poliovirus vaccine from different manufacturers in infants: Randomized, blinded, controlled trial.
    Vaccine. 2025;61:127448.
    >> Share

  763. GIULIANO AR, Beltrame A, Villa LL, Lazcano-Ponce E, et al
    Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial
    Vaccine. 2025;61:127447.
    >> Share

  764. AL-KASSAB-CORDOVA A, Mezones-Holguin E, Kaufman JS
    Education as a mediator of ethnic disparities in adult COVID-19 vaccination in Peru.
    Vaccine. 2025;61:127436.
    >> Share

  765. YANAGI Y, Ichikawa H, Nguyen LBT, Hayashi A, et al
    mRNA vaccination mitigates pathological retinochoroidal neovascularization in animal models.
    Vaccine. 2025;61:127451.
    >> Share

  766. WILTON J, Velasquez Garcia HA, Naveed Z, Crabtree A, et al
    COVID-19 vaccine uptake and effectiveness among people with recent history of injection drug use in British Columbia, Canada: A retrospective analysis.
    Vaccine. 2025;61:127423.
    >> Share

  767. YU L, Chen C, He G, Meng Y, et al
    Oral vaccination with live Mycoplasma pneumoniae elicits a respiratory protective immunity in a murine model.
    Vaccine. 2025;61:127460.
    >> Share

  768. ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
    Cost-effectiveness and budget impact analyses of the 24-valent pneumococcal conjugate vaccine in adults aged 50 and older.
    Vaccine. 2025;61:127433.
    >> Share

  769. OSTROWSKY JT, Vestin NC, Mehr AJ, Ulrich AK, et al
    Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.
    Vaccine. 2025;61:127431.
    >> Share

  770. HANSEN S, Thomsen K, Mattsson AH, Comstedt P, et al
    Pseudomonas aeruginosa vaccine identified by the AI-immunology platform improves outcomes in a murine biofilm lung infection model.
    Vaccine. 2025;61:127416.
    >> Share

  771. AUROUX M, Fabacher T, Sauleau E, Arnaud L, et al
    Pneumococcal and influenza vaccination coverage and impact on COVID-19 infection severity in patients with inflammatory rheumatic diseases: A French National Healthcare Database analysis.
    Vaccine. 2025;61:127439.
    >> Share

  772. FREITAS C, Cooper CL, Kroch AE, Moineddin R, et al
    COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, Canada.
    Vaccine. 2025;61:127422.
    >> Share

  773. KAHN KE, Santibanez TA, Jain A, Zhou T, et al
    Parental reasons for non-receipt of influenza vaccination among children 6 months-17 years and changes over time, 2015-2024.
    Vaccine. 2025;61:127415.
    >> Share

    June 2025
  774. CHAN CCY, Ooi JSG, Koh CWT, Ong EZ, et al
    AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults.
    Vaccine. 2025;61:127396.
    >> Share

  775. CENAT JM, Beogo I, Dalexis RD, Muray M, et al
    Racial disparities in the rates of COVID-19 vaccine uptake among children from Arab, Asian, Black, Indigenous, White and Mixed racial families in Canada.
    Vaccine. 2025;61:127421.
    >> Share

  776. MACHIDA M, Inoue S, Furuse Y, Oka E, et al
    Exploring the knowledge and attitude toward respiratory syncytial virus vaccine and associated factors among pregnant women in Japan during the early post-marketing phase.
    Vaccine. 2025;61:127434.
    >> Share

  777. SONG Z, Ma Y, Jiao L, Yu R, et al
    Lovastatin enhanced immune response to avian influenza vaccine in chickens and changed mRNA expression in the bursa of fabricius.
    Vaccine. 2025;61:127438.
    >> Share

  778. CROKER Z, McLure A, Pillsbury A, Deng L, et al
    Reduction in self-reported adverse events in Australian adults after change to national immunisation schedule from polysaccharide to conjugate pneumococcal vaccine, 2016-2022.
    Vaccine. 2025;61:127432.
    >> Share

  779. SHINJOH M, Tamura K, Yamaguchi Y, Fukushima H, et al
    Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine.
    Vaccine. 2025;61:127429.
    >> Share

  780. TENUZZO M, Cacciamali A, Lelli D, Foglia EA, et al
    Development of an autogenous vaccine against encephalomyocarditis in pigs.
    Vaccine. 2025;61:127417.
    >> Share

  781. CARTER D, De La Rosa G, Garcon N, Moon HM, et al
    The success of toll-like receptor 4 based vaccine adjuvants.
    Vaccine. 2025;61:127413.
    >> Share

  782. ROSENTHAL S, Chuah ASF, Kim HK, Ho SS, et al
    Direct and indirect experiences, risk perceptions, and vaccine booster intention: A mediation study in Singapore using secondary risk theory.
    Vaccine. 2025;61:127435.
    >> Share

  783. KHOURY G, Spelman T, Jones P, Macesic N, et al
    Varicella zoster virus reactivation episodes and vaccination uptake in Spleen Australia registrants.
    Vaccine. 2025;61:127391.
    >> Share

  784. MA M, Zou J, Zeng X, Hu X, et al
    Bivalent fusion protein vaccine induces protective immunity against SARS-CoV-2 and Staphylococcus aureus.
    Vaccine. 2025;61:127411.
    >> Share

  785. SHAW J, Fergie JE, Conway JH, Marshall GS, et al
    Risks of removing the age 11-12-year meningococcal vaccine dose from the US immunization schedule.
    Vaccine. 2025;61:127428.
    >> Share

  786. BELLER NS, Beller M, Murmann JJ, Crisp RW, et al
    Impact of the medical briefing and vaccine type on adverse events following COVID-19 vaccination: A randomized clinical trial.
    Vaccine. 2025;61:127392.
    >> Share

  787. SONG Y, Feng Y, Jiang F, Xu X, et al
    The HBV seroprevalence and immune responses to hepatitis B vaccination among college students from four universities in China.
    Vaccine. 2025;61:127408.
    >> Share

  788. LANGLEY RJ, Clow F, Peterken K, Chan JYH, et al
    Refinement of a novel staphylococcal superantigen-like poly protein vaccine.
    Vaccine. 2025;61:127437.
    >> Share

  789. TONG S, Litwin SM, Epel ES, Lin J, et al
    COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response.
    Vaccine. 2025;61:127420.
    >> Share

  790. CACERES CF
    Letter to the editor RE: "Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case".
    Vaccine. 2025 Jun 23:127412. doi: 10.1016/j.vaccine.2025.127412.
    >> Share

  791. JWA S, Imanishi Y, Ascher MT, Dudley MZ, et al
    Communication interventions to reduce parental vaccine hesitancy: A systematic review.
    Vaccine. 2025;61:127401.
    >> Share

  792. KURTZ SL, Gould V, Flores-Valdez MA, Elkins KL, et al
    Corrigendum to "Recombinant BCGDeltaBCG1419c protects outbred mice against M. tuberculosis challenge" [Vaccine 61 (2025) 127347].
    Vaccine. 2025;61:127418.
    >> Share

  793. CHAULAGAIN S, Sachithanandham J, Liu JA, Creisher PS, et al
    COVID-19 vaccine (NVX-CoV2373 and NVX-CoV2540) doses and virus strain match impact sex- and age-specific immunity and protection in mice.
    Vaccine. 2025;61:127409.
    >> Share

  794. MBURU CN, Ojal J, Selim R, Ombati R, et al
    Seroprevalence of Immunoglobulin G against measles and rubella over a 12-year period (2009-2021) in Kilifi, Kenya and the impact of the Measles-Rubella (MR) vaccine campaign of 2016.
    Vaccine. 2025;61:127425.
    >> Share

  795. LEON-ARCIA K, Perez-Leal G, Quintero-Alvarez H, Zamora-Loyarte DI, et al
    Dual Abeta/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy.
    Vaccine. 2025;61:127414.
    >> Share

  796. YI Z, Owusu-Edusei K, Elbasha EH
    Economic evaluation of PCV21 in PCV-naive adults aged 50-64 years in the United States.
    Vaccine. 2025;59:127264.
    >> Share

  797. MARIJAM A, Marijic P, Puggina A, Cailloux O, et al
    Older adults' and physicians' preferences for respiratory syncytial virus vaccination in Germany and Italy: A discrete choice experiment.
    Vaccine. 2025;61:127390.
    >> Share

  798. SAMY A, Alber A, Fife M, Hammond JA, et al
    IFITM knockout DF1 cells produce higher influenza and newcastle disease viral yields: a proof of concept for avian origin cell-based vaccine production.
    Vaccine. 2025;61:127360.
    >> Share

  799. BRUMBAUGH KQ, de Figueiredo A, Gellert FR, Casas FR, et al
    Drivers of HPV vaccine hesitancy in New York and Florida.
    Vaccine. 2025;61:127395.
    >> Share

  800. IZZODDEEN A, Elhussien M, Abdalla O, Rashid MSJ, et al
    Vaccination against cholera in crisis: Coverage and cost efficiency in Sudan (2023-2024).
    Vaccine. 2025;61:127402.
    >> Share

  801. MISHINA M, Cao W, Ende Z, Sharma SS, et al
    Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel.
    Vaccine. 2025;61:127361.
    >> Share

  802. CHOQUE-GUEVARA R, Poma-Acevedo A, Montesinos-Millan R, Sernaque-Aguilar Y, et al
    Chimeric designs of rabies virus glycoprotein G enhance baculovirus pseudotyping and immunogenicity in mice: influence of the transmembrane domain and a flexible linker.
    Vaccine. 2025;61:127404.
    >> Share

  803. TSENG WP, Wu JL, Lin CH, Kang CM, et al
    Safety, immunogenicity, and breakthrough infection of nine homologous or heterologous COVID-19 vaccination booster regimens in healthy adults: A prospective study in Taiwan.
    Vaccine. 2025;61:127383.
    >> Share

  804. KOFF WC, Holtzman DM
    Accelerating development of vaccines for prevention and control of Alzheimer's disease.
    Vaccine. 2025;61:127410.
    >> Share

  805. PATZINA A, Trubner M, Lehmann J, Brinkhaus B, et al
    Attitudes towards conventional and non-conventional medical approaches and their relation to COVID-19 vaccination: Insights from Germany.
    Vaccine. 2025;61:127403.
    >> Share

  806. MUSTAJAB T, Kwamboka MS, Khan I, Song D, et al
    Immunologic responses to an extracellular vesicle-based vaccine expressing the full suite of SARS-CoV-2 structural proteins.
    Vaccine. 2025;61:127407.
    >> Share

  807. PHUMRATTANAPRAPIN W, Shalash AO, Skwarczynski M, Smout MJ, et al
    Development of an efficacious oral peptide vaccine against infection with the carcinogenic liver fluke Opisthorchis viverrini.
    Vaccine. 2025;61:127400.
    >> Share

  808. PURCELL RA, Aurelia LC, Allen LF, Bond KA, et al
    Genetic markers of enhanced functional antibody responses to COVID-19 vaccination.
    Vaccine. 2025;61:127379.
    >> Share

  809. BEZELJAK U, Jerman A, Kobal T, Birsa E, et al
    Development of multivalent SARS-CoV-2 virus-like particle vaccine candidates.
    Vaccine. 2025;61:127394.
    >> Share

  810. HANSEN BT, Dahl J, Greve-Isdahl M, Winje BA, et al
    Low and inequitable influenza and COVID-19 vaccination coverage among pregnant women in Norway: Nationwide population-based cohort study.
    Vaccine. 2025;61:127386.
    >> Share

  811. PUENTE-MASSAGUER E, Vasilev K, Krammer F
    Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice.
    Vaccine. 2025;61:127388.
    >> Share

  812. ESPARZA J
    The illness of empress Maria Theresa as a trigger for the adoption of variolation in Austria (1768).
    Vaccine. 2025;58:127253.
    >> Share

  813. LUYTEN J, van Hoek AJ
    Reasons for excluding adverse events in cost-effectiveness analyses of vaccines: A survey amongst authors.
    Vaccine. 2025;61:127341.
    >> Share

  814. JORDAN Z, Roderick M, Marlow R, Rowland E, et al
    "I'm not aware of anyone having died from chickenpox?": Acceptability of varicella vaccination in the UK, a mixed methods questionnaire and interview study.
    Vaccine. 2025;61:127322.
    >> Share

  815. HASSAN IA, Araoye JB, Olawuyi DA, Effiong FB, et al
    Malaria vaccine implementation in Nigeria: Addressing the coverage challenges within the national immunization program for high impact.
    Vaccine. 2025;61:127376.
    >> Share

  816. FAWOLE A, Boyer B, Shahid M, Bharali I, et al
    What are the key features of an equitable global vaccine strategy for the next pandemic? A qualitative study of pandemic control experts.
    Vaccine. 2025;61:127377.
    >> Share

  817. QIN XX, Deng M, Wu J, Yang J, et al
    Cellular response, persistent humoral response and efficacy elicited by a CV-A16 vaccine candidate in mice.
    Vaccine. 2025;61:127276.
    >> Share

  818. OMAR M, Shibli H, Edelstein M
    Comparative impact of the COVID-19 pandemic on parental behaviour towards childhood vaccination in Israel and the United Kingdom: A self-controlled matched cross-sectional study.
    Vaccine. 2025;61:127385.
    >> Share

  819. KEUTLER A, Lainka E, Hudert C, Bufler P, et al
    Erratum to "Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study" [Vaccine 59 (2025) 127288].
    Vaccine. 2025;61:127357.
    >> Share

  820. BERGER MN, Davies C, Mathieu E, Harmer-Ross J, et al
    Perceived safety, usability, and acceptability of microarray patches for vaccination among key populations: A mixed methods study.
    Vaccine. 2025;61:127387.
    >> Share

  821. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 17-21 February 2025.
    Vaccine. 2025;61:127384.
    >> Share

  822. DONG X, Schillie SF, McNamara LA, Leidner AJ, et al
    Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the United States.
    Vaccine. 2025;61:127332.
    >> Share

  823. MARTINS RM, Maia MLS, Camacho LAB, Noronha TG, et al
    Phase II/III randomized immunogenicity and safety study of a Brazilian meningococcal serogroup B vaccine in children.
    Vaccine. 2025;61:127363.
    >> Share

  824. SIEVERS BL, Sievers EL
    It's time to change how we vaccinate for measles.
    Vaccine. 2025;61:127382.
    >> Share

  825. LAPEYRE R, Rezk N, McClean S, Moore AC, et al
    Systematic mapping review of preclinical and clinical studies of Staphylococcus aureus vaccines.
    Vaccine. 2025;61:127333.
    >> Share

  826. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Psychometric validation of the COVID-19 vaccine hesitancy scale for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;61:127368.
    >> Share

  827. GARFIELD S, Ali F, Murdan S
    Enhancing faith and interfaith based facilitators and reducing related barriers to enhance vaccine acceptance: a qualitative study.
    Vaccine. 2025;61:127348.
    >> Share

  828. ROSENMAN KD, Wang L
    Variation of COVID-19 vaccination percentage by industry and occupation in Michigan.
    Vaccine. 2025;61:127349.
    >> Share

  829. TSCHERNE A, Krammer F
    A review of currently licensed mucosal COVID-19 vaccines.
    Vaccine. 2025;61:127356.
    >> Share

  830. KIM SH, You SH, Lee JW, Kim E, et al
    Association between COVID-19 vaccination and first healthcare utilization for chronic obstructive pulmonary disease: A nationwide population-based cohort study.
    Vaccine. 2025;61:127367.
    >> Share

  831. DUSSAULT JM, Rivera Torres AF, Oudin Doglioni D, Gagneux-Brunon A, et al
    The effect of school-based interventions on HPV vaccine-related knowledge, attitudes, and practices among adolescents in France: Secondary results from the PrevHPV trial.
    Vaccine. 2025;61:127344.
    >> Share

  832. ARCOLACI A, Guidolin L, Olivieri E, Bilo MB, et al
    A real-life multicenter experience for the post-pandemic management of hypersensitivity reactions to Covid-19 vaccines.
    Vaccine. 2025;61:127337.
    >> Share

  833. MOSHIRIAN FARAHI SMM, Xu Y, Dort J, Caulley L, et al
    Factors associated with COVID-19 vaccine confidence among Arab, Asian, Black, Indigenous, and White individuals in Canada: Latent profile analyses.
    Vaccine. 2025;61:127358.
    >> Share

  834. WILLIS DE, Moore R, Selig JP, Amin NS, et al
    Corrigendum to "Pediatric HPV vaccination: Provider recommendations matter among hesitant parents" [Vaccine 42(25) (2025) 126166].
    Vaccine. 2025;61:127343.
    >> Share

  835. MARIN-CABA E, Benavente-Fernandez A, Morales-Jimenez G, Comino-Fernandez S, et al
    Evaluation of vaccine uptake and opportunity of in-hospital vaccination against pneumococcus in vulnerable hospitalized patients.
    Vaccine. 2025;61:127364.
    >> Share

  836. LIU X, Li J, Zha Y, Wang Z, et al
    The efficacy and safety of SYN023 (Zamerovimab and Mazorelvimab injection), the recombinant humanized anti-rabies virus monoclonal antibody mixture, combined with rabies vaccine in a WHO category III rabies post-exposure population: A randomized, doub
    Vaccine. 2025;61:127289.
    >> Share

  837. MOK CC, Chan KL, Tse SM
    Long-term immunogenicity of a live attenuated herpes zoster vaccine in patients with systemic lupus erythematosus.
    Vaccine. 2025;61:127365.
    >> Share

  838. CHAIWONG W, Takheaw N, Laopajon W, Nisoong C, et al
    Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics.
    Vaccine. 2025;61:127330.
    >> Share

  839. ROUX K, Roux F, Burns S, Guy R, et al
    Effective strategies in human papillomavirus (HPV) vaccination interventions to increase uptake in rural, low socioeconomic, indigenous and migrant populations: A scoping review.
    Vaccine. 2025;61:127359.
    >> Share

  840. MOHAMMADI S, Sisay MM, Saraswati PW, Osman AK, et al
    COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials.
    Vaccine. 2025;61:127342.
    >> Share

  841. COSTELLO LM, Kerns EK, McCulloh RJ, Roberts JR, et al
    Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children.
    Vaccine. 2025;61:127245.
    >> Share

  842. KIM C, Lee D, Oh YW, Jung SJ, et al
    Association between parental and child influenza vaccination: A national health survey analysis.
    Vaccine. 2025;61:127345.
    >> Share

  843. KOBAYASHI K, Masuda K, Wu JT, Lin L, et al
    Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial.
    Vaccine. 2025;61:127327.
    >> Share

  844. HALONEN A, Fan HSL, Masina S, Chooniedass R, et al
    Understanding COVID-19 vaccine hesitancy during parenthood in British Columbia.
    Vaccine. 2025;61:127305.
    >> Share

  845. HU XX, Qin ZZ, Mo ZY, Wang R, et al
    Timeliness and completeness of serial routine vaccinations among 8062 rural children in southwest China during the COVID-19 pandemic: A multi-stage stratified cluster sampling survey in 1094 villages.
    Vaccine. 2025;61:127346.
    >> Share

  846. ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Poland GA, et al
    RSV vaccines and Guillain-Barre syndrome: Insights into an emerging concern.
    Vaccine. 2025;61:127338.
    >> Share

  847. AKTHER A, Laurie C, Elton-Marshall T, Ly V, et al
    Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review.
    Vaccine. 2025;61:127331.
    >> Share

  848. JOLFAYI AG, Alipour S, Aminizadeh S, Yaghoubi SM, et al
    Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.
    Vaccine. 2025;61:127340.
    >> Share

  849. WAN JIA AARON H, Yuan R, Chan SCS
    Socio-demographic and behavioral predictors of multiple-dose COVID-19 vaccine uptake among older adults in Hong Kong: A community-based cross-sectional study of the generations connect project.
    Vaccine. 2025;61:127308.
    >> Share

    May 2025
  850. NG YF, Lockhart K, Dawar M, Vigor D, et al
    Assessing measles immunity among healthcare workers, a systematic review of peer-reviewed literature (2013-2023). Where do we go from here?
    Vaccine. 2025;57:127214.
    >> Share

  851. STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
    Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
    Vaccine. 2025;57:127232.
    >> Share

  852. SIDORENKO SV, Rennert W, Zhdanov KV, Lobzin YV, et al
    Serotype dynamics of Streptococcus pneumoniae in some countries in Eastern Europe and Central Asia.
    Vaccine. 2025;57:127213.
    >> Share

  853. LIEN SB, Yang QW, Huang HW, Chiu KC, et al
    A novel immunogen comprising a bc loop and mutant fusion loop epitopes generates potent neutralization and protective abilities against flaviviruses without risk of disease enhancement.
    Vaccine. 2025;57:127219.
    >> Share

  854. BREWER NT, Rockwell EM, Tomar A, Fisher EB, et al
    Covid-19 vaccine incentives' effectiveness and differential impact on high-risk groups: A prospective cohort study.
    Vaccine. 2025;61:127302.
    >> Share

  855. SAYEM ASM, Musuka G, Atuhebwe PL, Dadari I, et al
    Childhood vaccination catch-up and recovery plans for mitigating immunity gap post the COVID-19 pandemic: A case study of selected African countries.
    Vaccine. 2025;61:127328.
    >> Share

  856. HARTON PE, Chamberlain AT, Moore A, Fletcher G, et al
    Estimating COVID-19 vaccine effectiveness among children and adolescents using data from a school-based weekly COVID-19 testing program.
    Vaccine. 2025;61:127292.
    >> Share

  857. COBELENS F, Pelzer PT, Churchyard GJ, Garcia-Basteiro A, et al
    Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants.
    Vaccine. 2025;61:127301.
    >> Share

  858. DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al
    Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus disease-19 pandemic.
    Vaccine. 2025;61:127329.
    >> Share

  859. YADAV G, Dandu H, Malhotra HS, Jain A, et al
    COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study.
    Vaccine. 2025;60:127325.
    >> Share

  860. HUNG CT, Wang LM, Liu DC
    National trends and disparities in herpes zoster vaccination coverage among U.S. older adults with cancer, 2008-2023.
    Vaccine. 2025;60:127326.
    >> Share

  861. NASREEN S, Jiang Y, Lu H, Lee A, et al
    Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
    Vaccine. 2025;60:127291.
    >> Share

  862. ESCOBAR-ZIEDE P, Borras-Bermejo B, Pinos-Tella L, Vivet-Escale M, et al
    Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative case-control study.
    Vaccine. 2025;59:127295.
    >> Share

  863. ABE M, Shinmura Y, Tokieda Y, Mitsuhiro Y, et al
    A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naive healthy adults.
    Vaccine. 2025;60:127313.
    >> Share

  864. ABU-RAYA B, Giles ML, Kollmann T
    Co-administration of vaccines in pregnancy: unique challenges and knowledge gaps.
    Vaccine. 2025;60:127309.
    >> Share

  865. SEILER P, Kaplan BS, Brice DC, Duan S, et al
    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
    Vaccine. 2025;60:127311.
    >> Share

  866. BHATIA D, Crowcroft N, Antoni S, Danovaro-Holliday MC, et al
    Prediction of subnational-level vaccination coverage estimates using routine surveillance data and survey data.
    Vaccine. 2025;60:127277.
    >> Share

  867. SENPUKU K, Kunishima Y, Taniguchi K, Ito T, et al
    Development and characterization of MRC-5 and Vero cell-adapted enterovirus D68 strains for vaccine production.
    Vaccine. 2025;60:127314.
    >> Share

  868. LEE N, Nguyen L, Nasreen S, Austin PC, et al
    Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada.
    Vaccine. 2025;60:127300.
    >> Share

  869. KATSEFF AS, Toumanios C, Barahim E, McCormick AA, et al
    PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response.
    Vaccine. 2025;60:127306.
    >> Share

  870. DEVKOTA B, Lal BK, Gautam A, Poudel L, et al
    Nationwide rollout of HPV vaccination in Nepal: Early key insights.
    Vaccine. 2025;60:127312.
    >> Share

  871. KROEGER M, Fano E, Sponheim A, Schwartz KJ, et al
    Assessment of homologous and heterologous PCV2 vaccine efficacy in a PCV2d/PRRSV co-challenge model.
    Vaccine. 2025;60:127303.
    >> Share

  872. MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
    Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
    Vaccine. 2025;59:127297.
    >> Share

  873. ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
    Understanding the shift in COVID-19 vaccine hesitancy and its associated factors for primary and booster doses among university students: A cross-sectional study.
    Vaccine. 2025;59:127296.
    >> Share

  874. LI M, Cai W, Chandrasekhar A, Hu H, et al
    Factors associated with primary care providers' recommendation of HPV vaccination for adolescent males in China: A mixed-methods study.
    Vaccine. 2025;59:127299.
    >> Share

  875. LAI SW, Liao KF
    Breakthrough herpes zoster risk after recombinant zoster vaccination.
    Vaccine. 2025 May 23:127294. doi: 10.1016/j.vaccine.2025.127294.
    >> Share

  876. BAKHT P, Hussain A, Pandey S, Pathania R, et al
    Live attenuated hfq-deleted Acinetobacter baumannii vaccine provides protection against systemic infection.
    Vaccine. 2025;59:127298.
    >> Share

  877. MOHAMED Y, Luey E, Kata ', Tukia O, et al
    "The only vaccine that we really question is the new vaccine": A qualitative exploration of the social and behavioural drivers of human papillomavirus (HPV) vaccination in Tonga.
    Vaccine. 2025;59:127280.
    >> Share

  878. RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
    Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
    Vaccine. 2025;59:127293.
    >> Share

  879. SHAHI N, Singh B, Pande A, Chandra S, et al
    Safe and efficacious inactivated immersion vaccine against KG+ phenotype of emerging bacterial pathogen Lactococcus garvieae for early developmental stage of rainbow trout (Oncorhynchus mykiss) in India.
    Vaccine. 2025;59:127266.
    >> Share

  880. KIBETI DM, Hoff NA, Merritt S, Lulebo AM, et al
    Quality and usability of home-based record photos to assess vaccine coverage: A case study from the 2022 Democratic Republic of the Congo Vaccine Coverage Survey.
    Vaccine. 2025;59:127248.
    >> Share

  881. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    >> Share

  882. SURI RK, Maugeais D, Maithal K
    COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers.
    Vaccine. 2025;59:127271.
    >> Share

  883. GIANNINI F, Hogan AB, Cameron E, Le H, et al
    Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
    Vaccine. 2025;56:127155.
    >> Share

  884. MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
    Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
    Vaccine. 2025;56:127203.
    >> Share

  885. KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
    Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
    Vaccine. 2025;56:127168.
    >> Share

  886. ISLAM MD, Islam MM, Inoue A, Yesmin S, et al
    Neutralizing antibodies against the Japanese encephalitis virus are produced by a 12 kDa E. coli- expressed envelope protein domain III (EDIII) tagged with a solubility-controlling peptide.
    Vaccine. 2025;56:127143.
    >> Share

  887. XU P, Lu J, Chen L, Chen X, et al
    Development of a chicken egg yolk antibody (IgY) could effectively prevent and treat goose astrovirus infection.
    Vaccine. 2025;56:127167.
    >> Share

  888. HASAN Z, Masood KI, Qaiser S, Kanji A, et al
    Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.
    Vaccine. 2025;59:127270.
    >> Share

  889. KEUTLER A, Lainka E, Hudert C, Bufler P, et al
    Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study.
    Vaccine. 2025;59:127288.
    >> Share

  890. TIAN X, Zhou Y, Deng P, Xu N, et al
    Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
    Vaccine. 2025;59:127268.
    >> Share

  891. QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
    Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
    Vaccine. 2025;58:127223.
    >> Share

  892. FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al
    Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.
    Vaccine. 2025;59:127254.
    >> Share

  893. BUSSINK-VOOREND D, Hulscher MEJL, Akkermans R, Krom A, et al
    Vaccine hesitancy among Dutch parents of newborn children and its associated characteristics, values and uptake of vaccines.
    Vaccine. 2025;59:127244.
    >> Share

  894. NHAM E, Song JY, Sohn JW, Choi WS, et al
    Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months.
    Vaccine. 2025;59:127275.
    >> Share

  895. SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al
    Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: Regression discontinuity analysis in OpenSAFELY-TPP.
    Vaccine. 2025;59:127257.
    >> Share

  896. MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
    Guided design for the development of an evolution-proof influenza vaccine.
    Vaccine. 2025;59:127281.
    >> Share

  897. HATTORI F, Higashimoto Y, Miura H, Kawamura Y, et al
    Epidemiology and clinical features of breakthrough varicella in the 9 years after universal vaccination began in Japan.
    Vaccine. 2025;59:127274.
    >> Share

  898. FURUSE Y, Tabuchi T
    Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan.
    Vaccine. 2025;59:127273.
    >> Share

  899. LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
    DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
    Vaccine. 2025;59:127231.
    >> Share

  900. MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
    Routine vaccination rates globally: A continuing and alarming situation.
    Vaccine. 2025;59:127269.
    >> Share

  901. SOARES LMC, de Medonca AEO, de Souza DLB, Carvalho AV, et al
    Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study.
    Vaccine. 2025;59:127278.
    >> Share

  902. LUPTON D, Whitten T, Tay AK, Beek K, et al
    Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
    Vaccine. 2025;58:127251.
    >> Share

  903. NUNEZ IA, Ross TM
    Corrigendum to "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine 38 (4) (2020) 830-839].
    Vaccine. 2025;58:127205.
    >> Share

  904. AVERIN A, Quinn E, Atwood M, Weycker D, et al
    Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
    Vaccine. 2025;58:127191.
    >> Share

  905. SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
    Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
    Vaccine. 2025;58:127267.
    >> Share

  906. NIINIKOSKI V, Barkoff AM, Mertsola J, Holubova J, et al
    Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland.
    Vaccine. 2025;58:127279.
    >> Share

  907. EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
    Corrigendum to "Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda" [Vaccine 53 (2025) 127089].
    Vaccine. 2025;58:127204.
    >> Share

  908. HUNG SH, Torres JL, Chen F, Giang E, et al
    Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
    Vaccine. 2025;58:127239.
    >> Share

  909. BUHL E, Vedel JO, Nanque LM, Correia C, et al
    Does timing of the Bacillus Calmette-Guerin vaccine affect weight in children under the age of 5 years? An observational study in Guinea-Bissau.
    Vaccine. 2025;58:127246.
    >> Share

  910. SOBLE A, Malhame M, Malvolti S, Mantel C, et al
    Identification and sizing of the current use cases for seasonal influenza vaccines.
    Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
    >> Share

  911. MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
    Childhood vaccine hesitancy: The power of metaphors.
    Vaccine. 2025;58:127221.
    >> Share

  912. PATTYN J, Hanning N, Valckx S, Claessens T, et al
    Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
    Vaccine. 2025;58:127250.
    >> Share

  913. MERRITT A, Bansal S
    Prison Vaccination in a pandemic: Geographic disparities and policy insights.
    Vaccine. 2025;58:127218.
    >> Share

  914. ELLIS JT, Kennedy PJ
    Multi-criteria decision making and its application to in silico discovery of vaccine candidates for Toxoplasma gondii.
    Vaccine. 2025;58:127242.
    >> Share

  915. VARMA A, Bolotin S, De Serres G, Didierlaurent AM, et al
    What is the current evidence base for measles vaccination earlier than 9 months of age?: Report from an informal technical consultation of the World Health Organization.
    Vaccine. 2025;57:127187.
    >> Share

  916. KUMARI M, Su SC, Lin HT, Ko SH, et al
    Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue.
    Vaccine. 2025;57:127216.
    >> Share

  917. PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
    Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
    Vaccine. 2025;57:127222.
    >> Share

  918. MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al
    Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.
    Vaccine. 2025;58:127207.
    >> Share

  919. LE DOARE K, Benassi V, Cavaleri M, Enwere G, et al
    Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries.
    Vaccine. 2025;58:127131.
    >> Share

  920. SPURGERS K, Wynn M, Charles L, Hamm S, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever.
    Vaccine. 2025;58:127137.
    >> Share

  921. WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
    Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
    Vaccine. 2025;58:127179.
    >> Share

  922. GELLERT FR, Gonzalez C, Mokdad AH
    Bridging the gap: A mixed-methods analysis of Canadian and U.S. immunization programs for enhancing racial equity in childhood vaccinations.
    Vaccine. 2025;57:127249.
    >> Share

  923. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    >> Share

  924. PATRICK E, Iuliano A, Bakare D, Salako J, et al
    Non-specific effects of routine vaccinations on child survival between 12-59 months of age in Jigawa, Nigeria: A secondary analysis of the INSPIRING Jigawa trial.
    Vaccine. 2025;57:127211.
    >> Share

  925. NAVARRETE JAY, Rodriguez D, Kanno AI, de Cerqueira Leite LC, et al
    Modulation of immune responses induced by recombinant BCG expressing LTAK63 adjuvant in an immunotherapeutic model vaccine.
    Vaccine. 2025;57:127215.
    >> Share

  926. NTAKIYISUMBA E, Tanveer M, Won G
    A comprehensive analysis of the current strategy for developing live attenuated vaccines against African swine fever: A systematic review and meta-analysis.
    Vaccine. 2025;57:127243.
    >> Share

  927. CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al
    Corrigendum to "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
    Vaccine. 2025;57:127174.
    >> Share

  928. SAXTON P, Hollingshead BM, Rich J, Saini S, et al
    Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men who have sex with men in Aotearoa New Zealand.
    Vaccine. 2025;57:127247.
    >> Share

  929. HU J, Cao H, Luan N, Zhang X, et al
    Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity.
    Vaccine. 2025;57:127241.
    >> Share

  930. ANGULO M, Ramos-Vega A, Angulo C
    Trained immunity-based Adjuvated vaccines (TIbAV) approach: beta-glucans as example.
    Vaccine. 2025;57:127240.
    >> Share

  931. MACLENNAN CA, Cunningham AF, Dean JE, Pope S, et al
    BactiVac, the Bacterial Vaccines Network.
    Vaccine. 2025;57:127210.
    >> Share

  932. XIONG Y, Wu C, Zhang Y, Guo D, et al
    Can levels of HPV vaccine knowledge mitigate HPV vaccine hesitation among guardians of children aged 9-14 years? A moderated mediation model.
    Vaccine. 2025;57:127208.
    >> Share

  933. MEESTERS K, Sadarangani M, Clark SA, Borrow R, et al
    Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013-2020.
    Vaccine. 2025;55:127030.
    >> Share

  934. GAGNON D, Gubany C, Ouakki M, Malo B, et al
    Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
    Vaccine. 2025;55:127062.
    >> Share

  935. SOTO-NOGUERON A, Carnalla-Barajas MN, Sanchez-Gonzalez G, Solorzano-Santos F, et al
    Distribution of pneumococcal serotypes causing invasive and non-invasive diseases in children in Mexico after introduction of PCV13 (2012-2023). Results from the GIVEBPVac group.
    Vaccine. 2025;55:127031.
    >> Share

  936. XIE F, Du K, Li J, Zhong S, et al
    Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
    Vaccine. 2025;55:127015.
    >> Share

  937. PUTZ EJ, Andreasen CB, Stasko JA, Hamond C, et al
    Circulating foamy macrophages and other features of bacillus Calmette-Guerin challenge in Golden Syrian hamsters.
    Vaccine. 2025;55:127037.
    >> Share

  938. HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al
    Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19.
    Vaccine. 2025;55:126987.
    >> Share

  939. KIM GL, Pyo SW, Kim SH, Song HJ, et al
    Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model.
    Vaccine. 2025;57:127212.
    >> Share

  940. ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
    Reactance as a cause of COVID-19 vaccination hesitancy.
    Vaccine. 2025;57:127209.
    >> Share

  941. ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
    New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
    Vaccine. 2025;57:127217.
    >> Share

  942. GEORGIADIS N, Katsimpris A, Tzanakaki G, Tsiodras S, et al
    Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis.
    Vaccine. 2025;56:127180.
    >> Share

  943. MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
    Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
    Vaccine. 2025;57:127133.
    >> Share

  944. RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al
    Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection.
    Vaccine. 2025;57:127206.
    >> Share

  945. GUMASING MJJ
    Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least Structural Equation Modeling Approach.
    Vaccine. 2025;57:127220.
    >> Share

  946. VIETHS S, Waibler Z, Schumann GG
    Opting for the appropriate methodology for quantification of residual DNA impurities in mRNA vaccines.
    Vaccine. 2025;56:127186.
    >> Share

  947. SZONDY I, Lorincz K, Walter A, Mohammed AA, et al
    Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention - A systematic review and meta-analysis.
    Vaccine. 2025;56:127188.
    >> Share

  948. PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN
    Morbidity of viral vaccine preventable diseases in the Mexican states bordering the U.S., 2014-2023.
    Vaccine. 2025;56:127192.
    >> Share

  949. ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al
    Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.
    Vaccine. 2025;56:127171.
    >> Share

  950. BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al
    Behavioural and social drivers of vaccination among child and adult migrants in Morocco: A qualitative interview study.
    Vaccine. 2025;56:127166.
    >> Share

  951. PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al
    Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults.
    Vaccine. 2025;56:127184.
    >> Share

  952. ANNEQUIN M, Mora M, Fressard L, Cogordan C, et al
    The relationship between men who have sex with men on PrEP and care providers is essential for HPV vaccination: A mixed-methods study in France.
    Vaccine. 2025;56:127190.
    >> Share

  953. ALGREN MH, Timmermann A, Valentiner-Branth P, Thygesen LC, et al
    Comparing Risk Behaviour among 14,614 Human Papillomavirus Vaccinated and Unvaccinated Danish Young Women.
    Vaccine. 2025;56:127202.
    >> Share

  954. SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al
    Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.
    Vaccine. 2025;56:127183.
    >> Share

  955. ZHANG Z, Yildirim M, Keskinocak P, Dasthagirisaheb YBS, et al
    Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis.
    Vaccine. 2025;56:127193.
    >> Share

  956. WHELDRAKE K, Sisnowski J, AHoure M, Anagnostou N, et al
    Surveillance of adverse events following immunisation with meningococcal B vaccine (4CMenB), South Australia, 2018-2022.
    Vaccine. 2025;56:127158.
    >> Share

  957. CHAN YT, Chair SY, Gao RT, Ng MH, et al
    Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis.
    Vaccine. 2025;56:127182.
    >> Share

  958. IBARZ-PAVON AB, Bielsky MC, Bose R, Cavaleri M, et al
    Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
    Vaccine. 2025;56:127189.
    >> Share

  959. AKMATOVA R, Otorbaeva D, Ebama MS
    Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative study.
    Vaccine. 2025;56:127159.
    >> Share

  960. OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
    Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
    Vaccine. 2025;56:127123.
    >> Share

  961. BADZI CD, Modey E, Apreku A, Guure C, et al
    Factors influencing COVID-19 vaccine uptake among pregnant women in Greater Accra Region, Ghana.
    Vaccine. 2025 May 1:127073. doi: 10.1016/j.vaccine.2025.127073.
    >> Share

  962. KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al
    Short-term side effects following COVID-19 vaccination in pregnancies complicated by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
    Vaccine. 2025;56:127194.
    >> Share

    April 2025
  963. MOTTA M, Callaghan T, Ross JC, Gargano L, et al
    Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
    Vaccine. 2025;56:127178.
    >> Share

  964. PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al
    Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
    Vaccine. 2025;56:127175.
    >> Share

  965. WAN J, Wu M, Zhu Z, Liu X, et al
    Vaccination of a CdrA fragment conferred protection against Pseudomonas aeruginosa in wound infection via inhibition of biofilm formation.
    Vaccine. 2025;56:127185.
    >> Share

  966. ZHENG F, Zhu M, Ran H, He J, et al
    Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.
    Vaccine. 2025;54:127093.
    >> Share

  967. JAROVSKY D, Cereda RF, Figueiredo LM, Berezin EN, et al
    Epidemiology and clinical burden of invasive pneumococcal disease in older adults in the city of Sao Paulo, Brazil.
    Vaccine. 2025;54:126992.
    >> Share

  968. BOLOTIN S, Wright J, McLachlan E, Severini A, et al
    Investigating the measles susceptibility gap in Ontario infants.
    Vaccine. 2025;54:126908.
    >> Share

  969. WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
    Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
    Vaccine. 2025;56:127130.
    >> Share

  970. SHANKER A, Vlaev I
    The social influence of the corrections of vaccine misinformation on social media.
    Vaccine. 2025;56:127177.
    >> Share

  971. OSEI I, Mendy E, van Zandvoort K, Sarwar G, et al
    Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in rural Gambia 10 years after its introduction: A population-based cross-sectional study.
    Vaccine. 2025;56:127181.
    >> Share

  972. BAYSAC DJ, Guay M, Chen R, Dube E, et al
    Did inequalities in COVID-19 vaccination resolve over time? Insights from the Canadian Community Health Survey.
    Vaccine. 2025;56:127153.
    >> Share

  973. LONG Q, Wang H, He Q, Liu W, et al
    Effectiveness of rBS/WC cholera vaccine against bacterial infectious diarrhea: A test-negative study on children aged 2-6 years in Guangzhou China.
    Vaccine. 2025;56:127139.
    >> Share

  974. MELN I, Van Molle W, Velez MP, Abrahamsen G, et al
    Advancing regulatory dialogue: In silico models for improved vaccine biomanufacturing - an expert meeting report.
    Vaccine. 2025;56:127170.
    >> Share

  975. HANSEN BT, Kristoffersen AB, Stecher M
    Vaccination readiness among adults in Norway: A cross-sectional survey using the 7C model.
    Vaccine. 2025;56:127169.
    >> Share

  976. SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al
    Collaborative influenza vaccine innovation centers (CIVICs) program.
    Vaccine. 2025;54:127118.
    >> Share

  977. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
    Vaccine. 2025;56:127127.
    >> Share

  978. FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al
    Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections.
    Vaccine. 2025;56:127165.
    >> Share

  979. OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al
    Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19.
    Vaccine. 2025;56:127173.
    >> Share

  980. MELCHINGER H, Khemsara M, Ahmed N, Belgaumi SM, et al
    Assessment of mpox awareness, attitudes, and vaccination intent among the United States public following an outbreak of mpox clade Ib in Africa.
    Vaccine. 2025;56:127141.
    >> Share

  981. JACOVETTY J, Wagner AL, Ichsan I, Yufika A, et al
    Associations between parental vaccine hesitancy, religion-based vaccine hesitancy, and childhood full vaccination in a cross-sectional study in Aceh, Indonesia, 2023.
    Vaccine. 2025;56:127154.
    >> Share

  982. SUH TY, Park JH, Hwang SY, Park CR, et al
    Safety and efficacy of a Vero-adapted live attenuated vaccine candidate for African swine fever.
    Vaccine. 2025;56:127172.
    >> Share

  983. LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al
    Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case.
    Vaccine. 2025;56:127176.
    >> Share

  984. BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al
    Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN.
    Vaccine. 2025;56:127160.
    >> Share

  985. AGRUPIS KA, Crisostomo MV, Daag JV, Sarol J Jr, et al
    Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study.
    Vaccine. 2025;56:127142.
    >> Share

  986. MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
    2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
    Vaccine. 2025;56:127120.
    >> Share

  987. HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
    Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
    Vaccine. 2025;56:127144.
    >> Share

  988. ZHANG X, Shi H, Ross TM
    Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
    Vaccine. 2025;56:127156.
    >> Share

  989. LUKA MM, Ferguson EA, Rees E, Hoffu H, et al
    Optimising human rabies vaccine supply chains: A modelling study.
    Vaccine. 2025 Apr 21:127108. doi: 10.1016/j.vaccine.2025.127108.
    >> Share

  990. JURADO-MARTIN I, Tomas-Cortazar J, Rezk N, Hou Y, et al
    The novel antigen, lipopolysaccharide export protein LptH, protects mice against Pseudomonas aeruginosa acute pneumonia in monovalent and multivalent vaccines.
    Vaccine. 2025;56:127145.
    >> Share

  991. KAHN R, Moiane B, Lessa FC, Massora S, et al
    Corrigendum to "Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction" Vaccine, Volume 47, 15 February 2025, 126,691.
    Vaccine. 2025;56:127124.
    >> Share

  992. FINNEY J, Kuraoka M, Song S, Watanabe A, et al
    Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
    Vaccine. 2025;56:127157.
    >> Share

  993. XIA Y, Zhu W, Shi Z, Shen Y, et al
    Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: A population-based survey.
    Vaccine. 2025;56:127122.
    >> Share

  994. FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
    Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
    Vaccine. 2025;53:127076.
    >> Share

  995. LUN J, Zheng P, Liang X, Hu Y, et al
    Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species.
    Vaccine. 2025;53:126964.
    >> Share

  996. TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al
    Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic.
    Vaccine. 2025;54:127138.
    >> Share

  997. DE MELO ARAUJO AC, Oliveira TM, Souza JFA, da Fonseca Victer TN, et al
    Incorporating vaccines into vaccination schedules around the world: A scoping review.
    Vaccine. 2025;54:127132.
    >> Share

  998. MANTLO EK, Huang YS
    Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype.
    Vaccine. 2025;54:127114.
    >> Share

  999. MO AX, McGugan G, Pesce JT
    Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
    Vaccine. 2025;54:127009.
    >> Share

  1000. ARSENAULT C, Ravishankar S, Lewis T, Armeni P, et al
    The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States.
    Vaccine. 2025;54:127134.
    >> Share

  1001. STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
    Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
    Vaccine. 2025;54:127136.
    >> Share

  1002. WANG Z, Wang M, Wang F, Luo Y, et al
    Corrigendum to "Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models" [Vaccine 42
    Vaccine. 2025;54:127126.
    >> Share

  1003. URIU K, Kaku Y, Kihara M, Sato K, et al
    Antiviral humoral immunity against SARS-CoV-2 omicron JN.1 subvariants induced by JN.1 recombinant protein vaccine.
    Vaccine. 2025;54:127129.
    >> Share

  1004. TONG F, Zhou T, Tang L, Wu X, et al
    Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
    Vaccine. 2025;54:127004.
    >> Share

  1005. WEETS CM, Wilson R, Swadley H, Katz R, et al
    Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
    Vaccine. 2025;54:127121.
    >> Share

  1006. ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
    Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
    Vaccine. 2025;54:127117.
    >> Share

  1007. YE Q, Li H, Xie Z, Gao X, et al
    Corrigendum to "Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT)" [Vaccine 49 (7) (2025) 126815].
    Vaccine. 2025;54:127125.
    >> Share

  1008. WANG F, Zheng J, Qiu F, Yang Y, et al
    Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
    Vaccine. 2025;54:127128.
    >> Share

  1009. LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
    Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
    Vaccine. 2025;54:127104.
    >> Share

  1010. SYROGIANNOPOULOS GA, Michoula AN, Moriondo M, Nieddu F, et al
    Childhood invasive pneumococcal disease and acute otitis media in Central Greece during 2005-2024 - A report at the doorstep of the new multivalent PCV era.
    Vaccine. 2025;52:126765.
    >> Share

  1011. OLIVEIRA LMA, Prasad N, Lynfield R, Ip M, et al
    WHO defeating meningitis symposium, 3rd international symposium on Streptococcus agalactiae disease (ISSAD) in Rio de Janeiro, Brazil: State-of-the-art overview of S. agalactiae meningitis.
    Vaccine. 2025;52:126895.
    >> Share

  1012. RESIK S, Lopez Cavestany R, Tejeda A, Diaz M, et al
    Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba.
    Vaccine. 2025;52:126903.
    >> Share

  1013. DEY A, Jackson J, Wang H, Lambert SB, et al
    Australia's rotavirus immunisation program: Impact on acute gastroenteritis and intussusception hospitalisations over 13 years.
    Vaccine. 2025;52:126789.
    >> Share

  1014. JOSHI R, Ayele HT, Johnson KD, Velentgas P, et al
    Anticipated impact of novel adult-specific pneumococcal conjugate vaccine.
    Vaccine. 2025;53:127080.
    >> Share

  1015. JOHN TJ, Dharmapalan D, Steinglass R, Hirschhorn N, et al
    Lessons for polio eradication from the geographic variations of vaccine efficacy of oral polio.
    Vaccine. 2025;53:127115.
    >> Share

  1016. WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
    Corrigendum to "Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda" [Vaccine 24 (22) (2024) 126031].
    Vaccine. 2025;54:127119.
    >> Share

  1017. CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
    Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
    Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
    >> Share

  1018. BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
    Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
    Vaccine. 2025;53:127074.
    >> Share

  1019. DYMOCK M, Marsh JA, Murray K, Snelling TL, et al
    What is the quality of evidence informing vaccine clinical practice recommendations in Australia?
    Vaccine. 2025;53:127105.
    >> Share

  1020. ZHANG L, Xia Y, Chu L, Sundaram ME, et al
    Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
    Vaccine. 2025;53:127106.
    >> Share

  1021. JANI B, Hokororo A, Mchomvu J, Cortese MM, et al
    Corrigendum to "Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland tanzania" [Vaccine 36(47) (2018 Nov 12) 7149-7156].
    Vaccine. 2025;53:127103.
    >> Share

  1022. NA EJ, Chae SB, Oh B, Jeong CG, et al
    A novel approach using IFNAR1 KO mice for assessing Akabane virus pathogenicity and vaccine efficacy.
    Vaccine. 2025;53:127094.
    >> Share

  1023. EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
    Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda.
    Vaccine. 2025;53:127089.
    >> Share

  1024. SHARIF E, Mobasheri T, Mohit E
    Bioengineered ClearColi-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model.
    Vaccine. 2025;53:127088.
    >> Share

  1025. LA EM, Sweeney C, Davenport E, Bunniran S, et al
    Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults.
    Vaccine. 2025;54:127057.
    >> Share

  1026. SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
    Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
    Vaccine. 2025;53:127091.
    >> Share

  1027. ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al
    Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
    Vaccine. 2025;53:127047.
    >> Share

  1028. LLOYD PC, Acharya G, Zhao H, Shah N, et al
    Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2025;53:127069.
    >> Share

  1029. YUILL S, Hall MT, Caruana M, Lui G, et al
    Erratum to "Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screeni
    Vaccine. 2025;53:127079.
    >> Share

  1030. ASSONI L, Valim V, Couto AJM, Trentini M, et al
    In-silico and experimental analysis of Klebsiella pneumoniae fimbriae subunits for vaccine development.
    Vaccine. 2025;53:127075.
    >> Share

  1031. PRALL S, Lopes A
    "Better to die trying": Vaccine perceptions and COVID-19 experiences in rural Namibian pastoralists.
    Vaccine. 2025;55:127061.
    >> Share

  1032. MOLLO A, Peri M, Lodi L, Gissi A, et al
    Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity.
    Vaccine. 2025;53:127072.
    >> Share

  1033. FROSTH S, Reddick D, Righetti F, Bjerketorp J, et al
    Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection.
    Vaccine. 2025;53:127077.
    >> Share

  1034. DIEZ A, Arrieta-Aguirre I, Carrano G, Bregon-Villahoz M, et al
    A synthetic peptide vaccine induces protective immune responses against Candida albicans infection in immunocompromised mice.
    Vaccine. 2025;53:127102.
    >> Share

  1035. SHEARN C, Postavaru GI, Hylton L, Morris H, et al
    COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
    Vaccine. 2025;53:127071.
    >> Share

  1036. MACKE CA, Carreon SA, Desai KR, Minard CG, et al
    COVID-19 vaccine uptake and attitudes in emerging adults with type 1 diabetes.
    Vaccine. 2025 Apr 6:127083. doi: 10.1016/j.vaccine.2025.127083.
    >> Share

  1037. LI G, Cao S, Xu B, Hu J, et al
    Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.
    Vaccine. 2025;53:127082.
    >> Share

  1038. LEADER AE, Burke-Garcia A, Afanaseva D, Cutroneo E, et al
    Partnering with social media influencers to promote HPV vaccination in diverse communities.
    Vaccine. 2025;53:127085.
    >> Share

  1039. SHALASH AO, Wang W, Xia Y, Hussein WM, et al
    Evaluation of novel single-dose vaccine candidates against gonadotropin-releasing hormone (GnRH) in mice.
    Vaccine. 2025;53:127092.
    >> Share

  1040. BERNARD C, Drouin J, Le Vu S, Botton J, et al
    COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
    Vaccine. 2025;53:127070.
    >> Share

  1041. FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
    Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
    Vaccine. 2025;53:127084.
    >> Share

  1042. FLYNN PM, Stull C, Jain VM, Evans MD, et al
    A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
    Vaccine. 2025;53:127035.
    >> Share

  1043. CHEN PL, Richardson RA, Rovito S, Yang G, et al
    Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets.
    Vaccine. 2025;53:127090.
    >> Share

  1044. PAYNE AB, Novosad S, Sung HM, Zhang Y, et al
    Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged >/=18 years with end stage kidney disease - United States, September 2023-April 2024.
    Vaccine. 2025;55:127010.
    >> Share

  1045. EIDEN AL, Mackie DS, Modi K, Drakeley S, et al
    Corrigendum to the article titled, "Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study" [Vaccine 50 (2025) 126807].
    Vaccine. 2025;53:127053.
    >> Share

  1046. FELIX P, Melo AA, Costa JP, Colaco M, et al
    Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
    Vaccine. 2025;53:127078.
    >> Share

  1047. MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
    COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
    Vaccine. 2025;53:127050.
    >> Share

  1048. ANTILLON M, Verjans A, El Sheikh F, Scarna T, et al
    Microarray patch vaccines for typhoid conjugate vaccines: A global cost-effectiveness analysis.
    Vaccine. 2025;53:127055.
    >> Share

  1049. DAVIDSON N, Fisher J
    "If I know about it of course I would give my son and daughter", barriers to and enablers of accessing human papillomavirus vaccination among women from refugee and asylum-seeking backgrounds resettling in Melbourne, Australia - A qualitative study.
    Vaccine. 2025;53:127064.
    >> Share

  1050. EIDEN AL, Drakeley S, Modi K, Mackie DS, et al
    Corrigendum to, "Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey" [Vaccine (2024) Dec 2 42(26) 126437].
    Vaccine. 2025;53:127054.
    >> Share

  1051. MCKECHNIE JL, Kepl E, Louth J, Sun CJ, et al
    Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens.
    Vaccine. 2025;51:126885.
    >> Share

  1052. CARNALLA M, Gaspar-Castillo C, Dimas-Gonzalez J, Aparicio-Antonio R, et al
    A population-based measles serosurvey in Mexico: Implications for re-emergence.
    Vaccine. 2025;51:126886.
    >> Share

  1053. MONCHAUSSE T, Launay T, Rossignol L, Ait El Belghiti F, et al
    Clinical characteristics of cases during the 2024 pertussis epidemic in France, January 2024 to December 2024.
    Vaccine. 2025;51:126862.
    >> Share

  1054. OLIVIERI G, Amodio D, Manno EC, Santilli V, et al
    Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
    Vaccine. 2025;51:126853.
    >> Share

  1055. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    >> Share

  1056. PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al
    Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.
    Vaccine. 2025;54:127045.
    >> Share

  1057. HE X, Pu Y, Li Z, Huan S, et al
    The global regulatory landscape for combined vaccines: A comparative case study of registration strategies for diphtheria-tetanus-pertussis-containing vaccines.
    Vaccine. 2025;54:127017.
    >> Share

  1058. PATRICK R, Mahale P, Ackerson BK, Hong V, et al
    Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
    Vaccine. 2025;53:127033.
    >> Share

  1059. FORAN AM, Jetten J, Muldoon OT
    Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
    Vaccine. 2025;53:127086.
    >> Share

  1060. ALVES K, Kouassi A, Plested JS, Kalkeri R, et al
    Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
    Vaccine. 2025;55:127046.
    >> Share

  1061. STRONG C, Joson P, Chu IY, Chuang TT, et al
    Prioritization and barriers of mpox vaccination uptake among gay, bisexual and other men who have sex with men in Taiwan: 2023 HEART survey.
    Vaccine. 2025;53:127059.
    >> Share

  1062. VADREVU KM, Chavan A, Chawla A, Chakravarthy BS, et al
    A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol(R)) in comparison to Shanchol.
    Vaccine. 2025;55:126998.
    >> Share

  1063. OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
    Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023.
    Vaccine. 2025;55:127052.
    >> Share

    March 2025
  1064. KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
    A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
    Vaccine. 2025;53:127063.
    >> Share

  1065. DA SILVA TMR, de Sa ACMGN, Prates EJS, Veloso GA, et al
    Trends and spatial distribution of the burden of vaccine-preventable diseases in children under five in Brazil from 2000 to 2019.
    Vaccine. 2025;55:127060.
    >> Share

  1066. JIANG J, Lam KF, Lau EHY, Yin G, et al
    Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
    Vaccine. 2025;55:127067.
    >> Share

  1067. NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al
    A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
    Vaccine. 2025;55:127044.
    >> Share

  1068. LEE JW, Lee DY, Baek S, Jeong JY, et al
    Sensitive detection of pertussis toxin in acellular pertussis vaccines using HRH1-mediated calcium signaling.
    Vaccine. 2025;54:127056.
    >> Share

  1069. CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al
    Vaccine hesitancy among racially diverse parents in Canada: The important role of health literacy, conspiracy beliefs and racial discrimination.
    Vaccine. 2025;55:127049.
    >> Share

  1070. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    >> Share

  1071. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    >> Share

  1072. STRAVORAVDI AS, Ladas AI, Frantzidis CA, Papazisis G, et al
    HAVI: A novel tool to explore vaccine hesitancy among adults in Greece.
    Vaccine. 2025;55:127042.
    >> Share

  1073. VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al
    Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus.
    Vaccine. 2025;55:127058.
    >> Share

  1074. MOUCHERAUD C, Ochieng E, Kweka A, Wang P, et al
    Parent-daughter agreement about HPV vaccination status in Kenya and Malawi.
    Vaccine. 2025;55:127025.
    >> Share

  1075. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    >> Share

  1076. FUNK T, Norgaard SK, Hallundbaek L, Grau J, et al
    Effect of a proactive childhood vaccination reminder system on vaccination coverage and uptake in Denmark: A register-based cohort study.
    Vaccine. 2025;54:126934.
    >> Share

  1077. ZHANG Y, Sullivan N, Abraham M, Haley HD, et al
    Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights for sustained-release vaccine development.
    Vaccine. 2025;55:127024.
    >> Share

  1078. VEDEL JO, Furtado O, Almeida LL, Martins JSD, et al
    Refresher training in administering intradermal BCG-vaccine increased BCG-scarring rates in rural Guinea-Bissau.
    Vaccine. 2025;55:127039.
    >> Share

  1079. EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al
    Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.
    Vaccine. 2025;55:127008.
    >> Share

  1080. BAKARE AA, Gobbo E, Akinsola KO, King C, et al
    "It's easier to deal with the vaccines you know than the ones you don't know": A qualitative study on healthcare workers' vaccine confidence in Nigeria.
    Vaccine. 2025;55:127020.
    >> Share

  1081. FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al
    Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
    Vaccine. 2025;55:126996.
    >> Share

  1082. BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al
    Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
    Vaccine. 2025;55:127041.
    >> Share

  1083. GOEDERS N, Vanneste K, Roosens NHC, Bogaerts B, et al
    Molecular and WGS-based characterization of invasive Neisseria meningitidis isolates collected in Belgium (2016-2022) and MenB-FHbp vaccine coverage estimation of serogroup B.
    Vaccine. 2025;55:127026.
    >> Share

  1084. MELOT L, Thyfault E, Hester K, Prausnitz MR, et al
    Perceptions of non-needle-based vaccination devices in the state of Georgia.
    Vaccine. 2025;55:127038.
    >> Share

  1085. HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al
    Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
    Vaccine. 2025;55:127023.
    >> Share

  1086. FRANCIS MJ
    A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
    Vaccine. 2025;55:127040.
    >> Share

  1087. AHMAD I, Burton R, Arshad R, Younis BB, et al
    Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in individuals with type 2 diabetes mellitus.
    Vaccine. 2025;55:127029.
    >> Share

  1088. YAN K, Xu S, Fang H, Yang H, et al
    Next-generation immunotherapeutic strategy and clinical advances of vaccines against nicotine addiction.
    Vaccine. 2025;55:127036.
    >> Share

  1089. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.
    Vaccine. 2025;55:127001.
    >> Share

  1090. SALLOUM M, Lariviere Y, Bikioli Bolombo F, Zola Matuvanga T, et al
    The exclusion of pregnant women from an Ebola vaccine trial in Boende, western DRC: Perceptions of female participants who became pregnant and community members.
    Vaccine. 2025;55:127000.
    >> Share

  1091. VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al
    Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.
    Vaccine. 2025;55:127034.
    >> Share

  1092. KAISER S, Kaiser S, Reis J, Marschalek R, et al
    Quantification of objective concentrations of DNA impurities in mRNA vaccines.
    Vaccine. 2025;55:127022.
    >> Share

  1093. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    >> Share

  1094. HAMID S, Simeone RM, Newhams MM, Halasa N, et al
    Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
    Vaccine. 2025;54:126891.
    >> Share

  1095. SHINO MY, Ibarrondo FJ, Yang OO
    SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.
    Vaccine. 2025;50:126851.
    >> Share

  1096. HAGEDORN B, Frey K, Scarna T, El Sheikh F, et al
    Microarray patches likely to reduce the operational costs of immunization: A Monte Carlo simulation study.
    Vaccine. 2025;50:126840.
    >> Share

  1097. ILIYASU Z, Danzomo AA, Jeyaseelan V, Gofama MM, et al
    Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022.
    Vaccine. 2025;54:126978.
    >> Share

  1098. THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
    Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
    Vaccine. 2025;55:126981.
    >> Share

  1099. RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
    Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
    Vaccine. 2025;55:126997.
    >> Share

  1100. NAZIAT H, Rahman MH, Das RC, Islam M, et al
    Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media with otorrhea among Bangladeshi children.
    Vaccine. 2025;55:126995.
    >> Share

  1101. CHOI J, Feelemyer J, Choe K, Lynch K, et al
    Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
    Vaccine. 2025;55:127003.
    >> Share

  1102. BALDOLLI A, Fournier A, Roger H, Piednoir E, et al
    Implementation of school-based vaccination in French middle schools: Efficient or not?
    Vaccine. 2025;55:127007.
    >> Share

  1103. MPABALWANI EM, Sakala C, Kamiji E, Simwaka J, et al
    Challenges and lessons learned during the switching of rotavirus vaccine from Rotarix to Rotavac in Zambia.
    Vaccine. 2025;55:127012.
    >> Share

  1104. HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
    A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
    Vaccine. 2025;54:126991.
    >> Share

  1105. GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
    Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
    Vaccine. 2025;54:126860.
    >> Share

  1106. MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al
    Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024.
    Vaccine. 2025;55:127014.
    >> Share

  1107. YANAI T, Yoshida S, Kawakami K
    Gastroenteritis hospitalizations over 19 years before and after introduction of rotavirus vaccine in Japan: A nationwide claims database.
    Vaccine. 2025;55:127027.
    >> Share

  1108. YUILL S, Hall MT, Caruana M, Lui G, et al
    Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening.
    Vaccine. 2025;54:126986.
    >> Share

  1109. ZHANG X, Zhao T, Cai X, Zhang W, et al
    Are health education effective to improve herpes zoster vaccine willingness in vulnerable elderly.
    Vaccine. 2025;54:126975.
    >> Share

  1110. XU J, Davoudpour S, Phillips G 2nd
    Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
    Vaccine. 2025;54:127002.
    >> Share

  1111. PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
    Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
    Vaccine. 2025;54:127006.
    >> Share

  1112. RICCI L, Fery C, Tubach F, Agrinier N, et al
    Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
    Vaccine. 2025;54:127005.
    >> Share

  1113. MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
    Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
    Vaccine. 2025;54:126989.
    >> Share

  1114. LU H
    Generative AI for vaccine misbelief correction: Insights from targeting extraversion and pseudoscientific beliefs.
    Vaccine. 2025;54:127018.
    >> Share

  1115. FIRTH C, Emary K, Stuart A, Browne R, et al
    Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men.
    Vaccine. 2025;54:127013.
    >> Share

  1116. SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al
    The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease in Polish children.
    Vaccine. 2025;54:126999.
    >> Share

  1117. TAMIR TT, Tekeba B, Techane MA, Alemu TG, et al
    Coverage of complete basic childhood vaccination and its variation by basic characteristics among children aged 12-23 months in 41 low- and middle-income countries: A Meta-analysis of demographic and health survey reports between 2015 and 2025.
    Vaccine. 2025;54:127019.
    >> Share

  1118. VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al
    Childhood vaccination coverages in rural Guinea-Bissau before and during the early COVID-19 pandemic, a cohort study.
    Vaccine. 2025;54:127011.
    >> Share

  1119. MARTINON-TORRES F, Martinez SN, Kline MJ, Drozd J, et al
    A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2025;53:126931.
    >> Share

  1120. DAVIS P, Montroy J, Warshawsky B, Abrams EM, et al
    Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses.
    Vaccine. 2025;53:126878.
    >> Share

  1121. SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
    Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
    Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
    >> Share

  1122. BOLU O, Alo OD, Iwara E, Longley AT, et al
    Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.
    Vaccine. 2025;52:126907.
    >> Share

  1123. DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al
    A review of Canadian online resources providing information on COVID-19 vaccination for caregivers of children aged 5-11 years.
    Vaccine. 2025;54:126990.
    >> Share

  1124. MEERAUS W, Postema A, Gray CM, Lee A, et al
    Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
    Vaccine. 2025;53:126955.
    >> Share

  1125. KRAMMER F
    Next-generation seasonal influenza virus vaccines need a neuraminidase component.
    Vaccine. 2025;54:126994.
    >> Share

  1126. OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al
    Seasonal influenza vaccination in Kenya: What determines healthcare Workers' willingness to accept and recommend vaccination?
    Vaccine. 2025;54:126963.
    >> Share

  1127. DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al
    Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis.
    Vaccine. 2025;54:126911.
    >> Share

  1128. JI C, Senthinathan A, Apajee J, Dubey V, et al
    Impact of the COVID-19 pandemic on routine immunization coverage of children and teenagers in Ontario, Canada.
    Vaccine. 2025;49:126811.
    >> Share

  1129. FORZY T, Tesfaye L, Getnet F, Misganew A, et al
    Assessing the geographic and socioeconomic determinants of vaccine coverage in Ethiopia: A spatial and multistage analysis at the district level.
    Vaccine. 2025;53:126834.
    >> Share

  1130. DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al
    Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024.
    Vaccine. 2025;54:126958.
    >> Share

  1131. DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al
    Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
    Vaccine. 2025;54:126960.
    >> Share

  1132. NAVAEISEDDIGHI Z, Schmit T, Wang Z, Ahamed N, et al
    The vaccine dosing effect overcomes the reduced immunogenic potential and in vivo efficacy of 33F pneumococcal serotype.
    Vaccine. 2025;54:126983.
    >> Share

  1133. LEE DW, Nasir A, Elbashir S, Jani H, et al
    mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
    Vaccine. 2025;54:126961.
    >> Share

  1134. ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
    Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
    Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
    >> Share

  1135. KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
    COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
    Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
    >> Share

  1136. CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al
    Corrigendum to "Long-Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine" [Vaccine, Volume 50, 19 March 2025, 126,817].
    Vaccine. 2025;54:126974.
    >> Share

  1137. TILLYA R, Abdallah G, Msuya H, Bajaria S, et al
    Associated factors for dropout of first versus third doses of pentavalent vaccination in Tanzania.
    Vaccine. 2025;54:126962.
    >> Share

  1138. XIMENES R, Simmons AE, Gebretekle GB, Nam A, et al
    Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada.
    Vaccine. 2025;54:126985.
    >> Share

  1139. MINUTTI AF, Sasse JP, Dos Santos Silva AC, Martins TA, et al
    Evaluation of a DNA vector plasmid encoding a partial rop18 gene from toxoplasma gondii in domestic cats as a vaccine candidate.
    Vaccine. 2025;54:126965.
    >> Share

  1140. GORDON JL, Boespflug EL, Coleman A, Taylor K, et al
    Development of broadly protective coronavirus vaccines: A joint NIAID-CEPI workshop report.
    Vaccine. 2025;54:126909.
    >> Share

  1141. CARROLL M, Fox HB, Tran A, Chellappan G, et al
    SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
    Vaccine. 2025;54:126988.
    >> Share

  1142. PROCTOR RA, Jackson AM, Fowler VG
    The lack of a biorepository during vaccine trials: A lost opportunity to understand staphylococcal immunity.
    Vaccine. 2025;53:126896.
    >> Share

  1143. GATES CJ, Brazel EB, Kennedy EV, Brown JS, et al
    A gamma-irradiated pneumococcal vaccine elicits superior immunogenicity in comparison to heat or chemically inactivated whole-cell vaccines.
    Vaccine. 2025;54:126982.
    >> Share

  1144. MOORE M, Anderson L, Schiffer JT, Matrajt L, et al
    Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
    Vaccine. 2025;54:126966.
    >> Share

  1145. CHISNALL G, Letley L, Mounier-Jack S, Bedford H, et al
    Parents' experiences of accessing childhood vaccination services in England: A qualitative longitudinal cohort study.
    Vaccine. 2025;52:126921.
    >> Share

  1146. RAMIREZ-BENCOMO F, Thistlethwaite A, Viviani V, Bartolini E, et al
    Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray.
    Vaccine. 2025;53:126953.
    >> Share

  1147. PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
    Vaccine. 2025;52:126680.
    >> Share

  1148. CHU CF, Chang TH, Ho JJ
    Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
    Vaccine. 2025;52:126830.
    >> Share

  1149. HAMIDI A, Willemsen M, Robert T, Drugmand JC, et al
    Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.
    Vaccine. 2025;53:126950.
    >> Share

  1150. ZHAO T, Xu Q, Cai X, Wang M, et al
    Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
    Vaccine. 2025;53:126933.
    >> Share

  1151. MAFUTA EM, Lulebo AM, Kasonga JN, Mvuama NM, et al
    Designing a National Rapid Vaccine Coverage Survey in low-resource settings: Experiences from the Democratic Republic of the Congo 2018-2023.
    Vaccine. 2025;53:126956.
    >> Share

  1152. FRANCA AP, Domingues CMAS, Domingues RAS, Barata RB, et al
    Vaccine hesitancy in the vaccination of children in Brazil.
    Vaccine. 2025;53:126905.
    >> Share

  1153. COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al
    Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment.
    Vaccine. 2025;53:126947.
    >> Share

  1154. AYAD C, Porter D, Lambert E, Libeau P, et al
    An LNP-mRNA vaccine protects fish against rhabdovirus infection.
    Vaccine. 2025;53:126957.
    >> Share

  1155. TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
    Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
    Vaccine. 2025;53:126932.
    >> Share

  1156. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    >> Share

  1157. DAVIES A, Schreiber D, Carey C, Tucker SB, et al
    Community pharmacists' pneumococcal vaccine knowledge and perceived barriers to vaccination.
    Vaccine. 2025;53:126930.
    >> Share

  1158. KEELING MJ, Hill EM, Petrou S, Tran PB, et al
    Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
    Vaccine. 2025;53:126948.
    >> Share

  1159. NIU Y, Yan Y, Hu Y, Yang X, et al
    A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
    Vaccine. 2025;53:126959.
    >> Share

    February 2025
  1160. SHAO Q
    Corrigendum to The origin of vaccine nationalism [Vaccine 51 (2025) 126897].
    Vaccine. 2025;53:126935.
    >> Share

  1161. RIGAMONTI V, Torri V, Morris SK, Ieva F, et al
    Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children.
    Vaccine. 2025;53:126946.
    >> Share

  1162. WANG B, Lassi Z, Andraweera P, Chen G, et al
    Pregnant women's choices for preventing respiratory syncytial virus (RSV).
    Vaccine. 2025;48:126790.
    >> Share

  1163. ZHOU S, Wang J, Lv M, Lan W, et al
    Long-term antibody trajectories after PPSV23 in elderly: Results from a 4-year follow-up study.
    Vaccine. 2025;48:126737.
    >> Share

  1164. ADU P, Popoola T, Iqbal N, Roemer A, et al
    A cross-country network analysis of disease infodemics: Looking through the lens of the COVID-19 pandemic.
    Vaccine. 2025;48:126733.
    >> Share

  1165. AN SJ, Yang JS, Chae MH, Woo JS, et al
    Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine.
    Vaccine. 2025;52:126913.
    >> Share

  1166. GUTTIERES D, Van Riet C, Vandaele N, Decouttere C, et al
    Dynamics of global emergency vaccine stockpiles: A systems analysis and application to cholera.
    Vaccine. 2025;52:126889.
    >> Share

  1167. KIM HJ, Lee SH, Park YS, Seo DW, et al
    Utility of edible plant-derived exosome-like nanovesicles as a novel delivery platform for vaccine antigen delivery.
    Vaccine. 2025;52:126902.
    >> Share

  1168. SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al
    COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in the post-pandemic period: A cross-sectional study from Saudi Arabia.
    Vaccine. 2025;52:126937.
    >> Share

  1169. SINGER D, Salem A, Stempniewicz N, Ma S, et al
    Corrigendum to "The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years" [Vaccine 41 (37) (23 August 2023) 5360-5367].
    Vaccine. 2025;52:126805.
    >> Share

  1170. MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al
    COVID-19 vaccination integration, innovations and key populations: Results from a global survey.
    Vaccine. 2025;52:126863.
    >> Share

  1171. ARABIAN S, Sadr M, Ayati MH, Ince F, et al
    The earliest report of smallpox oral vaccination by Baha' al-Dawlah Razi in the 16th century.
    Vaccine. 2025;52:126949.
    >> Share

  1172. PEREZ-PEREZ A, Vallejo JR
    Francisco Oller y Ferrer (1758-1831). The surgeon who performed the first smallpox vaccination in a Hispanic American territory.
    Vaccine. 2025;51:126875.
    >> Share

  1173. GRIFFIN LB, Polnaszek BE, Shin J, Clark MA, et al
    Parental status and gender are associated with differences in Tdap vaccination rates among United States adults.
    Vaccine. 2025;52:126901.
    >> Share

  1174. BENDERA A, Nakamura K, Tran XMT, Kapologwe NA, et al
    Persistent socioeconomic disparities in childhood vaccination coverage in Tanzania: Insights from multiple rounds of demographic and health surveys.
    Vaccine. 2025;52:126904.
    >> Share

  1175. DHINGRA MS, Peterson J, Hedrick J, Pan J, et al
    Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201].
    Vaccine. 2025;52:126912.
    >> Share

  1176. DIYA O, Gayed J, Lowry FS, Ma H, et al
    A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
    Vaccine. 2025;52:126869.
    >> Share

  1177. LEBLANG D, Smith MD, Wesselbaum D
    Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality.
    Vaccine. 2025;52:126906.
    >> Share

  1178. ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al
    Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
    Vaccine. 2025;52:126881.
    >> Share

  1179. DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al
    Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
    Vaccine. 2025;52:126888.
    >> Share

  1180. GARLING A, Goursat C, Seguy C, Martin P, et al
    Development of intimin-enriched outer membrane vesicles (OMVs) as a vaccine to control intestinal carriage of Enterohemorrhagic Escherichia coli.
    Vaccine. 2025;52:126899.
    >> Share

  1181. FARAH Z, Bazant ES, Basha I, Saleh N, et al
    Determinants of seasonal influenza vaccination uptake, intention and recommendations among Lebanese physicians.
    Vaccine. 2025;52:126890.
    >> Share

  1182. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Correction to "Recombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2" [Vaccine 2023 Sep 22 41(41) 6025-6035. Doi: 10.1016/j.vaccine.2023.08.054].
    Vaccine. 2025;52:126880.
    >> Share

  1183. YE Q, Xiao Z, Bai C, Yao H, et al
    Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation.
    Vaccine. 2025;52:126900.
    >> Share

  1184. MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al
    What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).
    Vaccine. 2025;51:126892.
    >> Share

  1185. VAN BEEK LF, van der Gaast-de Jongh C, Platenburg PP, Hilgers L, et al
    Improving the immunogenicity of the pneumococcal conjugate vaccine using a synthetic carbohydrate fatty acid monosulphate squalane-in-water adjuvant.
    Vaccine. 2025;51:126893.
    >> Share

  1186. ATTI A, England A, Sung J, Foulkes S, et al
    Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.
    Vaccine. 2025;51:126898.
    >> Share

  1187. MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al
    SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
    Vaccine. 2025;51:126865.
    >> Share

  1188. BERGSTROM F, Gunther F, Britton T
    A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
    Vaccine. 2025;52:126870.
    >> Share

  1189. DERBISE A, Guillas C, Echenique-Rivera H, Carniel E, et al
    Contribution of the type 3 secretion system to adaptive and innate immunity induced by a live Yersinia pseudotuberculosis plague vaccine.
    Vaccine. 2025;51:126887.
    >> Share

  1190. SHAO Q
    The origin of vaccine nationalism.
    Vaccine. 2025;51:126897.
    >> Share

  1191. HALL C, Lanning J, Romano CJ, Bukowinski AT, et al
    COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021.
    Vaccine. 2025;51:126894.
    >> Share

  1192. ZHAO T, Liu X, Huang X, Wang L, et al
    Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice.
    Vaccine. 2025;51:126882.
    >> Share

  1193. TAAFFE J, Goldin S, Lambach P, Sparrow E, et al
    Global production capacity of seasonal and pandemic influenza vaccines in 2023.
    Vaccine. 2025;51:126839.
    >> Share

  1194. DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al
    Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.
    Vaccine. 2025;50:126776.
    >> Share

  1195. SIERRA MS, Carvajal LJ, Dull P, Herrero R, et al
    Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT).
    Vaccine. 2025;50:126841.
    >> Share

  1196. APPEL AM, Janbek J, Laursen TM, Gasse C, et al
    Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults.
    Vaccine. 2025;51:126864.
    >> Share

  1197. MONTROY J, Yan C, Khan F, Forbes N, et al
    Post-exposure prophylaxis for the prevention of measles: A systematic review.
    Vaccine. 2025;47:126706.
    >> Share

  1198. KAHN R, Moiane B, Lessa FC, Massora S, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction.
    Vaccine. 2025;47:126691.
    >> Share

  1199. YILDIRIM M, Keskinocak P, Hinderstein S, Tran K, et al
    A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.
    Vaccine. 2025;47:126692.
    >> Share

  1200. KEMP M, Capriola A, Schauer S
    RSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
    Vaccine. 2025;47:126674.
    >> Share

  1201. YE Q, Li H, Xie Z, Gao X, et al
    Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT).
    Vaccine. 2025 Feb 15:126815. doi: 10.1016/j.vaccine.2025.126815.
    >> Share

  1202. CHANG C, Patel H, Ferrari A, Scalzo T, et al
    sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.
    Vaccine. 2025;51:126883.
    >> Share

  1203. BENN CS
    Non-specific effects of vaccines: The status and the future.
    Vaccine. 2025;51:126884.
    >> Share

  1204. THOMPSON EL, Akpan IN, Alkhatib S, Grace J, et al
    Implementation of mid-adult HPV vaccination guidelines into clinical practice.
    Vaccine. 2025;51:126867.
    >> Share

  1205. SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al
    Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
    Vaccine. 2025;51:126879.
    >> Share

  1206. DEANE A, White C, Morrissey Y, Jessop L, et al
    The impact of HPV vaccine disinformation and misinformation in disadvantaged educational settings in Ireland: A multi-year analysis of a school immunisation system.
    Vaccine. 2025;51:126868.
    >> Share

  1207. BERRYMAN S, Asfor A, Benham E, Howe N, et al
    Foot-and-mouth disease vaccine quality: A universal test for intact viral capsids based on detection of VP4.
    Vaccine. 2025;51:126845.
    >> Share

  1208. VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al
    Evaluation of a nanoparticle influenza vaccine in the pig model.
    Vaccine. 2025;49:126844.
    >> Share

  1209. KIM SY, Song M, Kwon SL
    Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
    Vaccine. 2025;49:126852.
    >> Share

  1210. COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
    Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
    Vaccine. 2025;49:126778.
    >> Share

  1211. SHERMAN ME, Michalski J, Das S, Yang H, et al
    BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.
    Vaccine. 2025;50:126779.
    >> Share

  1212. ADAMS L, Karachaliou Prasinou A, Trotter C
    Modelling the impact and cost effectiveness of universal varicella vaccination in England.
    Vaccine. 2025;50:126831.
    >> Share

  1213. ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
    A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
    Vaccine. 2025;51:126791.
    >> Share

  1214. WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al
    Co-creation of pediatric influenza digital stories via rapid community translation.
    Vaccine. 2025;51:126866.
    >> Share

  1215. O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al
    Protective efficacy of a bivalent equine influenza H3N8 virus-like particle vaccine in horses.
    Vaccine. 2025;50:126861.
    >> Share

  1216. CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al
    Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
    Vaccine. 2025;50:126785.
    >> Share

  1217. HOULE SKD, Constantinescu C, Dube E
    Navigating the 'sea of Cs' in vaccine hesitancy: Where does collaboration fit?
    Vaccine. 2025;51:126876.
    >> Share

  1218. SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
    Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
    Vaccine. 2025;50:126846.
    >> Share

  1219. GEIGER M, Betsch C, Bohm R
    Mind the jingle: A call to consider construct validity of the 7C of vaccination readiness.
    Vaccine. 2025 Feb 8:126843. doi: 10.1016/j.vaccine.2025.126843.
    >> Share

  1220. FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al
    Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults.
    Vaccine. 2025;49:126770.
    >> Share

  1221. NAFICY A, Chugh Y, Tariq M, Hawksworth H, et al
    Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.
    Vaccine. 2025;50:126819.
    >> Share

  1222. SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
    Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
    Vaccine. 2025;50:126783.
    >> Share

  1223. FU Y, Xu Z, Wang Q, Zhang J, et al
    Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China.
    Vaccine. 2025;50:126836.
    >> Share

  1224. FRITSCHI N, Heininger U
    Pertussis vaccination campaign among health care workers and validity of recall of previous adverse events following immunization.
    Vaccine. 2025;50:126850.
    >> Share

  1225. ABBAD A, Yueh J, Yellin T, Singh G, et al
    Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.
    Vaccine. 2025;50:126825.
    >> Share

  1226. KRAJCAR N, Trkulja V, Butic I, Tesovic G, et al
    Impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on pneumococcal carriage in healthy children and children with acute otitis media and pneumonia: emergence of serotypes 3, 6C and 19A in Croatia.
    Vaccine. 2025;50:126848.
    >> Share

  1227. GEBREAL A, Ashmawy R, Ahmed MJ, Khattab M, et al
    A systematic review and meta-analysis on parental uptake and willingness to vaccinate children against human papillomavirus in the Eastern Mediterranean Region.
    Vaccine. 2025 Feb 6:126832. doi: 10.1016/j.vaccine.2025.126832.
    >> Share

  1228. NAKAYAMA T, Hamada S, Kawamura A, Sogawa Y, et al
    Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.
    Vaccine. 2025 Feb 6:126698. doi: 10.1016/j.vaccine.2024.126698.
    >> Share

  1229. VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al
    Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.
    Vaccine. 2025;49:126838.
    >> Share

  1230. MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
    Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
    Vaccine. 2025;50:126818.
    >> Share

  1231. KANG HS, Kim SY, De Gagne JC, Chae SM, et al
    Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A qualitative descriptive study.
    Vaccine. 2025;50:126835.
    >> Share

  1232. SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
    A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
    Vaccine. 2025;50:126847.
    >> Share

  1233. JENNINGS MC, Nabia S, Morgan C, Nduka CC, et al
    Realist review of low- to upper-middle-income country experiences on integration of HPV vaccination with other adolescent health services.
    Vaccine. 2025;50:126833.
    >> Share

  1234. HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al
    Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.
    Vaccine. 2025;49:126744.
    >> Share

  1235. PORTER RM, Bednarczyk RA
    Better, worse, or holding the course? Analysis of HPV vaccination patterns in the US, 2008-2020.
    Vaccine. 2025;50:126824.
    >> Share

  1236. DOUA J, Ndembi N, Auerbach J, Kaseya J, et al
    Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
    Vaccine. 2025;50:126829.
    >> Share

  1237. CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al
    Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine.
    Vaccine. 2025;50:126817.
    >> Share

  1238. WALKER RI
    Conserved antigens for enteric vaccines.
    Vaccine. 2025;50:126828.
    >> Share

  1239. SORENSEN JK, Jensen A, Zimakoff AC, Vittrup DM, et al
    Genetic associations with measles PRNT and IgG antibody response to MMR vaccination in 6- and 15-month-old children.
    Vaccine. 2025;50:126788.
    >> Share

  1240. GAO MZ, Awonusi OO, Ramkumar SP, Myint JA, et al
    The Affordable Care Act and change in human papillomavirus (HPV) vaccine uptake in the United States.
    Vaccine. 2025;50:126842.
    >> Share

  1241. KAN AKC, Mak HWF, Chiang V, Yim JSH, et al
    Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life.
    Vaccine. 2025;50:126849.
    >> Share

  1242. URSELLI F, Gomez A, Gray MD, Cameron CE, et al
    Identification of antibodies induced by immunization with the syphilis vaccine candidate Tp0751.
    Vaccine. 2025;50:126804.
    >> Share

  1243. POWELL A, Jones A, Van Hout MC, Montgomery C, et al
    Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
    Vaccine. 2025;50:126837.
    >> Share

  1244. VAN ENTER BJD, de Zeeuw J, Bakar O, Bakhlakh S, et al
    Health system barriers to HPV-vaccination in adolescent females with a Moroccan or Turkish migration background in the Netherlands: A qualitative study.
    Vaccine. 2025;50:126827.
    >> Share

  1245. GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
    Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
    Vaccine. 2025;49:126802.
    >> Share

  1246. PIGHI L, Salvagno GL, Lippi G
    Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine.
    Vaccine. 2025 Feb 1:126803. doi: 10.1016/j.vaccine.2025.126803.
    >> Share

  1247. CHUNG H, Krishnasamy M, Joyce T, Dryden T, et al
    "It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia.
    Vaccine. 2025;50:126826.
    >> Share

  1248. EIDEN AL, Mackie DS, Modi K, Drakeley S, et al
    Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study.
    Vaccine. 2025;50:126807.
    >> Share

    January 2025
  1249. MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic.
    Vaccine. 2025;49:126782.
    >> Share

  1250. GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
    Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
    Vaccine. 2025;49:126777.
    >> Share

  1251. GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al
    Implementing behavioural science-informed letter interventions to increase COVID-19 vaccination uptake in London residents. A difference-in-difference study in London, United Kingdom.
    Vaccine. 2025;49:126781.
    >> Share

  1252. FETENSA G, Tolossa T, Besho M, Yadesa G, et al
    Willingness to take Mpox vaccine and associated factors among health professionals in Ethiopia: A cross-sectional study.
    Vaccine. 2025;49:126822.
    >> Share

  1253. BARAL R, Amponsa-Achiano K, Barros I, Cofie P, et al
    What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis.
    Vaccine. 2025;49:126769.
    >> Share

  1254. DALE KD, Denholm JT
    Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on the phase 2b trial results.
    Vaccine. 2025;49:126816.
    >> Share

  1255. ONO S, Nakajima M, Yamana H, Michihata N, et al
    Tetanus toxoid vaccination uptake by trauma patients in Japan: A retrospective cohort study using large administrative claims data.
    Vaccine. 2025;49:126812.
    >> Share

  1256. YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al
    A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.
    Vaccine. 2025;49:126787.
    >> Share

  1257. MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al
    A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
    Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768.
    >> Share

  1258. JIANG Y, Luo Y, Xiao X, Li X, et al
    Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55-89 years from 1990 to 2021: Results from the global burden of disease study 2021.
    Vaccine. 2025;49:126786.
    >> Share

  1259. HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
    A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
    Vaccine. 2025;49:126780.
    >> Share

  1260. VIGEZZI GP, Vecchio R, Barbati C, Bonazza G, et al
    Historical analysis of the first smallpox vaccination campaigns in early 19-century northern Italy: organisation and communication insights for contemporary epidemics' prevention and control.
    Vaccine. 2025;49:126764.
    >> Share

  1261. WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al
    Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.
    Vaccine. 2025;49:126808.
    >> Share

  1262. KHAN A, Zhu Y, Babcock HM, Busse LW, et al
    COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022.
    Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806.
    >> Share

  1263. STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
    Corrigendum to "General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis" [Vaccine 40 (23) (2022 May 20) 3236-3243].
    Vaccine. 2025;48:126741.
    >> Share

  1264. FLECK-VIDAL C, Doubell A, Gerke C, Lamichhane U, et al
    Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries.
    Vaccine. 2025;49:126771.
    >> Share

  1265. ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al
    Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
    Vaccine. 2025;49:126754.
    >> Share

  1266. LAO G, Feng J, Wu L, Su W, et al
    Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
    Vaccine. 2025;49:126799.
    >> Share

  1267. ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al
    A framework for monitoring RSV prevention product effectiveness in the United States.
    Vaccine. 2025;45:126633.
    >> Share

  1268. EURICH DT, Weaver O, McDermott C, Soprovich A, et al
    Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.
    Vaccine. 2025;45:126614.
    >> Share

  1269. CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al
    Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
    Vaccine. 2025;45:126582.
    >> Share

  1270. WEI Y, Wang J, Wang L, Liu B, et al
    Comparative study on the inactivation and immunogenicity of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different inactivants.
    Vaccine. 2025 Jan 24:126766. doi: 10.1016/j.vaccine.2025.126766.
    >> Share

  1271. KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al
    Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination.
    Vaccine. 2025;48:126743.
    >> Share

  1272. GLOANEC N, Guyard-Nicodeme M, Chemaly M, Dory D, et al
    Reverse vaccinology: A strategy also used for identifying potential vaccine antigens in poultry.
    Vaccine. 2025;48:126756.
    >> Share

  1273. OKA E, Ueda Y, Yagi A, Machida M, et al
    Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
    Vaccine. 2025;48:126767.
    >> Share

  1274. FARNSWORTH MG, Khanipov K, Botnar K, Weaver SC, et al
    Real-world evidence of yellow Fever vaccination data-driven study.
    Vaccine. 2025;48:126758.
    >> Share

  1275. SATO R
    Closing the gap on vaccine uptake in developing countries: Is there a role for cash incentives?
    Vaccine. 2025;48:126763.
    >> Share

  1276. BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al
    Corrigendum to "The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review" [Vaccine 42 (2024) 84-98].
    Vaccine. 2025;48:126732.
    >> Share

  1277. PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al
    The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
    Vaccine. 2025;48:126725.
    >> Share

  1278. NGOCHO JS, de Jongh CEVG, Sebba J, Mtei M, et al
    Emerging of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-vallent pneumococcal conjugate vaccine era in Moshi district, Tanzania. A short communication.
    Vaccine. 2025;48:126724.
    >> Share

  1279. HINMAN AR, Banerjee E, Brewer NT, Hayes ES, et al
    Corrigendum to "Sustainability of measles, rubella, and congenital rubella syndrome (CRS) elimination in the United States, January 2022 - June 2024" [Vaccine 46C (2025) 126681].
    Vaccine. 2025;48:126739.
    >> Share

  1280. GIOVANETTI M, Cella E, Sampaio SC, Elias MC, et al
    Dengue vaccination and outbreaks: Bridging clinical diagnosis with genomic surveillance.
    Vaccine. 2025 Jan 20:126755. doi: 10.1016/j.vaccine.2025.126755.
    >> Share

  1281. CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al
    Navigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions.
    Vaccine. 2025;47:126694.
    >> Share

  1282. MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al
    Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-339
    Vaccine. 2025;48:126628.
    >> Share

  1283. LIAO Z, Deng L, Luo J, Shi M, et al
    Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
    Vaccine. 2025;48:126757.
    >> Share

  1284. RAINERI D, Mazzucca CB, Moia R, Bruna R, et al
    Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination.
    Vaccine. 2025;48:126723.
    >> Share

  1285. BANU S, Kishor PV, Krishnappa S, Ramasamy Periyasamy TS, et al
    Effect of vaccination against foot-and-mouth disease during mid-pregnancy on the neutralizing antibody response in the cow.
    Vaccine. 2025;48:126738.
    >> Share

  1286. MADESH S, McGill J, Jaworski DC, Ferm J, et al
    Prolonged immune response to tick-borne Ehrlichia chaffeensis infection using a genetically modified live vaccine.
    Vaccine. 2025;48:126730.
    >> Share

  1287. SILVA-FERNANDES AT, Moreira SB, Gaspar LP, Cajaraville ACDRA, et al
    Safety and immunogenicity of different 17DD yellow fever vaccines in golden-headed tamarins (Leontopithecus chrysomelas): Inhibition of viremia and RNAemia after homologous live-attenuated vaccination.
    Vaccine. 2025;48:126721.
    >> Share

  1288. TRANTER I, Judd D, Stickley M, Vasant B, et al
    Promoting aged care COVID-19 and influenza vaccination through education of Australian residential aged care staff: A mixed methods project evaluation.
    Vaccine. 2025;48:126742.
    >> Share

  1289. SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al
    Childhood opportunity index and vaccine uptake in pediatric COVID-19 hospitalizations.
    Vaccine. 2025;48:126734.
    >> Share

  1290. DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al
    The impact of vaccination on the length of stay of hospitalized COVID-19 patients in Brazil.
    Vaccine. 2025;48:126735.
    >> Share

  1291. POURAKBARI B, Mahmoudi S, Sajedi Moghaddam S, Jafari E, et al
    Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is it time to include booster acellular Pertussis Vaccines in the immunization schedule?
    Vaccine. 2025;48:126736.
    >> Share

  1292. KUMAR S, Hazlett K, Bai G
    Mucosal immunity elicited by a human-Fcgamma receptor-I targeted intranasal vaccine platform enhances resistance against nasopharyngeal colonization of Streptococcus pneumoniae and induces broadly protective immunity against respiratory pathogens.
    Vaccine. 2025;48:126729.
    >> Share

  1293. SONG H, Jin S, Yang GJ, Lim NWH, et al
    Modelling the impact and cost-effectiveness of upcoming Zika virus vaccines on congenital Zika syndrome.
    Vaccine. 2025;48:126728.
    >> Share

  1294. SANTANA AP, Soborg B, Jacobsen SU, Zettler I, et al
    Danish parents' vaccination readiness is associated with their children's officially registered vaccination history.
    Vaccine. 2025;47:126693.
    >> Share

  1295. ISLAM EA, Fegan JE, Zeppa JJ, Ahn SK, et al
    Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria.
    Vaccine. 2025;48:126709.
    >> Share

  1296. AANYU HT, Nalunkuma C, Kaudha E, Nalumansi E, et al
    Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.
    Vaccine. 2025;48:126726.
    >> Share

  1297. DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al
    Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
    Vaccine. 2025;48:126727.
    >> Share

  1298. ZHANG Y, Li X, Yang Y, Yin Y, et al
    Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
    Vaccine. 2025;48:126722.
    >> Share

  1299. COROMINAS J, Garriga C, Prenafeta A, Moros A, et al
    Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
    Vaccine. 2025;47:126685.
    >> Share

  1300. XIE W, Luo D, Soni V, Wang Z, et al
    Functional characterization of MMAR_1296 in Mycobacterium marinum and its potential as a vaccine candidate.
    Vaccine. 2025;48:126720.
    >> Share

  1301. GONG X, Huang Z, Zheng Y, Xiao W, et al
    Rotavirus vaccine effectiveness and coverage among children younger than 5 years old in Shanghai, China: A test-negative case control study.
    Vaccine. 2025;48:126731.
    >> Share

  1302. ROSENTHAL M, Stoecker C, Leidner AJ, Cho BH, et al
    Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions.
    Vaccine. 2025;44:126567.
    >> Share

  1303. ESCABI-WOJNA E, Alvelo-Fernandez PM, Suarez E, Colon-Lopez V, et al
    Sex differences in parental reasons for lack of intent to initiate HPV vaccination among adolescents ages 13-17 years: National Immunization Survey - Teen 2019-2021.
    Vaccine. 2025;44:126584.
    >> Share

  1304. MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al
    Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
    Vaccine. 2025;44:126569.
    >> Share

  1305. FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al
    The trend in national childhood immunization program coverage throughout Serbian communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs. COVID-19 pandemic.
    Vaccine. 2025;44:126576.
    >> Share

  1306. CARNEIRO GB, Yerneni SS, Chinaia K, Araujo AP, et al
    Protection induced by Streptococcus pneumoniae extracellular vesicles against nasal colonization and invasive infection in mice and the role of PspA.
    Vaccine. 2025;44:126566.
    >> Share

  1307. OLIVERO-DEIBE N, Frigini EN, Ramos N, Carrion F, et al
    The stability of PCV2 virus-like particles from mammalian cells and challenges for biotechnological applications.
    Vaccine. 2025;44:126549.
    >> Share

  1308. HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al
    Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
    Vaccine. 2025;44:126541.
    >> Share

  1309. LI Y, Chen L, Xiao J, Feng K, et al
    Immunoprotective efficacy of Escherichia coli-derived outer membrane vesicles displaying PlpE protein of Pasteurella multocida.
    Vaccine. 2025;44:126532.
    >> Share

  1310. DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al
    Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
    Vaccine. 2025;44:126550.
    >> Share

  1311. SILVA HM
    Return of poliomyelitis: A real risk in a country afflicted by scientific denialism.
    Vaccine. 2025;44:126449.
    >> Share

  1312. DAVIES C, Baker B, Berger MN, Knox SL, et al
    Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over.
    Vaccine. 2025 Jan 12:126699. doi: 10.1016/j.vaccine.2024.126699.
    >> Share

  1313. VITTRUP DM, Charabi S, Jensen A, Stensballe LG, et al
    A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age.
    Vaccine. 2025;47:126687.
    >> Share

  1314. RITCHIE AJ, Meeyai A, Trotter C, Douglas AD, et al
    Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
    Vaccine. 2025;47:126703.
    >> Share

  1315. OSEI I, Schmidt-Chanasit J, Licciardi PV, Secka O, et al
    Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.
    Vaccine. 2025;47:126712.
    >> Share

  1316. FREY SE, Brady R, Jackson L, Goepfert P, et al
    Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59(R).
    Vaccine. 2025;47:126702.
    >> Share

  1317. HONDA-OKUBO Y, Vaghasiya U, Petrovsky N
    Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
    Vaccine. 2025;47:126707.
    >> Share

  1318. GENDLER Y, Ofri L, Videl H
    Understanding factors contributing to vaccination underutilization among Jewish ultra-orthodox communities in Israel: A cross-sectional study.
    Vaccine. 2025;47:126711.
    >> Share

  1319. SHIELDS T, King KD, Cripps S, Edwards SA, et al
    Perspectives on vaccination among unvaccinated members of a Canadian indigenous population.
    Vaccine. 2025;47:126665.
    >> Share

  1320. CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al
    Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule.
    Vaccine. 2025;47:126705.
    >> Share

  1321. NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
    Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Ep
    Vaccine. 2025;47:126701.
    >> Share

  1322. CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al
    Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
    Vaccine. 2025;47:126664.
    >> Share

  1323. CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
    Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
    Vaccine. 2025;47:126696.
    >> Share

  1324. LE N, McMann TJ, Wenzel C, Li Z, et al
    COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified twitter accounts.
    Vaccine. 2025;47:126688.
    >> Share

  1325. SEO H, Kim BJ, Oh J, Jung S, et al
    Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
    Vaccine. 2025;47:126710.
    >> Share

  1326. SU Q, Qiu F, Gao Z, Zhao Y, et al
    Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
    Vaccine. 2025;47:126655.
    >> Share

  1327. ZHANG S, Liu G, Wang C, Guo A, et al
    Enhanced immunogenicity of a BoHV-1 gG-/tk- vaccine.
    Vaccine. 2025;47:126704.
    >> Share

  1328. LI W, Li YA, Wang S, Shi H, et al
    A universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein.
    Vaccine. 2025;47:126700.
    >> Share

  1329. DE LA FUENTE J, Gortazar C, Contreras M, Kabi F, et al
    Anti-tick vaccine in Uganda - from bench to field.
    Vaccine. 2025 Jan 6:126695. doi: 10.1016/j.vaccine.2024.126695.
    >> Share

  1330. EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al
    Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
    Vaccine. 2025;47:126689.
    >> Share

  1331. NAKANO T, Tanaka T
    Looking back at the 27th Academic Conference of the Japanese Society for Vaccinology.
    Vaccine. 2025;47:126697.
    >> Share

  1332. DUAN Y, Suo L, Li X, Bai C, et al
    Association between underlying conditions, multimorbidity, and COVID-19 vaccination status of adults aged >/=80 years old in Beijing, China.
    Vaccine. 2025;47:126677.
    >> Share

  1333. ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al
    Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
    Vaccine. 2025;46:126669.
    >> Share

  1334. ANSELEM O, Charlier C, Viaud M, Lelong N, et al
    Barriers to influenza vaccination during pregnancy in France: A national population-based study.
    Vaccine. 2025;47:126671.
    >> Share

  1335. KAUL R, Leidner AJ, Chesson HW
    Trends in costs of routinely recommended vaccines in the United States, 2001-2023.
    Vaccine. 2025;47:126667.
    >> Share

  1336. POLAND GA, de la Fuente J
    Quantum vaccinology: A new science and epistemological abstraction framework for developing new vaccines and understanding the generation of the immune response.
    Vaccine. 2025;46:126641.
    >> Share

  1337. GALETTI SC, Gadoth A, Halbrook M, Tobin NH, et al
    Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures.
    Vaccine. 2025;46:126661.
    >> Share

  1338. GIERSING B, Mo AX, Hwang A, Baqar S, et al
    Meeting summary: Global vaccine and immunization research forum, 2023.
    Vaccine. 2025;46:126686.
    >> Share

  1339. POSTON TB, Girardi J, Kim M, Zwarycz P, et al
    Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.
    Vaccine. 2025;43.
    >> Share

  1340. LANG BALIJA M, Jagusic M, Forcic D, Ivancic-Jelecki J, et al
    Mumps virus neurovirulence assessment-impact of viral doses, animal sex and age on results dispersion.
    Vaccine. 2025;43.
    >> Share

  1341. CHAUDHARY M, Cutland CL, Bonet M, Gentile A, et al
    Burden of Lassa fever disease in pregnant women and children and options for prevention.
    Vaccine. 2025;43.
    >> Share

  1342. DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al
    Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry.
    Vaccine. 2025;46:126682.
    >> Share

  1343. FLORES-VALDEZ MA
    Intravenous vaccination with BCG against tuberculosis: Strengths and questions deserving further research.
    Vaccine. 2025 Jan 1:126666. doi: 10.1016/j.vaccine.2024.126666.
    >> Share

    December 2024
  1344. GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
    Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
    Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
    >> Share

  1345. FERNANDEZ A, Askenazy F, Thummler S
    Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders.
    Vaccine. 2024 Dec 30:126679. doi: 10.1016/j.vaccine.2024.126679.
    >> Share

  1346. HUSSEIN I, Valiverronen E, Nohynek H, Lamsa R, et al
    What makes an expert in childhood vaccinations? Perceptions of parents in Finland.
    Vaccine. 2024;46:126645.
    >> Share

  1347. PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al
    Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
    Vaccine. 2024;46:126668.
    >> Share

  1348. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;46:126676.
    >> Share

  1349. ERBS G, Jakobsen JT, Schmidt ST, Christensen D, et al
    Retinoic acid-adjuvanted vaccine induces antigen-specific secretory IgA in the gut of newborn piglets.
    Vaccine. 2024;46:126672.
    >> Share

  1350. TANG E, Ray I, Arnold BF, Acharya NR, et al
    Recombinant zoster vaccine and the risk of dementia.
    Vaccine. 2024;46:126673.
    >> Share

  1351. NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al
    Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
    Vaccine. 2024;46:126651.
    >> Share

  1352. MALTEZOU HC, Poland GA, de Lejarazu RO
    Influenza vaccination for children in Europe: The health of every child matters.
    Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675.
    >> Share

  1353. SAHA R, Lo M, De P, Deb AK, et al
    Epidemiology of viral gastroenteritis in children and genetic diversity of rotavirus strains in Kolkata, West Bengal after introduction of rotavirus vaccine.
    Vaccine. 2024;45:126637.
    >> Share

  1354. ZHANG J, Zhang L, Li J, Ma J, et al
    Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.
    Vaccine. 2024;46:126662.
    >> Share

  1355. MA Y, Dong C, Kim JK, Zhu W, et al
    Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.
    Vaccine. 2024;46:126670.
    >> Share

  1356. CHO JY, Lee H, Wannaadisai W, Vietri J, et al
    Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.
    Vaccine. 2024;46:126656.
    >> Share

  1357. AI L, Gao Z, Lv H, Zhang J, et al
    Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China.
    Vaccine. 2024;46:126653.
    >> Share

  1358. BEERENS D
    Navigating the future of vaccination strategies: Insights from the 17(th) annual vaccine congress.
    Vaccine. 2024;46:126634.
    >> Share

  1359. ZHANG Y, Zhao K, Liu Y, Xu J, et al
    An oral probiotic vaccine loaded by Lactobacillus casei effectively increases defense against GCRV infection in grass carp.
    Vaccine. 2024;45:126660.
    >> Share

  1360. GRIMES DR
    Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
    Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657.
    >> Share

  1361. SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al
    Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
    Vaccine. 2024;45:126615.
    >> Share

  1362. KILANY WH, Zain El-Abideen MA, Hisham I, Van Gaver D, et al
    Laboratory safety and immunogenicity evaluation of live attenuated avian infectious bronchitis GI-23 virus vaccine.
    Vaccine. 2024;45:126659.
    >> Share

  1363. PEREZ-SAUCEDO D, Castro-Perea NV, Ruiz-Cruz A, Bustos-Jaimes I, et al
    Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
    Vaccine. 2024;45:126663.
    >> Share

  1364. SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al
    Trust in government vaccine recommendations during the Covid-19 pandemic in Singapore: A longitudinal survey study.
    Vaccine. 2024;45:126643.
    >> Share

  1365. BARAL R, Fleming JA, Barros I, Cofie P, et al
    What will it take? Perspectives from five low- and middle-income countries on opportunities and challenges of introducing new maternal vaccines.
    Vaccine. 2024;45:126654.
    >> Share

  1366. CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al
    "They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
    Vaccine. 2024;45:126618.
    >> Share

  1367. WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al
    Client satisfaction, safety, and insights from a three-season survey on influenza vaccinations delivered at community pharmacies in Germany.
    Vaccine. 2024;45:126650.
    >> Share

  1368. GOMEZ JA, Pannunzio ME, Karwala P, Nocita F, et al
    Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina.
    Vaccine. 2024;45:126589.
    >> Share

  1369. TANAKA H, Takahashi Y, Matsumoto S, Matsuyama M, et al
    Shorter incubation period in symptomatic measles patients who had no history of measles vaccination.
    Vaccine. 2024;45:126652.
    >> Share

  1370. LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al
    Corrigendum to "Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023".
    Vaccine. 2024;45:126640.
    >> Share

  1371. SERPA GONCALVES M, de Oliveira MM, Andrade RS, de Oliveira LF, et al
    Systematic review on the effectiveness of Brucella abortus S19 and RB51 vaccine strains in field studies.
    Vaccine. 2024;45:126649.
    >> Share

  1372. FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al
    Immunization and challenge trials in a murine model using different inactivated recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
    Vaccine. 2024;45:126638.
    >> Share

  1373. WANG J, Tonnies T, Brinks R
    Seasonal influenza vaccination coverage and the social determinants of influenza vaccination among people over 50 with diabetes in Europe: Analyzing population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
    Vaccine. 2024;45:126646.
    >> Share

  1374. KASSAM P, El-Zein M, Tota JE, Tellier PP, et al
    HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.
    Vaccine. 2024;45:126644.
    >> Share

  1375. DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
    Corrigendum to Assessment of the Bnt162b2 covid-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine Volume 43, Part 1, 1 January 2025, 126494.
    Vaccine. 2024;45:126630.
    >> Share

  1376. YANG J, Yao YL, Lv XY, Geng LH, et al
    The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.
    Vaccine. 2024;45:126635.
    >> Share

  1377. NUZHATH T, Yang Y, Couture MC, Gu NY, et al
    Structural equation modeling to evaluate the adult vaccine hesitancy scale for vaccines recommended during pregnancy.
    Vaccine. 2024;45:126568.
    >> Share

  1378. BIAN S, Cai Q, Wang S, Xie Y, et al
    Evaluation of the toxoplasma Urm1 gene deletion mutant (PruDeltaUrm1) as a promising vaccine candidate against toxoplasmosis in mice.
    Vaccine. 2024;45:126632.
    >> Share

  1379. SINGER R, Hubotter I, Holzner F, Genedl C, et al
    School vaccination programmes to increase HPV vaccination coverage - Experiences from Bremen, Germany.
    Vaccine. 2024;45:126636.
    >> Share

  1380. SUN JW, Dodge LE, Kim EJ, Zhou L, et al
    Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
    Vaccine. 2024;45:126629.
    >> Share

  1381. PERRIER Q, Noble J, Bonadona A, Augier C, et al
    Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
    Vaccine. 2024;45:126617.
    >> Share

  1382. MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al
    Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
    Vaccine. 2024;45:126631.
    >> Share

  1383. WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al
    Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.
    Vaccine. 2024;45:126572.
    >> Share

  1384. LIMA JLC, da Silva AB, Cabral AS, de Miranda FM, et al
    Changes in population genetic structure of serotype 19A Streptococcus pneumoniae after universal childhood use of the 10-valent pneumococcal conjugate vaccine in Brazil.
    Vaccine. 2024;45:126588.
    >> Share

  1385. BAINBRIDGE S, Mappi T, Cleaveland S, Chubwa C, et al
    Field vaccination of locally-owned cattle against malignant catarrhal fever under environmentally challenging conditions in Tanzania.
    Vaccine. 2024;45:126587.
    >> Share

  1386. KARACHALIOU M, Espinosa A, Farre X, Blay N, et al
    Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.
    Vaccine. 2024;45:126591.
    >> Share

  1387. SLAMANIG S, Lemus N, Lai TY, Singh G, et al
    A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
    Vaccine. 2024;45:126586.
    >> Share

  1388. ENDER E, Joshi A, Snyder M, Kumar S, et al
    Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus.
    Vaccine. 2024;45:126592.
    >> Share

  1389. MASSEY PM, Murray RM, Kostizak K, Lo WJ, et al
    Exploring the ethics of using fictional stories for health education on social media to share information and emotions about the HPV vaccine: A cross-sectional study with interdisciplinary health experts.
    Vaccine. 2024 Dec 10:126575. doi: 10.1016/j.vaccine.2024.126575.
    >> Share

  1390. HOMSI MR, Davey-Rothwell MA, Alonge O, Caniza MA, et al
    Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean.
    Vaccine. 2024;45:126578.
    >> Share

  1391. MASEMOLA NM, Burnett RJ, Makamba-Mutevedzi PC, Schonfeldt M, et al
    Vaccine stock-outs: A preventable health facility obstacle contributing to missed vaccinations in South African children.
    Vaccine. 2024;45:126583.
    >> Share

  1392. ESKENAZI B, Rauch S, Elsiwi B, Bornman R, et al
    Undernutrition and antibody response to measles, tetanus and Haemophilus Influenzae type b (Hib) vaccination in pre-school south African children: The VHEMBE birth cohort study.
    Vaccine. 2024 Dec 7:126564. doi: 10.1016/j.vaccine.2024.126564.
    >> Share

  1393. BODY A, Lal L, Srihari S, MacIntyre CR, et al
    Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
    Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547.
    >> Share

  1394. CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al
    Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study.
    Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581.
    >> Share

  1395. XIA M, Huang P, Vago FS, Jiang W, et al
    Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
    Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585.
    >> Share

  1396. SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
    Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
    Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
    >> Share

  1397. KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al
    A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
    Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574.
    >> Share

  1398. LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al
    Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023.
    Vaccine. 2024 Dec 5:126571. doi: 10.1016/j.vaccine.2024.126571.
    >> Share

  1399. HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al
    Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
    Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579.
    >> Share

  1400. HSIAO A, Lewis N, Hansen J, Timbol J, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults.
    Vaccine. 2024;44:126543.
    >> Share

  1401. MATTHEWS RL, Khan N, Beckman B, Sharma S, et al
    Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.
    Vaccine. 2024 Dec 3:126577. doi: 10.1016/j.vaccine.2024.126577.
    >> Share

  1402. MOUSTAFA DA, Lou E, Schafer-Kestenman ME, Mateu-Borras M, et al
    Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.
    Vaccine. 2024;42:126476.
    >> Share

  1403. TANG A, Zhu M, Zhu J, Zhang D, et al
    The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is safe and effective in cats.
    Vaccine. 2024;42:126468.
    >> Share

  1404. TONG K, Hernandez EM, Basore K, Fremont DH, et al
    Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.
    Vaccine. 2024;42:126405.
    >> Share

  1405. WU R, Chen Z, Yang X, Chen Y, et al
    Investigating the characteristics of mumps outbreaks in Fujian Province, China.
    Vaccine. 2024;42:126415.
    >> Share

  1406. FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al
    Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024).
    Vaccine. 2024;42:126375.
    >> Share

  1407. PRY JM, McCullough K, Lai KW, Lim E, et al
    Defining long COVID using a population-based SARS-CoV-2 survey in California.
    Vaccine. 2024;42:126358.
    >> Share

  1408. CHUN J, Yoon D, Nowakowska A, Lee HD, et al
    Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126355.
    >> Share

  1409. CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al
    Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers.
    Vaccine. 2024;42:126308.
    >> Share

    November 2024
  1410. PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al
    COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
    Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539.
    >> Share

  1411. GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al
    Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
    Vaccine. 2024;44:126563.
    >> Share

  1412. ANABE D, Terasjarvi JT, Barkoff AM, Knuutila A, et al
    Association of baseline cytokines with antibody concentrations after diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children.
    Vaccine. 2024 Nov 30:126573. doi: 10.1016/j.vaccine.2024.126573.
    >> Share

  1413. GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al
    Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.
    Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561.
    >> Share

  1414. COSMA C, Radi A, Cattano R, Zanobini P, et al
    Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature.
    Vaccine. 2024;44:126559.
    >> Share

  1415. NYIKA P, Yankey D, Elam-Evans LD, Meyer S, et al
    Human papillomavirus vaccination coverage among adolescent boys and girls in the United States: A birth year cohort analysis of the National Immunization Survey-Teen, 2016-2022.
    Vaccine. 2024;44:126560.
    >> Share

  1416. FLORES D, Luna EM
    The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
    Vaccine. 2024;44:126565.
    >> Share

  1417. BHAT N, Vodicka E, Clifford A, Ananth KB, et al
    The evidence base for rotavirus vaccination in India: Current status, future needs.
    Vaccine. 2024;44:126551.
    >> Share

  1418. THIEM VD, Anh DD, Ha VH, Van Thom N, et al
    Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
    Vaccine. 2024;44:126542.
    >> Share

  1419. WANG Q, Yang L, Li L, Xiu S, et al
    Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
    Vaccine. 2024;44:126570.
    >> Share

  1420. EDELSTEIN M, Shibli H, Bornstein J
    Differences in knowledge, attitudes and intentions towards HPV vaccination among young adults from diverse socio-cultural groups in Israel: A cross-sectional study.
    Vaccine. 2024;44:126548.
    >> Share

  1421. BORYS D, Smulders R, Haranaka M, Nakano T, et al
    Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naive Japanese adults: A phase 1 randomized dose-escalation trial.
    Vaccine. 2024;44:126545.
    >> Share

  1422. LINK EK, Tscherne A, Sutter G, Smith ER, et al
    A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
    Vaccine. 2024;43.
    >> Share

  1423. PITTS PJ, Poland GA
    Addressing vaccine misinformation: The critical need for complete product information disclosure.
    Vaccine. 2024;44:126558.
    >> Share

  1424. KASAIJA PD, Kabi F, Semakula J, Kyakuwa I, et al
    One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.
    Vaccine. 2024;44:126562.
    >> Share

  1425. GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al
    COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.
    Vaccine. 2024;44:126544.
    >> Share

  1426. BLUKACZ A, Obach A, Vasquez P, Campana C, et al
    Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis.
    Vaccine. 2024;44:126546.
    >> Share

  1427. AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al
    Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.
    Vaccine. 2024;43.
    >> Share

  1428. CHOI YJ, Jung J, Kang M, Choi MJ, et al
    The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
    Vaccine. 2024;44:126506.
    >> Share

  1429. DEAN NE, Halloran ME, Zarnitsyna VI
    Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
    Vaccine. 2024;43.
    >> Share

  1430. CASTILLO-ZUNINO F, Hester KA, Keskinocak P, Nazzal D, et al
    Associations between family planning, healthcare access, and female education and vaccination among under-immunized children.
    Vaccine. 2024;44:126540.
    >> Share

  1431. GLESER D, Cohen M, Kenigswald G, Kedmi M, et al
    Optimizing protocols for the 919 strain-based bovine ephemeral fever virus vaccine (Ultravac(R), Zoetis): Evaluation of dose-dependent effectiveness and long-term immunity.
    Vaccine. 2024;43.
    >> Share

  1432. REED NS, Brewer CC, Akintunde G, Blackie FF, et al
    Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.
    Vaccine. 2024;43.
    >> Share

  1433. TSAI Y, Leung J, Anderson TC, Zhou F, et al
    Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage.
    Vaccine. 2024;43.
    >> Share

  1434. LEE M, Qin C, Lee Y, Deng J, et al
    COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.
    Vaccine. 2024;43.
    >> Share

  1435. WANTUCH PL, Knoot CJ, Marino EC, Harding CM, et al
    Klebsiella pneumoniae bioconjugate vaccine functional durability in mice.
    Vaccine. 2024;43.
    >> Share

  1436. DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
    Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.
    Vaccine. 2024;43.
    >> Share

  1437. COULTER FJ, Messer WB
    Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades.
    Vaccine. 2024;43.
    >> Share

  1438. SUFFEL AM, Carreira H, Walker J, Grint D, et al
    The association of maternal mental health with vaccination coverage and timeliness in early childhood - A historical cohort study in England using electronic health records.
    Vaccine. 2024;43.
    >> Share

  1439. HUNG CT, Wang LM, Hung YC
    Trends and characteristics of herpes zoster vaccination among older adults with asthma in the United States, 2008-2023: Findings from self-reported national surveys.
    Vaccine. 2024;43.
    >> Share

  1440. MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al
    How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.
    Vaccine. 2024;43.
    >> Share

  1441. MAO J, Kang HJ, Eom GD, Yoon KW, et al
    Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.
    Vaccine. 2024;43.
    >> Share

  1442. MARSZALEK M, Hawking MKD, Gutierrez A, Firman N, et al
    Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care.
    Vaccine. 2024;43.
    >> Share

  1443. VASQUEZ WF, Trudeau JM
    Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications.
    Vaccine. 2024;42:126126.
    >> Share

  1444. KIRK B, Bush C, Toyip A, Mues KE, et al
    Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States.
    Vaccine. 2024;42:126113.
    >> Share

  1445. BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al
    Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
    Vaccine. 2024;42:126119.
    >> Share

  1446. TOMATIS C, Ferrer MF, Aquila S, Thomas PD, et al
    Baculovirus surface display of a chimeric E-NS1 protein of YFV protects against YFV infection.
    Vaccine. 2024;42:126045.
    >> Share

  1447. LEE YS, Cheong MS, Lee J, Bang EK, et al
    Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus.
    Vaccine. 2024;43.
    >> Share

  1448. PARK JY, Senevirathne A, Lee JH
    Development of a candidate vaccine against severe fever with thrombocytopenia syndrome virus using Gn/Gc glycoprotein via multiple expression vectors delivered by attenuated Salmonella confers effective protection in hDC-SIGN transduced mice.
    Vaccine. 2024;43.
    >> Share

  1449. FURUICHI M, Ohnishi T, Yaginuma M, Yamada Y, et al
    Live-attenuated vaccine failure after liver transplantation: A 20-year cohort study.
    Vaccine. 2024;43.
    >> Share

  1450. KIM SS, Garcia Quesada M, Prasad PV, Nelson KN, et al
    Challenges of using the test-negative design to measure vaccine effectiveness of multi-pathogen combination vaccines targeting one syndrome.
    Vaccine. 2024 Nov 12:126520. doi: 10.1016/j.vaccine.2024.126520.
    >> Share

  1451. BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al
    A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
    Vaccine. 2024;43.
    >> Share

  1452. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 10-13 September 2024.
    Vaccine. 2024;43.
    >> Share

  1453. LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al
    Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.
    Vaccine. 2024;43.
    >> Share

  1454. JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al
    Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
    Vaccine. 2024;43.
    >> Share

  1455. WIJDICKS EFM
    Fatal ascending paralysis after typhoid vaccine: Guillain and Barre's description of the very first case.
    Vaccine. 2024;42:126443.
    >> Share

  1456. CHOE S, Park GN, Kim KS, Shin J, et al
    Immunogenicity of a classical swine fever bait vaccine (Flc-LOM- BE(rns)) in hybrid-wild boars.
    Vaccine. 2024;43.
    >> Share

  1457. REGAN AK, Couture MC, Callaghan T, Agnew B, et al
    Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination.
    Vaccine. 2024;43.
    >> Share

  1458. LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al
    Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
    Vaccine. 2024;43.
    >> Share

  1459. PERALTA ALVAREZ MP, Downward K, White A, Harris SA, et al
    Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route.
    Vaccine. 2024;42:126444.
    >> Share

  1460. GWAK E, Choe SA, Bolormaa E, Choe YJ, et al
    Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea.
    Vaccine. 2024;43.
    >> Share

  1461. GOKTUNA PT, Cokcaliskan C
    Concurrent use of the foot-and-mouth disease and other vaccines in livestock.
    Vaccine. 2024;43.
    >> Share

  1462. DE LUCA C, Hess M
    Vaccination strategies to protect chickens from fowl adenovirus (FAdV)-induced diseases: A comprehensive review.
    Vaccine. 2024;43.
    >> Share

  1463. DILANGE L, El Belghiti FA, Demiguel V, Anselem O, et al
    Pertussis vaccination coverage in women at two months postpartum and associated factors in France, National Perinatal Survey 2021.
    Vaccine. 2024;43.
    >> Share

  1464. PETERSON J, Drazan D, Moughan B, Maguire JD, et al
    Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
    Vaccine. 2024;43.
    >> Share

  1465. MATTES F, Dratva J, Schmelzer S, Wagner A, et al
    The association between service experience in vaccination centers and expectation confirmation as a driver of future vaccination intentions: Results from a survey among users of a Swiss mass COVID-19 vaccination center.
    Vaccine. 2024;43.
    >> Share

  1466. AGUIRRE-CAMACHO A, Hidalgo B, Rash JA
    Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study.
    Vaccine. 2024;43.
    >> Share

  1467. ANGULO M, Angulo C
    Trained immunity-based vaccines: A vision from the one health initiative.
    Vaccine. 2024;43.
    >> Share

  1468. WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al
    Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
    Vaccine. 2024;43.
    >> Share

  1469. LEWIS NM, Harker EJ, Leis A, Zhu Y, et al
    Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
    Vaccine. 2024;43.
    >> Share

  1470. DENG Y, Hayes KN, Zhao Y, Chachlani P, et al
    Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults.
    Vaccine. 2024;43.
    >> Share

  1471. STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al
    Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.
    Vaccine. 2024;43.
    >> Share

  1472. LE MARCHAND C, Singson JRC, Clark A, Shah D, et al
    Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.
    Vaccine. 2024;43.
    >> Share

  1473. KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al
    Corrigendum to "Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection" [Vaccine 42 (1-12) (2024) 126325].
    Vaccine. 2024;43.
    >> Share

  1474. DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al
    Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices.
    Vaccine. 2024;43.
    >> Share

  1475. KIM SA, Maeda M, Murata F, Fukuda H, et al
    Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study.
    Vaccine. 2024;43.
    >> Share

  1476. THOBARI JA, Watts E, Carvalho N, Haposan JH, et al
    Cost effectiveness analysis of rotavirus vaccination in Indonesia.
    Vaccine. 2024;43.
    >> Share

  1477. CHARLAND K, Quach C, Papenburg J, Pierce L, et al
    Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.
    Vaccine. 2024;43.
    >> Share

  1478. WARIRI O, Utazi CE, Okomo U, Dotse-Gborgbortsi W, et al
    Multi-level determinants of timely routine childhood vaccinations in The Gambia: Findings from a nationwide analysis.
    Vaccine. 2024;43.
    >> Share

    October 2024
  1479. ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
    RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
    Vaccine. 2024;42:126490.
    >> Share

  1480. KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
    Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
    Vaccine. 2024;42:126488.
    >> Share

  1481. HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al
    On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.
    Vaccine. 2024;42:126455.
    >> Share

  1482. MOSCHESE V, Graziani S, Spadea A, D'Amore M, et al
    Vaccinations in children of non-European origin: The Vax4globe survey.
    Vaccine. 2024;42:126466.
    >> Share

  1483. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
    SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
    Vaccine. 2024;42:126463.
    >> Share

  1484. MACINTYRE CR, Akhtar Z, Moa A
    Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]".
    Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
    >> Share

  1485. WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al
    Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.
    Vaccine. 2024;42:126475.
    >> Share

  1486. LEIS AM, Wagner A, Flannery B, Chung JR, et al
    Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
    Vaccine. 2024;42:126493.
    >> Share

  1487. EBERHARDT J, Al-Qerem W, Ling J
    Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.
    Vaccine. 2024;42:126474.
    >> Share

  1488. GAM PH, Dung NM, Aziz JMA, Makram AM, et al
    Vaccine for hand, foot, and mouth disease (HFMD): A call to action.
    Vaccine. 2024 Oct 27:126491. doi: 10.1016/j.vaccine.2024.126491.
    >> Share

  1489. MAURE C, Khazhidinov K, Kang H, Auzenbergs M, et al
    Chikungunya vaccine development, challenges, and pathway toward public health impact.
    Vaccine. 2024;42:126483.
    >> Share

  1490. MCGREGOR R, Paterson A, Lavender B, Hooker C, et al
    The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.
    Vaccine. 2024;42:126482.
    >> Share

  1491. VIELOT NA, Ballard CAP, St Jean DT, Page S, et al
    Documenting human papillomavirus vaccine refusal among adolescents in electronic health records: A mixed methods study.
    Vaccine. 2024;42:126467.
    >> Share

  1492. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126458.
    >> Share

  1493. HO TC, Chuang SC, Hung KC, Chang CC, et al
    Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
    Vaccine. 2024;42:126470.
    >> Share

  1494. LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
    Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review.
    Vaccine. 2024;42:126472.
    >> Share

  1495. MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al
    Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
    Vaccine. 2024;42:126471.
    >> Share

  1496. JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al
    A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
    Vaccine. 2024;42:126427.
    >> Share

  1497. VALENCIA-HERNANDEZ AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, et al
    A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
    Vaccine. 2024;42:126291.
    >> Share

  1498. ROWE M, Collier AY, Barouch DH
    Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
    Vaccine. 2024;42:126306.
    >> Share

  1499. PHAM-HUY A, Bowes J, Russell K, Amira A, et al
    Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
    Vaccine. 2024;42:126090.
    >> Share

  1500. KILIC G, Debisarun PA, Alaswad A, Baltissen MP, et al
    Seasonal variation in BCG-induced trained immunity.
    Vaccine. 2024;42:126109.
    >> Share

  1501. SHANMUGASUNDARAM D, Viswanathan R, Winter AK, Agarwal A, et al
    Rubella immunity among pregnant women and the burden of congenital rubella syndrome (CRS) in India, 2022.
    Vaccine. 2024;42:126077.
    >> Share

  1502. SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al
    Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
    Vaccine. 2024;42:126079.
    >> Share

  1503. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course.
    Vaccine. 2024;42 Suppl 4:125541.
    >> Share

  1504. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    >> Share

  1505. ESSALIM S, Tachet C, Demingo S, Bruel S, et al
    Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations.
    Vaccine. 2024;42:126473.
    >> Share

  1506. DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al
    Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
    Vaccine. 2024;42:126460.
    >> Share

  1507. AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al
    Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
    Vaccine. 2024;42:126465.
    >> Share

  1508. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system.
    Vaccine. 2024;42:126440.
    >> Share

  1509. BREWER SE, Cataldi JR, Perreira C, Nederveld A, et al
    "But then that's another barrier": A qualitative study of parent and provider perspectives on rural versus urban disparities in adolescent vaccination.
    Vaccine. 2024;42:126456.
    >> Share

  1510. WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al
    Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
    Vaccine. 2024;42:126374.
    >> Share

  1511. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Seroprevalence of diphtheria, tetanus and pertussis antibodies and Tdap vaccination in pregnant women in Greece - A cross- sectional study.
    Vaccine. 2024;42:126435.
    >> Share

  1512. HARRACHE A, Saker K, Mokdad B, Generenaz L, et al
    Anti-RBD IgG dynamics following infection or vaccination.
    Vaccine. 2024;42:126464.
    >> Share

  1513. SMOK-KALWAT J, Gozdz S, Macek P, Wasinski P, et al
    FTIR monitoring of the 13-valent pneumococcal conjugate vaccine for lung cancer patients: Changes in amides vibrations correlated with biochemical assays.
    Vaccine. 2024;42:126459.
    >> Share

  1514. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    >> Share

  1515. MA SH, Chen TL, Ou WF, Chao WC, et al
    The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX.
    Vaccine. 2024;42:126451.
    >> Share

  1516. EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al
    Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
    Vaccine. 2024;42:126426.
    >> Share

  1517. ESHRAGHISAMANI R, Facciuolo A, De Buck J
    Oral paratuberculosis vaccine efficacy and mucosal immunity in cattle.
    Vaccine. 2024;42:126447.
    >> Share

  1518. NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al
    Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.
    Vaccine. 2024;42:126418.
    >> Share

  1519. BERENDSEN MLT, Bles P, de Bree LCJ, Jensen KJ, et al
    Bacillus Calmette-Guerin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau.
    Vaccine. 2024;42:126439.
    >> Share

  1520. DUBE E, Gagnon D, Pelletier C, Comeau JL, et al
    Enhancing HPV vaccine uptake in girls and boys - A qualitative analysis of Canadian school-based vaccination programs.
    Vaccine. 2024;42:126425.
    >> Share

  1521. TRAVILL DI, Machalek DA, Rees H, Mbulawa Z, et al
    High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV.
    Vaccine. 2024;42:126442.
    >> Share

  1522. TYAGI A, Bajaj SS, Nayeu EN, Stanford FC, et al
    No person left behind: Understanding vaccine hesitancy in low- and middle-income countries.
    Vaccine. 2024 Oct 16:126446. doi: 10.1016/j.vaccine.2024.126446.
    >> Share

  1523. SANO K, Kurosawa T, Horikawa K, Kimura Y, et al
    Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
    Vaccine. 2024;42:126452.
    >> Share

  1524. NUZHATH T, Colwell B, Callaghan T, Hotez P, et al
    Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A mixed-method study.
    Vaccine. 2024;42:126420.
    >> Share

  1525. LI J, Li X, Liu F, Jiang S, et al
    Development and characterization of HCMV recombinant subunit vaccines based on T-cell epitopes.
    Vaccine. 2024;42:126454.
    >> Share

  1526. EIDEN AL, Drakeley S, Modi K, Mackie D, et al
    Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.
    Vaccine. 2024;42:126437.
    >> Share

  1527. PHADKE VK, Gromer DJ, Rebolledo PA, Graciaa DS, et al
    Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
    Vaccine. 2024;42:126441.
    >> Share

  1528. COCKERILL R, Horney JA, Penta SC, Silver A, et al
    Factors associated with COVID-19 vaccination or intent to be vaccinated across three U.S. states.
    Vaccine. 2024;42:126457.
    >> Share

  1529. TOP KA, Shulha HP, Muller MP, Valiquette L, et al
    Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
    Vaccine. 2024;42:126445.
    >> Share

  1530. HSIEH HC, Chen CC, Liu WC, Wu SC, et al
    Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
    Vaccine. 2024;42:126448.
    >> Share

  1531. TASKIN T, Roncancio AM, Cano MA, Valente M, et al
    Cancer fatalism is associated with HPV vaccine uptake among Hispanic emerging adult women in the US.
    Vaccine. 2024;42:126417.
    >> Share

  1532. MASON LMK, Betancur E, Riera-Montes M, Lienert F, et al
    MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings.
    Vaccine. 2024;42:126409.
    >> Share

  1533. SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al
    Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers.
    Vaccine. 2024;42:126424.
    >> Share

  1534. LITAO L, Feng C, Hongyu Z, Wenbin C, et al
    Field production efficiency investigation of broilers immunized with a turkey herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian influenza virus.
    Vaccine. 2024;42:126436.
    >> Share

  1535. SCHULTZE A, Martin I, Messina D, Bots S, et al
    Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048].
    Vaccine. 2024 Oct 12:126438. doi: 10.1016/j.vaccine.2024.126438.
    >> Share

  1536. BAMOUH Z, Semmate N, Mouahid M, Kerbal I, et al
    Safety and efficacy of 9R live attenuated vaccine against fowl typhoid in partridge's species.
    Vaccine. 2024;42:126413.
    >> Share

  1537. MOUCHERAUD C, Ochieng E, Ogutu V, Chang LC, et al
    Intervention-amenable factors associated with lack of HPV vaccination in Kenya: Results from a large national phone survey.
    Vaccine. 2024;42:126410.
    >> Share

  1538. WANG J, Gan Y, Yuan T, Huang Y, et al
    Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains.
    Vaccine. 2024;42:126421.
    >> Share

  1539. GERA S, Hoq M, Danchin M, Tuckerman J, et al
    Association between parental vaccine hesitancy and geographical coverage for childhood vaccination: A cross-sectional study.
    Vaccine. 2024;42:126422.
    >> Share

  1540. DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al
    Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in National Immunization Technical Advisory Groups Guidance during the first two years of the pandemic.
    Vaccine. 2024;42:126406.
    >> Share

  1541. MYLONA E, Pereira-Dias J, Keane JA, Karkey A, et al
    Phenotypic variation in the lipopolysaccharide O-antigen of Salmonella Paratyphi A and implications for vaccine development.
    Vaccine. 2024;42:126404.
    >> Share

  1542. TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al
    Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.
    Vaccine. 2024;42:126408.
    >> Share

  1543. MWAMBA G, Gibson EM, Toko C, Tunda C, et al
    Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
    Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
    >> Share

  1544. PASCOE KM, Bishop S, Ci X, Ramirez M, et al
    Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study.
    Vaccine. 2024;42:126389.
    >> Share

  1545. HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al
    SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.
    Vaccine. 2024;42:126394.
    >> Share

  1546. TAHA, Eskandari S, Slesarenko VA, Haselhorst T, et al
    Refinement and optimisation of Neisseria gonorrhoeae NHBA and MetQ vaccine candidates.
    Vaccine. 2024;42:126416.
    >> Share

  1547. ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al
    Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2024;42:126411.
    >> Share

  1548. PERCIO J, Kobayashi CD, Silva RMA, Marinho AKBB, et al
    Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) - Brazil, march 1, 2023-march 11, 2024.
    Vaccine. 2024;42:126407.
    >> Share

  1549. EARP M, Meng L, Black CL, Carter RJ, et al
    Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
    Vaccine. 2024;42:126372.
    >> Share

  1550. REN J, Gao Q, Zhou X, Chen L, et al
    Identification of gene and protein signatures associated with long-term effects of COVID-19 on the immune system after patient recovery by analyzing single-cell multi-omics data using a machine learning approach.
    Vaccine. 2024;42:126253.
    >> Share

  1551. BARBOSA TN, Ferreira MRA, Scholl NR, Pegoraro HG, et al
    Iridaea cordata lipid extract associated with the rCP01850 protein of C. pseudotuberculosis elicited a Th1 immune response in immunized sheep.
    Vaccine. 2024;42:126220.
    >> Share

  1552. SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al
    The EEHV1A gH/gL complex elicits humoral and cell-mediated immune responses in mice.
    Vaccine. 2024;42:126227.
    >> Share

  1553. RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al
    Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
    Vaccine. 2024;42:126203.
    >> Share

  1554. IQBAL I, Shahid S, Kanwar S, Kabir F, et al
    Pneumococcal carriage and changes in serotype distribution post- PCV13 introduction in children in Matiari, Pakistan.
    Vaccine. 2024;42:126238.
    >> Share

  1555. GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
    Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
    Vaccine. 2024;42:126234.
    >> Share

  1556. BROWN L, Bingham J, Pulliam J, Mthombothi Z, et al
    Estimation of the poliovirus type 2 immunity gap in South Africa.
    Vaccine. 2024;42:126062.
    >> Share

  1557. HOWARD LUDLAM A, Paynter J, Goodyear-Smith F, Petousis-Harris H, et al
    Pertussis epidemiology in adults: Retrospective analysis of pertussis incidence and association with comorbidities among adult populations in Aotearoa New Zealand, using national administrative datasets.
    Vaccine. 2024;42:126048.
    >> Share

  1558. LANGER S, Holzapfel S, August L, Badura A, et al
    Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?
    Vaccine. 2024;42:126050.
    >> Share

  1559. RUSSELL FA, Trim L, Bryan E, Fisher MA, et al
    Stability and antigenicity of Chlamydia muridarum major outer membrane protein antigen at body temperature.
    Vaccine. 2024;42:126047.
    >> Share

  1560. NAHAR UJ, Wang J, Shalash AO, Lu L, et al
    Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant.
    Vaccine. 2024;42:126060.
    >> Share

  1561. WEGMAN AD, Kalimuddin S, Marques ETA, Adams LE, et al
    Proceedings of the dengue endgame summit: Imagining a world with dengue control.
    Vaccine. 2024;42:126071.
    >> Share

  1562. COLOMBATTI OLIVIERI MA, Cuerda MX, Moyano RD, Gravisaco MJ, et al
    Superior protection against paratuberculosis by a heterologous prime-boost immunization in a murine model.
    Vaccine. 2024;42:126055.
    >> Share

  1563. GARLAND SM, Bhatla N, Woo YL
    IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards achieving WHO vaccine targets.
    Vaccine. 2024;42:126400.
    >> Share

  1564. GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
    Corrigendum to "Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina" [Vaccine. Volume 42, Issue 23, 3 October 2024, 126234].
    Vaccine. 2024 Oct 2:126402. doi: 10.1016/j.vaccine.2024.126402.
    >> Share

  1565. MIRANDA FM, da Silva LD, Fortuna LBDP, Silva AB, et al
    Long-term predominance in childhood colonization of the multidrug-resistant lineage 6C/ST386 of Streptococcus pneumoniae after universal immunization with the 10-valent pneumococcal conjugate vaccine in Brazil.
    Vaccine. 2024;42:126414.
    >> Share

  1566. CHOI YJ, Song JY, Wie SH, Choi WS, et al
    Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch.
    Vaccine. 2024;42:126381.
    >> Share

  1567. PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al
    Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.
    Vaccine. 2024;42:126391.
    >> Share

  1568. KANG S, Chung E, Hong C, Aziz AB, et al
    Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
    Vaccine. 2024;42:126398.
    >> Share

    September 2024
  1569. TEUFEL LU, Taks EJM, van Gemert J, Neacsu M, et al
    Interleukin 38 reduces antigen-presentation capacity and antibody production after vaccination.
    Vaccine. 2024;42:126396.
    >> Share

  1570. FLETCHER MA, Vojicic J, Daigle D, Taysi B, et al
    National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific.
    Vaccine. 2024;42:126390.
    >> Share

  1571. MOTTA M, Motta G, Stecula D
    Conceptual debates in the study of canine & feline vaccine hesitancy: A response to Haeder 2023.
    Vaccine. 2024 Sep 28:126397. doi: 10.1016/j.vaccine.2024.126397.
    >> Share

  1572. SPASENOSKA D, Bloem P, Akaba H, Kahn AL, et al
    Using human papillomavirus (HPV) vaccine in controlled temperature chain (CTC): A solution looking for a problem? Or a solution to problems that are not systematically documented?
    Vaccine. 2024 Sep 28:126399. doi: 10.1016/j.vaccine.2024.126399.
    >> Share

  1573. LYU X, Liu X, Hong H
    Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates.
    Vaccine. 2024;42:126395.
    >> Share

  1574. SOTOODEH A, Hedberg P, Granath F, Alfven T, et al
    Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden.
    Vaccine. 2024;42:126388.
    >> Share

  1575. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Corrigendum to "Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received" [Vaccine 42 (22) (2024) 126025].
    Vaccine. 2024 Sep 27:126403. doi: 10.1016/j.vaccine.2024.126403.
    >> Share

  1576. ARCIDIACO S, Schreiber P, Poincelot L, Loukeri S, et al
    Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen FeLV/RCP and Purevax RCPFeLV vaccines.
    Vaccine. 2024;42:126393.
    >> Share

  1577. BARBIERI E, Cocchio S, Furlan P, Scamarcia A, et al
    A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022.
    Vaccine. 2024;42:126387.
    >> Share

  1578. DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al
    Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study.
    Vaccine. 2024;42:126379.
    >> Share

  1579. ENGLAND A, Sung J, Deulofeu M, Soler LF, et al
    Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax(R)) by HIPRA.
    Vaccine. 2024;42:126386.
    >> Share

  1580. DANZELLE C, Cunha P, Noleto PG, Gilbert FB, et al
    Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis.
    Vaccine. 2024;42:126385.
    >> Share

  1581. TAN M, Zhang R, Shen T, Li A, et al
    Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus.
    Vaccine. 2024;42:126384.
    >> Share

  1582. WEITZMAN ER
    Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe institute for advanced study conference proceedings.
    Vaccine. 2024 Sep 23:126324. doi: 10.1016/j.vaccine.2024.126324.
    >> Share

  1583. LAZARUS R, Harris R, Thirard R, Baos S, et al
    Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal inf
    Vaccine. 2024;42:126369.
    >> Share

  1584. AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
    The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
    Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
    >> Share

  1585. BERNADIN O, Cochin M, Driouich JS, Laprie C, et al
    Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.
    Vaccine. 2024;42:126378.
    >> Share

  1586. LUI L, Requia WJ, Dos Santos F, Albert CE, et al
    Determining factors associated with vaccination coverage in the first year of life in Brazil (2013-2022).
    Vaccine. 2024;42:126382.
    >> Share

  1587. LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al
    Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.
    Vaccine. 2024;42:126368.
    >> Share

  1588. SHARMA H, Parekh S, Pujari P, Shewale S, et al
    A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL(R)) in Indian toddlers.
    Vaccine. 2024;42:126380.
    >> Share

  1589. WEE LE, Malek MIBA, Tan J, Chiew C, et al
    Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
    Vaccine. 2024;42:126356.
    >> Share

  1590. GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al
    Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022.
    Vaccine. 2024;42:126274.
    >> Share

  1591. IMRAN M, Mills C, McDermott KW, Dean A, et al
    Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.
    Vaccine. 2024;42:126316.
    >> Share

  1592. CHOI KY, El-Hamdi N, McGregor A
    T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein provides high level cross strain protection against congenital CMV.
    Vaccine. 2024;42:126357.
    >> Share

  1593. CANDEIAS C, Almeida ST, Paulo AC, Simoes AS, et al
    Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study.
    Vaccine. 2024;42:126219.
    >> Share

  1594. ROELS S, Bruckner M, Sadoff J, Cardenas V, et al
    Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease risk.
    Vaccine. 2024;42:126159.
    >> Share

  1595. SHEN AK, Gutu V, Druc A, Ebama M, et al
    An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024.
    Vaccine. 2024;42:126322.
    >> Share

  1596. WITTESAELE C, Toska E, Cluver L, Weiss HA, et al
    Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the eastern cape, South Africa.
    Vaccine. 2024;42:126318.
    >> Share

  1597. MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al
    Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
    Vaccine. 2024;42 Suppl 3.
    >> Share

  1598. JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al
    Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.
    Vaccine. 2024;42 Suppl 3:125667.
    >> Share

  1599. MAHAPATRA B, Singh A, Banerjee A, Sirohi S, et al
    A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites.
    Vaccine. 2024;42:126373.
    >> Share

  1600. WADA YA, Mazlan M, Noordin MM, Mohd-Lila MA, et al
    Rabies epidemiology in Malaysia (2015-2023): A cross-sectional insights and strategies for control.
    Vaccine. 2024;42:126371.
    >> Share

  1601. KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
    Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
    Vaccine. 2024;42:126320.
    >> Share

  1602. HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al
    Measuring the impact of influenza vaccination in the Netherlands using retrospective observational primary care, hospitalisation and mortality data.
    Vaccine. 2024;42:126244.
    >> Share

  1603. LAMBACH P, Silal S, Sbarra AN, Crowcroft NS, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1 July 2024.
    Vaccine. 2024;42:126307.
    >> Share

  1604. SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al
    Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
    Vaccine. 2024;42:126317.
    >> Share

  1605. ARTETA-ACOSTA C, Villena R, Hormazabal JC, Fernandez J, et al
    Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction.
    Vaccine. 2024;42:126311.
    >> Share

  1606. VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al
    Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
    Vaccine. 2024;42:126273.
    >> Share

  1607. KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al
    Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection.
    Vaccine. 2024;42:126325.
    >> Share

  1608. CHANG JY, Chang M, Huang S, Bosco J, et al
    COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
    Vaccine. 2024;42:126260.
    >> Share

  1609. PHAM M, Pichichero M
    Modeling conjugate vaccine and natural induced antibody correlates of protection for pneumococcal colonization and acute otitis media infection in young children.
    Vaccine. 2024;42:126295.
    >> Share

  1610. BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al
    Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
    Vaccine. 2024;42:126354.
    >> Share

  1611. RABOBA JL, Rahajamanana VL, Rakotojoelimaria HE, Masembe YV, et al
    Monovalent rotavirus vaccine effectiveness and long-term impact among children <5 years old in Antananarivo, Madagascar, 2010-2022.
    Vaccine. 2024;42:126321.
    >> Share

  1612. ABARA WE, Modaressi S, Fireman B, Klein NP, et al
    Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study.
    Vaccine. 2024;42:126312.
    >> Share

  1613. KING LM, Lewnard JA
    Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines.
    Vaccine. 2024;42:126310.
    >> Share

  1614. GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al
    Determinants of influenza and COVID vaccine uptake in healthcare workers: A cross-sectional survey during the post-pandemic era in a network of academic hospitals in France.
    Vaccine. 2024;42:126272.
    >> Share

  1615. REGAN AK, Sullivan SG, Arah OA
    Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study.
    Vaccine. 2024;42:126256.
    >> Share

  1616. WANG C, Damiano RJ, Ruebush LE, Engelen MPKJ, et al
    A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study.
    Vaccine. 2024;42:126292.
    >> Share

  1617. PETRI E, Biswal S, Lloyd E, Tricou V, et al
    Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial.
    Vaccine. 2024;42:126309.
    >> Share

  1618. BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al
    Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome.
    Vaccine. 2024;42:126305.
    >> Share

  1619. RAMIREZ OR, Farraye FA, Hayney MS, Caldera F, et al
    Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy.
    Vaccine. 2024;42:126319.
    >> Share

  1620. WOO EJ, Miller ER, Stroud E
    Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024).
    Vaccine. 2024;42:126290.
    >> Share

  1621. GROOM HC, Biel FM, Crane B, Sun E, et al
    Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers.
    Vaccine. 2024;42:126288.
    >> Share

  1622. HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al
    A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters.
    Vaccine. 2024;42:126269.
    >> Share

  1623. HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
    Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.
    Vaccine. 2024;42:126294.
    >> Share

  1624. SCHLEY K, Whichello C, Hauber B, Krucien N, et al
    Preferences of US adolescents and parents for vaccination against invasive meningococcal disease.
    Vaccine. 2024;42:126264.
    >> Share

  1625. POH XY, Torres-Ruesta A, Yoong T, Wong N, et al
    Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
    Vaccine. 2024;42:126275.
    >> Share

  1626. CUI Y, Cibichakravarthy B, Tang X, Alameh MG, et al
    Salp14 epitope-based mRNA vaccination induces early recognition of a tick bite.
    Vaccine. 2024;42:126304.
    >> Share

  1627. KIM C, Dunphy C, Duggar C, Pike J, et al
    Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.
    Vaccine. 2024;42:126287.
    >> Share

  1628. BONNER C, Taba M, Fajardo MA, Batcup C, et al
    Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculator.
    Vaccine. 2024;42:126296.
    >> Share

  1629. KARUNAKARAN KP, Yu H, Jiang X, Chan QWT, et al
    Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development.
    Vaccine. 2024;42:126266.
    >> Share

  1630. LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al
    mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
    Vaccine. 2024;42:126250.
    >> Share

  1631. BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al
    Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study.
    Vaccine. 2024;42:126252.
    >> Share

  1632. HOU X, Li N, Zhang H, Liu W, et al
    Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China.
    Vaccine. 2024;42:126259.
    >> Share

  1633. RICHMOND P, Nolan T, McGirr A, Napier-Flood F, et al
    Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.
    Vaccine. 2024;42:126251.
    >> Share

  1634. COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al
    Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines.
    Vaccine. 2024;42:126271.
    >> Share

    August 2024
  1635. LI G, Ren T, Zhang H, Ti J, et al
    Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
    Vaccine. 2024;42:126209.
    >> Share

  1636. VIETRI J, Maculaitis MC, Cappelleri JC, Yu H, et al
    Preferences for a Clostridioides difficile vaccine among adults in the United States.
    Vaccine. 2024;42:126261.
    >> Share

  1637. KELLY M, Janardhanan J, Wagh C, Verma S, et al
    Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Vaccine. 2024;42:126263.
    >> Share

  1638. MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al
    Confidence and barriers: Analysis of factors associated with timely routine childhood vaccination in Canada during the COVID-19 pandemic.
    Vaccine. 2024;42:126236.
    >> Share

  1639. AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al
    Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.
    Vaccine. 2024;42:126137.
    >> Share

  1640. MAI W, Shen J, Ma F, Zhu J, et al
    Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
    Vaccine. 2024;42:126108.
    >> Share

  1641. EYAWO O, Ugoji UC, Pan S, Oyibo P, et al
    Predictors of the willingness to accept a free COVID-19 vaccine among households in Nigeria.
    Vaccine. 2024;42:126225.
    >> Share

  1642. CHI X, Han F, Jiang Y, Cao L, et al
    Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59.
    Vaccine. 2024;42:126245.
    >> Share

  1643. BRESEE JS, Lafond KE
    The partnership for international vaccine initiatives: The importance and opportunity to develop influenza vaccination programs in low- and middle-income countries.
    Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255.
    >> Share

  1644. NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
    How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
    Vaccine. 2024;42:126215.
    >> Share

  1645. FOURIE KR, Jeffery A, Chand D, Choudhary P, et al
    Vaccination with a Lawsonia intracellularis subunit water in oil emulsion vaccine mitigated some disease parameters but failed to affect shedding.
    Vaccine. 2024;42:126254.
    >> Share

  1646. HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al
    Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.
    Vaccine. 2024;42:126242.
    >> Share

  1647. DONG R, Luo Z, Shao J, Xue H, et al
    Understanding hepatitis E vaccination intention among women of childbearing-age: A theory-based cross-sectional study.
    Vaccine. 2024;42:126258.
    >> Share

  1648. LLABRE MM, Timpano KR, Broos HC, Leite RO, et al
    Lessons from a longitudinal community-based investigation of adherence to guidelines and intent to vaccinate during the COVID-19 pandemic.
    Vaccine. 2024;42:126265.
    >> Share

  1649. PETRI FAM, Malcher CS, Mechler-Dreibi ML, Panneitz AK, et al
    Shedding reduction and immunity modulation in piglets with an inactivated Mycoplasma hyopneumoniae vaccine encapsulated in nanostructured SBA-15 silica.
    Vaccine. 2024;42:126268.
    >> Share

  1650. PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
    Vaccine. 2024;42:126165.
    >> Share

  1651. KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al
    Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.
    Vaccine. 2024;42:126222.
    >> Share

  1652. FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al
    COVID-19 vaccine hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.
    Vaccine. 2024;42:126247.
    >> Share

  1653. HUANG X, Yang S, Zhao J, Yang J, et al
    Generation and evaluation of Salmonella entericaserovar Choleraesuis mutant strains as a potential live-attenuated vaccine.
    Vaccine. 2024;42:126262.
    >> Share

  1654. GUZMAN RUIZ L, Zollner AM, Hoxie I, Kuchler J, et al
    Enhancing NA immunogenicity through novel VLP designs.
    Vaccine. 2024;42:126270.
    >> Share

  1655. ADAMS K, Diallo D, Tadount F, Mouajou V, et al
    Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review.
    Vaccine. 2024;42:126246.
    >> Share

  1656. SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al
    Editorial: ML-driven vaccine against COVID-19: Developmental challenges and foresight.
    Vaccine. 2024;42:126267.
    >> Share

  1657. EVANS I, Jury S, Morrison A, Best E, et al
    Onward transmission of measles virus among vaccinated cases in a large community outbreak in Auckland, New Zealand, 2019.
    Vaccine. 2024;42:126257.
    >> Share

  1658. VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al
    Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.
    Vaccine. 2024;42:126237.
    >> Share

  1659. UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al
    Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study.
    Vaccine. 2024;42:126221.
    >> Share

  1660. SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al
    Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.
    Vaccine. 2024;42:126241.
    >> Share

  1661. ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al
    Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
    Vaccine. 2024;42:126240.
    >> Share

  1662. OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al
    Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
    Vaccine. 2024;42:126196.
    >> Share

  1663. SKIRROW H, Lewis C, Haque H, Choudary-Salter L, et al
    'Why did nobody ask us?': A mixed-methods co-produced study in the United Kingdom exploring why some children are unvaccinated or vaccinated late.
    Vaccine. 2024;42:126172.
    >> Share

  1664. POURAKBARI B, Ashraf Talesh S, Mahmoudi S, Sotoudeh M, et al
    Measles immunity status in Iranian infants and children and outbreak concerns: Time for reconsidering the vaccination schedule?
    Vaccine. 2024;42:126243.
    >> Share

  1665. CHEN Z, Gou Q, Yuan Y, Zhang X, et al
    Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia.
    Vaccine. 2024;42:126217.
    >> Share

  1666. ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al
    "REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
    Vaccine. 2024;42:126208.
    >> Share

  1667. SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al
    Associations of mental health with vaccination readiness in informal caregivers and the vaccination status of their care recipients during the Covid-19 pandemic - A cross sectional analysis.
    Vaccine. 2024;42:126218.
    >> Share

  1668. CASEY RM, Najjengo MS, Lubega I, Sekiziyivu AB, et al
    Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.
    Vaccine. 2024;42:126197.
    >> Share

  1669. WANDERA EA, Kurokawa N, Mutua MM, Muriithi B, et al
    Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis.
    Vaccine. 2024;42:126210.
    >> Share

  1670. HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al
    Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
    Vaccine. 2024;42:126223.
    >> Share

  1671. SNIDER CJ, Zaman K, Estivariz CF, Aziz AB, et al
    Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.
    Vaccine. 2024;42:126216.
    >> Share

  1672. HADLEY L, Soeters HM, Cooper LV, Fernandez K, et al
    Modelling control strategies for pneumococcal meningitis outbreaks in the African meningitis belt.
    Vaccine. 2024;42:125983.
    >> Share

  1673. IHENETU G, Aylin P, Novov V, Skirrow H, et al
    Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.
    Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214.
    >> Share

  1674. FINN MB, Penfound TA, Salehi S, Ogega CO, et al
    Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
    Vaccine. 2024;42:126205.
    >> Share

  1675. VALDES I, Suzarte E, Lazo L, Cobas K, et al
    Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice.
    Vaccine. 2024 Aug 12:126213. doi: 10.1016/j.vaccine.2024.126213.
    >> Share

  1676. GLEASON A, Kumar CK, Klein E, Laxminarayan R, et al
    Effect of rotavirus vaccination on the burden of rotavirus disease and associated antibiotic use in India: A dynamic agent-based simulation analysis.
    Vaccine. 2024;42:126211.
    >> Share

  1677. CAMERON RL, Palmer TJ, Cuschieri K, Kavanagh K, et al
    Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease.
    Vaccine. 2024;42:126177.
    >> Share

  1678. NASIR S, Anwer F, Ishaq Z, Saeed MT, et al
    VacSol-ML(ESKAPE)(:) Machine learning empowering vaccine antigen prediction for ESKAPE pathogens.
    Vaccine. 2024;42:126204.
    >> Share

  1679. JOB MJ, Kim D, Acosta F, Valera S, et al
    Attitudes of pregnant women in the Dominican Republic towards a future maternal Group B Streptococcus vaccine.
    Vaccine. 2024;42:126169.
    >> Share

  1680. WALDEN J, Stanek JR, Young J, Griffith MM, et al
    Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.
    Vaccine. 2024;42:126212.
    >> Share

  1681. GRAF DD, Westphal L, Hallgreen CE
    The life cycle of vaccines evaluated by the European Medicines Agency.
    Vaccine. 2024;42:126186.
    >> Share

  1682. BAJPAI D, Bose S, Saxena N, Kulkarni B, et al
    Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
    Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206.
    >> Share

  1683. BLOODWORTH S, Singleton D, Perkins E, Radford A, et al
    Temporal trends and factors associated with vaccination uptake in dogs and cats from 2016 to 2022 in the United Kingdom.
    Vaccine. 2024;42:126185.
    >> Share

  1684. O'MAHONY E, Sherman SM, Marlow R, Bedford H, et al
    UK paediatricians' attitudes towards the chicken pox vaccine: The SPOTTY study.
    Vaccine. 2024;42:126199.
    >> Share

  1685. GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al
    The impact of the COVID-19 pandemic on childhood vaccination rates and the role of sociodemographic factors: A cohort study.
    Vaccine. 2024;42:126207.
    >> Share

  1686. D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
    Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
    Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
    >> Share

  1687. GAO Y, Yang X, Li X, Chen H, et al
    Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
    Vaccine. 2024;42:126182.
    >> Share

  1688. BUTLER AM, Newland JG, Sahrmann JM, O'Neil CA, et al
    Characterizing timeliness of recommended vaccinations among privately-insured children in the United States, 2009-2019.
    Vaccine. 2024;42:126179.
    >> Share

  1689. GEORGE G, Strauss M, Lansdell E, Nota P, et al
    Factors associated with COVID-19 vaccine uptake among south African health care workers.
    Vaccine. 2024;42:126181.
    >> Share

  1690. BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al
    Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in Brazil.
    Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175.
    >> Share

  1691. BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
    Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.
    Vaccine. 2024;42:126198.
    >> Share

  1692. AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al
    Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.
    Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184.
    >> Share

  1693. MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al
    Healthcare personnel acceptance and recommendations for influenza vaccine in twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
    Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024.
    >> Share

  1694. WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al
    A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.
    Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158.
    >> Share

  1695. JIANG M, Zhang H, Yao X, Wang Y, et al
    Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.
    Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024.
    >> Share

    July 2024
  1696. ABIL OZ, Liu S, Yeh YW, Wu Y, et al
    A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule.
    Vaccine. 2024 Jul 31:126151. doi: 10.1016/j.vaccine.2024.
    >> Share

  1697. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    Corrigendum to "COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study" [Vaccine 2023;41(41):6048-6054].
    Vaccine. 2024 Jul 31:126180. doi: 10.1016/j.vaccine.2024.126180.
    >> Share

  1698. SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
    The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
    Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
    >> Share

  1699. DE WEERDT L, Herzog SA, Van Damme P, Maertens K, et al
    Timing of pertussis vaccination during pregnancy: Evidence and implementation - A systematic review.
    Vaccine. 2024;42:126152.
    >> Share

  1700. GUO S, Li Z, Zheng M, Wu F, et al
    Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China.
    Vaccine. 2024;42:126183.
    >> Share

  1701. MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al
    Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
    Vaccine. 2024;42:126156.
    >> Share

  1702. BESBASSI H, Elias G, Meysman P, Jansens H, et al
    Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.
    Vaccine. 2024;42:126148.
    >> Share

  1703. ASUPOTO O, Li X, Hemberg JL, Emerson A, et al
    COVID-19 and influenza vaccine uptake in women with criminal-legal system involvement.
    Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176.
    >> Share

  1704. ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al
    Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study.
    Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171.
    >> Share

  1705. GE Y, Lu Y, Allen JD, Einav T, et al
    Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 vaccine-induced antibody responses.
    Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024.
    >> Share

  1706. TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al
    Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma among COVID-19 vaccinated Bangladeshi adults.
    Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157.
    >> Share

  1707. GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al
    Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
    Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164.
    >> Share

  1708. WILLIS DE, Moore R, Selig JP, Shafeek Amin N, et al
    Pediatric HPV vaccination: Provider recommendations matter among hesitant parents.
    Vaccine. 2024 Jul 29:126166. doi: 10.1016/j.vaccine.2024.126166.
    >> Share

  1709. MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al
    The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children.
    Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024.
    >> Share

  1710. SULEMAN A, Vicente P
    COVID-19 vaccination reluctance across Europe: Lessons for the future.
    Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168.
    >> Share

  1711. REN J, Huang Z, Tian J, Li Z, et al
    Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
    Vaccine. 2024 Jul 27:126162. doi: 10.1016/j.vaccine.2024.126162.
    >> Share

  1712. WILLIS DE, Moore R, Purvis RS, McElfish PA, et al
    Hesitant but vaccinated: Lessons learned from hesitant adopters.
    Vaccine. 2024 Jul 27:126135. doi: 10.1016/j.vaccine.2024.
    >> Share

  1713. JENA D, Ghosh A, Jha A, Prasad P, et al
    Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
    Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024.
    >> Share

  1714. ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al
    Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children.
    Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154.
    >> Share

  1715. WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al
    Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.
    Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167.
    >> Share

  1716. BILGIN GM, Munira SL, Lokuge K, Glass K, et al
    Mathematical modelling of the 100-day target for vaccine availability after the detection of a novel pathogen: A case study in Indonesia.
    Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163.
    >> Share

  1717. KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al
    A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.
    Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160.
    >> Share

  1718. JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
    Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Vaccine. 2024;42:4011-4021.
    >> Share

  1719. JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al
    Vaccine value profile for herpes simplex virus.
    Vaccine. 2024;42.
    >> Share

  1720. MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al
    Vaccine value profile for invasive non-typhoidal Salmonella disease.
    Vaccine. 2024;42.
    >> Share

  1721. LAWAL S, St-Jean M, Hu Y, Bakos B, et al
    Assessing sociodemographic disparities in HPV vaccine uptake among grade 6 and 9 students in the Vancouver Coastal Health region.
    Vaccine. 2024 Jul 25:126147. doi: 10.1016/j.vaccine.2024.
    >> Share

  1722. SILVER ER, Fink L, Baylis KR, Faust RA, et al
    Challenging the 'acceptable option': Public health's advocacy for continued care in the case of pediatric vaccine refusal.
    Vaccine. 2024 Jul 23:126144. doi: 10.1016/j.vaccine.2024.
    >> Share

  1723. YAMEY G, McDade KK, Anderson RM, Bartsch SM, et al
    Vaccine value profile for schistosomiasis.
    Vaccine. 2024 Jul 23:126020. doi: 10.1016/j.vaccine.2024.
    >> Share

  1724. WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al
    Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024.
    >> Share

  1725. ZOU GQ, Li K, Yan C, Li YQ, et al
    Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity.
    Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024.
    >> Share

  1726. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    >> Share

  1727. SANADA T, Honda T, Kohara M
    Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.
    Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024.
    >> Share

  1728. CHAU M, Kaufman J, Holland P, Danchin M, et al
    Co-designing an intervention to improve the childhood catch-up vaccination process for migrant parents in Australia.
    Vaccine. 2024 Jul 18:S0264-410X(24)00745-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1729. BAUER BU, Herms TL, Jahnke R, Ossowski N, et al
    Control of Coxiella burnetii shedding in a dairy goat herd by annual offspring vaccination.
    Vaccine. 2024 Jul 18:S0264-410X(24)00787-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1730. WASSIL J, Sisti M, Fairman J, Rankin B, et al
    A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
    Vaccine. 2024 Jul 17:S0264-410X(24)00786-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1731. ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al
    Perceptions of vaccine requirements among students at four Pennsylvania universities.
    Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1732. JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al
    Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.
    Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1733. SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
    Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
    Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1734. HU TH, Tou CY, Lee YH, Chang HH, et al
    Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan.
    Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1735. JIN F, Zhu L, Wang Y, Qin G, et al
    Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
    Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1736. LIU G, Pang Y, Lv M, Lu M, et al
    Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
    Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1737. STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al
    Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1738. LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al
    Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
    Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1739. TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al
    Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
    Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1740. HATFIELD K, Wiegand R, Reddy S, Patel A, et al
    Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
    Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1741. ALTAWALBEH SM, Wateska AR, Patricia Nowalk M, Lin CJ, et al
    Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].
    Vaccine. 2024 Jul 15:S0264-410X(24)00789-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1742. STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al
    Increasing vaccination coverage among healthcare workers: Active call and mandatory laws. Data from a large general hospital in Southern Italy.
    Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1743. FISMAN DN, Simmons AE, Tuite AR
    Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
    Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1744. JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al
    GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
    Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1745. DULL PM, Achilles SL, Ahmed R, Barnabas RV, et al
    Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
    Vaccine. 2024 Jul 13:S0264-410X(24)00741-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1746. VERANI JR, Omondi D, Odoyo A, Odiembo H, et al
    Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction.
    Vaccine. 2024 Jul 13:S0264-410X(24)00782-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1747. MIAO Q, Nguyen W, Zhu J, Liu G, et al
    A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.
    Vaccine. 2024 Jul 13:S0264-410X(24)00799-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1748. LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al
    Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
    Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1749. HUANG WT, Law B, Tran H, Schonborn L, et al
    Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
    Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1750. DANELIAN G, Burton L, Bayley T, Sanchez-Marroquin A, et al
    The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Vaccine. 2024;42:3838-3850.
    >> Share

  1751. AGARWAL S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, et al
    Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus.
    Vaccine. 2024;42:3899-3915.
    >> Share

  1752. BUCHHORN DE FREITAS S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, et al
    Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver nanoparticles protects mice from lethal infection by multidrug-resistant Acinetobacter baumannii.
    Vaccine. 2024;42:3802-3810.
    >> Share

  1753. LI J, Gong L, Li J, Gong Z, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Vaccine. 2024;42:3751-3755.
    >> Share

  1754. SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al
    Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1755. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Corrigendum to "Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024" [Vaccine 42(15) (2024) 3379-3383].
    Vaccine. 2024 Jul 11:S0264-410X(24)00743-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1756. HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al
    COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1757. MILLER E, Michel A, Singh P, Limaye R, et al
    Countering vaccine misinformation: Designing a learning resource for healthcare workers in eight countries.
    Vaccine. 2024 Jul 11:S0264-410X(24)00732-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1758. GARCIA S, Shin M, Gill M, He Z, et al
    Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.
    Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1759. BOLIO A, Waheed DE, Mugo N, Garland SM, et al
    Overview of CHIC symposia series: Summary of Africa and South Asia symposia.
    Vaccine. 2024;42 Suppl 2:S9-S15.
    >> Share

  1760. NDIAYE C, Kyesi F, Masupha T, Ranyali M, et al
    Integrating HPV vaccine service delivery with adolescent health programmes - Experiences and perspectives from selected countries in Africa.
    Vaccine. 2024;42 Suppl 2:S45-S48.
    >> Share

  1761. SIDIBE A, Kouassi KS, Ekra D, Bloem P, et al
    Accelerating and broadening multisectoral partnerships for introducing and rebuilding HPV vaccination programmes.
    Vaccine. 2024;42 Suppl 2:S41-S44.
    >> Share

  1762. WAHEED DE, Bolio A, Kyesi F, Miano CW, et al
    Routine HPV vaccination: Reflection on delivery strategies based on countries' experiences.
    Vaccine. 2024;42 Suppl 2:S37-S40.
    >> Share

  1763. KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al
    Pandemic-related resilience in HPV vaccination programmes - Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030.
    Vaccine. 2024;42 Suppl 2:S33-S36.
    >> Share

  1764. NJOGU R, Deb Roy A, Bagudu Z, Borda H, et al
    Effective communication by health care workers to promote HPV vaccination: Lessons learned from Kenya, India, and Nigeria.
    Vaccine. 2024;42 Suppl 2:S27-S32.
    >> Share

  1765. WAHEED DE, Mumba M, Alfred D, Bogale M, et al
    Identifying key challenges and optimizing approaches for training of health care professionals for HPV vaccination programmes.
    Vaccine. 2024;42 Suppl 2:S22-S26.
    >> Share

  1766. STANLEY M, Schuind A, Muralidharan KK, Guillaume D, et al
    Evidence for an HPV one-dose schedule.
    Vaccine. 2024;42 Suppl 2:S16-S21.
    >> Share

  1767. BORDA H, Bloem P, Akaba H, Guillaume D, et al
    Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue.
    Vaccine. 2024;42 Suppl 2:S1-S8.
    >> Share

  1768. GHARPURE R, Longley AT, Takamiya M, Hidle A, et al
    Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.
    Vaccine. 2024 Jul 10:S0264-410X(24)00727-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1769. WEITZMAN ER, Pierce SE, Blakemore LM, Murdock A, et al
    Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl.
    Vaccine. 2024 Jul 10:S0264-410X(24)00722-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1770. ZOU M, Lei C, Huang D, Liu L, et al
    Application of plant-derived products as adjuvants for immune activation and vaccine development.
    Vaccine. 2024 Jul 9:S0264-410X(24)00756-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1771. SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
    Corrigendum to "Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness" [Vaccine 41(41) (2023) 6105-6111].
    Vaccine. 2024 Jul 8:S0264-410X(24)00726-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1772. JITENDER, Vikram Kumar B, Singh S, Verma G, et al
    Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1773. BANG JY, Kim YJ, Seo YJ, Hong SH, et al
    Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
    Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1774. KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al
    Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
    Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1775. WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al
    Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
    Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1776. ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al
    Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
    Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1777. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
    Vaccine. 2024 Jul 5:S0264-410X(24)00730-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1778. NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
    Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1779. MESHRAM R, Kolte B, Gacche R
    Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
    Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1780. KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
    An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1781. KAFADAR AH, Sabatini S, Jones KA, Dening T, et al
    Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
    Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1782. ZHANG D, Jiang Y, Wang M, Zhao J, et al
    A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
    Vaccine. 2024 Jul 2:S0264-410X(24)00738-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1783. HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al
    Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
    Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.
    >> Share

    June 2024
  1784. GAO H, Zhang S, Chang H, Guo Y, et al
    Generation of a novel attenuated IBDV vaccine strain by mutation of critical amino acids in IBDV VP5.
    Vaccine. 2024 Jun 28:S0264-410X(24)00723-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1785. ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al
    Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
    Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1786. BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al
    COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
    Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1787. PLEY C, Kampmann B
    Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.
    Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1788. KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al
    Factors predicting primary and booster COVID-19 vaccination in a community sample of African American men and women in the United States Midwest.
    Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1789. JIN F, Zhu L, Wang Y, Qin G, et al
    Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
    Vaccine. 2024 Jun 26:S0264-410X(24)00700-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1790. GUTIERREZ MP, Huckaby AB, Yang E, Weaver KL, et al
    Antibody-mediated immunological memory correlates with long-term Lyme veterinary vaccine protection in mice.
    Vaccine. 2024 Jun 26:S0264-410X(24)00725-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1791. COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
    Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
    Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1792. YOO YM, Katz MA, Greenberg D, Marcenac P, et al
    Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
    Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1793. HUSSEIN I, Mohamud H, Hussein A, Luomala O, et al
    "If the nurse tells me this is a good thing, I trust her completely" - Exploring health system enablers of MMR vaccine uptake in the Finnish Somali community: A mixed method study.
    Vaccine. 2024 Jun 25:S0264-410X(24)00728-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1794. VIANNA CM, Noronha TG, Camacho LAB, Andrade RC, et al
    Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.
    Vaccine. 2024 Jun 25:S0264-410X(24)00724-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1795. CHATZILENA A, Hyams C, Challen R, Marlow R, et al
    Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
    Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1796. LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1797. LIN M, Deng JZ, Scapin G, Yuan Y, et al
    Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.
    Vaccine. 2024 Jun 24:S0264-410X(24)00709-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1798. HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al
    Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1799. FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al
    Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1800. RIMAL RN, Ganjoo R, Jamison A, Parida M, et al
    Social norms, vaccine confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.
    Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1801. POVEDA-URKIXO I, Mena-Bueno S, Ramirez GA, Zabalza-Barangua A, et al
    Brucella melitensis Rev1Deltawzm: Placental pathogenesis studies and safety in pregnant ewes.
    Vaccine. 2024;42:3710-3720.
    >> Share

  1802. MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
    Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
    Vaccine. 2024;42:3647-3654.
    >> Share

  1803. PISCHEL L, Martini BA, Yu N, Cacesse D, et al
    Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
    Vaccine. 2024 Jun 20:S0264-410X(24)00694-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1804. CHU X, Ge S, Zuo Y, Cui J, et al
    Thoughts on the research of African swine fever live-attenuated vaccines.
    Vaccine. 2024 Jun 20:S0264-410X(24)00693-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1805. ZHANG X, Monnat SM
    Watchful, skeptics, and system distrusters: Characteristics associated with different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
    Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1806. CARLSON CJ, Garnier R, Tiu A, Luby SP, et al
    Strategic vaccine stockpiles for regional epidemics of emerging viruses: A geospatial modeling framework.
    Vaccine. 2024 Jun 19:S0264-410X(24)00690-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1807. CARLOS GUILLERMO B, Tomas Alberto O, Julio I
    First vaccine confidence and access index in Argentina: Comparison of results from 2019 to 2022.
    Vaccine. 2024 Jun 19:S0264-410X(24)00711-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1808. AHMED T, Tauheed I, Hoque S, Sarower Bhuyan G, et al
    A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.
    Vaccine. 2024 Jun 18:S0264-410X(24)00704-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1809. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2002) 4190-4198].
    Vaccine. 2024 Jun 18:S0264-410X(24)00650-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1810. HOPKINS KL, Lihemo G, Underwood T, Sommers T, et al
    The second annual Vaccination Acceptance Research Network Conference (VARN2023): Shifting the immunization narrative to center equity and community expertise.
    Vaccine. 2024 Jun 18:S0264-410X(24)00655-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1811. CHENG TM, Chen YS, Wei KC, Chang YC, et al
    Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
    Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1812. LAEMMLE-RUFF I, Morgan HJ, Harris A, Abruzzo V, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines - Progress over time.
    Vaccine. 2024 Jun 17:S0264-410X(24)00714-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1813. YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al
    Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
    Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1814. FERM J, Jaworski DC, Stoll I, Kleinhenz MD, et al
    Genetically modified live vaccine offers protective immunity against wild-type Anaplasma marginale tick-transmission challenge.
    Vaccine. 2024 Jun 15:S0264-410X(24)00710-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1815. DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al
    Comparison of parent-reported motivators of non-vaccination for children 5-11 years old in Australia and Canada: Results of the iCARE study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1816. WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
    Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.
    Vaccine. 2024 Jun 15:S0264-410X(24)00658-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1817. GUL C, Gul A, Karakavuk T, Erkunt Alak S, et al
    A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis.
    Vaccine. 2024 Jun 15:S0264-410X(24)00706-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1818. JIANG X, Wang J, Li C, Yeoh EK, et al
    Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1819. REY-ARES L, Ta A, Freigofaite D, Warren S, et al
    Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Vaccine. 2024 Jun 14:S0264-410X(24)00670-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1820. TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al
    Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada.
    Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1821. SONG T, Cao F, Huang X, Wu S, et al
    Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion.
    Vaccine. 2024 Jun 13:S0264-410X(24)00649-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1822. WHITE MC, Osazuwa-Peters OL, Abouelella DK, Barnes JM, et al
    Trends and factors associated with receipt of human papillomavirus (HPV) vaccine in private, public, and alternative settings in the United States.
    Vaccine. 2024 Jun 13:S0264-410X(24)00663-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1823. DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al
    Investigating the predictors of COVID-19 vaccine decision-making among parents of children aged 5-11 in the UK.
    Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1824. HASSO-AGOPSOWICZ M, Sparrow E, Cameron AM, Sati H, et al
    The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens.
    Vaccine. 2024 Jun 13:S0264-410X(24)00676-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1825. CARDOSO N, Eschbaumer M, Capozzo AV
    An IgG1 single-dilution avidity ELISA predicts cross-protection against heterologous foot-and-mouth disease virus challenge after vaccination.
    Vaccine. 2024 Jun 13:S0264-410X(24)00707-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1826. EMILIE HARTVIG RASMUSSEN C, Odgaard Vedel J, Moller Jensen A, Da Silva Borges I, et al
    Implementation of the vaccination program in Guinea-Bissau: Coverage and missed opportunities for BCG at birth.
    Vaccine. 2024 Jun 12:S0264-410X(24)00697-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1827. QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
    The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
    Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1828. CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
    Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Vaccine. 2024;42:3536-3546.
    >> Share

  1829. SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
    Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
    Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1830. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1831. HOFFMAN E, Kahan T, Auerbach E, Brody H, et al
    Peer education as a strategy to promote vaccine acceptance: A randomized controlled trial within New York community healthcare practices.
    Vaccine. 2024 Jun 10:S0264-410X(24)00654-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1832. OTSUKI T, Akada S, Anami A, Kosaka K, et al
    Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1833. BRADY K, Lee A, Bassler J, Young Pierce J, et al
    Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
    Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1834. BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
    Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
    Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1835. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
    Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1836. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1837. JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
    Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
    Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1838. DE POUVOURVILLE G, Guyot E, Farge G, Belhassen M, et al
    Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study.
    Vaccine. 2024 Jun 7:S0264-410X(24)00667-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1839. VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
    Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
    Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1840. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1841. KANG DW, June Choe Y, Lee JY, Suk IA, et al
    Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Vaccine. 2024 Jun 5:S0264-410X(24)00616-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1842. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1843. KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
    Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
    Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1844. GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
    Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1845. FENG J, Du Y, Chen L, Su W, et al
    A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
    Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1846. FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
    Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
    Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1847. QUIAMBAO BP, Payumo RA, Roa C, Borja-Tabora CF, et al
    A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.
    Vaccine. 2024 Jun 3:S0264-410X(24)00643-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1848. BEJKO D, Ernst C, Vergison A, Stranges S, et al
    High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
    >> Share

    May 2024
  1849. KUPEK E
    Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
    Vaccine. 2024;42:3437-3444.
    >> Share

  1850. WOLFSCHMIDT-FIETKAU A, Goertz RS, Goertzen S, Schmid K, et al
    Immunity against vaccine-preventable diseases among pregnant employees in Germany. A situation analysis before the introduction of the Measles Protection Act.
    Vaccine. 2024 May 31:S0264-410X(24)00604-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1851. HE Q, Chen Y, Li Y, Cheng X, et al
    Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus.
    Vaccine. 2024 May 31:S0264-410X(24)00583-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1852. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1853. COMER D, Warner NZ, Noone C
    Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms, and connectedness to the LGBT+ community.
    Vaccine. 2024 May 31:S0264-410X(24)00639-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1854. MANSFIELD LN, Kahn BZ, Kokitkar S, Kritikos KI, et al
    HPV vaccine standing orders and communication in primary care: A qualitative study.
    Vaccine. 2024 May 29:S0264-410X(24)00554-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1855. NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
    The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
    Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1856. LUO H, Ma Y, Bi J, Li Z, et al
    Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
    Vaccine. 2024 May 28:S0264-410X(24)00599-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1857. BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
    Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
    Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1858. BEGUM T, Efstathiou N, Bailey C, Guo P, et al
    Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
    Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1859. EOM J, Kim Y, Kim D, Lee E, et al
    Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting.
    Vaccine. 2024 May 27:S0264-410X(24)00622-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1860. MENA-BUENO S, Garrido V, Romero F, Zabalza-Barangua A, et al
    Rev1Deltawzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams.
    Vaccine. 2024 May 27:S0264-410X(24)00605-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1861. LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
    Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1862. VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
    Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
    Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1863. RENDUCHINTALA K, Arevalo M, Fonseca G, Haver MK, et al
    Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.
    Vaccine. 2024 May 27:S0264-410X(24)00602-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1864. TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
    Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
    Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1865. DOHERTY K, Bonnett L, Agbla SC, Beveridge NER, et al
    The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.
    Vaccine. 2024 May 24:S0264-410X(24)00618-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1866. OKOLI GN, Neilson CJ, Grossman Moon A, Kimmel Supron H, et al
    Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis
    Vaccine. 2024 May 24:S0264-410X(24)00601-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1867. LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
    Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
    Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1868. WU JY, Zhang W, Pu J, Liu Y, et al
    A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
    Vaccine. 2024 May 24:S0264-410X(24)00559-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1869. BAK J, Hasan Q, Kissa J, Mere MO, et al
    Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
    Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1870. MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
    Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
    Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1871. TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al
    Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
    Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1872. BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
    Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
    Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1873. EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
    Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
    Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1874. KANDASAMY R, Gurung M, Shrestha S, Gautam MC, et al
    Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
    Vaccine. 2024 May 23:S0264-410X(24)00564-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1875. YEGANEH N, Yin S, Moir O, Danza P, et al
    Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.
    Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1876. CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
    Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
    Vaccine. 2024;42:3273-3276.
    >> Share

  1877. RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
    Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
    Vaccine. 2024;42:3355-3364.
    >> Share

  1878. PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
    Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
    Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1879. ZHOU H, Zhao W, Ma R, Zheng Y, et al
    Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
    Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1880. ZHANG WX, Zhang Y, Du J, Shi W, et al
    Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
    Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1881. PAN X, Guo X, Shi J
    Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
    Vaccine. 2024 May 21:S0264-410X(24)00568-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1882. CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al
    Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
    Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1883. VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
    Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1884. MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al
    Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.
    Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1885. KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
    Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1886. GARG R, Liu Q, Van Kessel J, Asavajaru A, et al
    Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
    Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1887. TSUJII A, Takahashi K, Harada H, Kawashima S, et al
    Evaluation of the protective effect of the intranasal vaccines adjuvanted with bacterium-like particles against intestinal infection.
    Vaccine. 2024 May 18:S0264-410X(24)00582-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1888. ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
    Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1889. YANG T, Tong F, Tang L, Li P, et al
    Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
    Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1890. KIM S, Choi JK, Suh J, Park SH, et al
    The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Vaccine. 2024 May 17:S0264-410X(24)00562-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1891. GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al
    Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.).
    Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1892. GARCIA-VICENTE EJ, Rey-Casero I, Martin M, Perez A, et al
    Oral supplementation with postbiotics modulates the immune response produced by myxomatosis vaccination in wild rabbits.
    Vaccine. 2024 May 16:S0264-410X(24)00585-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1893. URAGUCHI K, Matsumoto N, Mitsuhashi T, Takao S, et al
    Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010.
    Vaccine. 2024 May 16:S0264-410X(24)00567-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1894. NG'OMBE H, Bosomprah S, Phiri B, Muchimba M, et al
    Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia.
    Vaccine. 2024 May 16:S0264-410X(24)00587-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1895. URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
    Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1896. MIRANDA-LOPEZ A, Gonzalez-Ortega O, Govea-Alonso DO, Betancourt-Mendiola L, et al
    Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice.
    Vaccine. 2024 May 14:S0264-410X(24)00518-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1897. MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
    Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1898. KARIM S, Rehana Siddiqui A, Karim N, Pradhan NA, et al
    Role of rotavirus vaccine in reducing diarrheal episodes in infants visiting private primary health care clinics in Karachi, Pakistan: A mixed-methods study.
    Vaccine. 2024 May 13:S0264-410X(24)00558-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1899. EJNAR HANSEN M, David Pickering S
    The role of religion and COVID-19 vaccine uptake in England.
    Vaccine. 2024;42:3215-3219.
    >> Share

  1900. MUTTUCUMARU R, Lau CL, Leeb A, Mills DJ, et al
    Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.
    Vaccine. 2024;42:3166-3171.
    >> Share

  1901. LIU F, Li Z, Wang H, Cao Y, et al
    Effectiveness of the varicella vaccine in the real world, a matched case-control study.
    Vaccine. 2024 May 10:S0264-410X(24)00552-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1902. DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
    A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1903. MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
    Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
    Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1904. SHANI M, Hermesh I, Feldhamer I, Reges O, et al
    The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
    Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1905. LEE KY, Song KH, Lee KH, Baek JY, et al
    Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
    Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1906. KIM DH, Lee SH, Kim J, Lee J, et al
    Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
    Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1907. LAURA SORIANO PEREZ M, Montironi I, Alejandro Funes J, Margineda C, et al
    Nanogel-Mediated antigen delivery: Biocompatibility, immunogenicity, and potential for tailored vaccine design across species.
    Vaccine. 2024 May 7:S0264-410X(24)00525-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1908. BASKOL ELIK D, Yildirim C, Akyol Seyhan D, Aytac Erdem H, et al
    Evaluation of antibody responses in healthcare workers before & after meningococcal vaccine and determination of meningococcal carriage rates.
    Vaccine. 2024 May 7:S0264-410X(24)00540-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1909. TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
    Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
    Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1910. DIONNE M, Etienne D, Witteman HO, Sauvageau C, et al
    Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec.
    Vaccine. 2024 May 6:S0264-410X(24)00528-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1911. CAO A, Ueta M, Uchibori M, Murakami M, et al
    Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
    Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1912. SONG H, Waheed Abdullah S, Yin S, Dong H, et al
    Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs.
    Vaccine. 2024 May 6:S0264-410X(24)00530-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1913. SOE P, Wong H, Naus M, Muller MP, et al
    mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
    Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1914. JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
    Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
    Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1915. KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al
    Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region.
    Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1916. KIM J, Chang J
    Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
    Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1917. LI H, Li Q, Hao Z, Zhang L, et al
    A recombinant IL-1beta vaccine attenuates bleomycin-induced pulmonary fibrosis in mice.
    Vaccine. 2024 May 6:S0264-410X(24)00531-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1918. CROWE CL, Dreyfus J, Lanes S, Chung H, et al
    Variation in incidence rates of outcomes relevant to vaccine safety monitoring in a US commercially insured population by case identification algorithm.
    Vaccine. 2024 May 6:S0264-410X(24)00534-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1919. MAJE BELLO A, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, et al
    Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.
    Vaccine. 2024 May 4:S0264-410X(24)00526-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1920. ANDREJKO KL, Gierke R, Rowlands JV, Rosen JB, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Vaccine. 2024 May 3:S0264-410X(24)00499-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1921. ADINUGROHO I, Stafford T, Bentall RP
    The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
    Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1922. CHRISTOU-ERGOS M, Bleicher K, Leask J
    Factors associated with vaccination intention and uptake over time in a sample of older Australians.
    Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1923. ESPARZA J
    Introduction of the smallpox vaccine in Napoleonic France, as recorded in contemporary medals.
    Vaccine. 2024 May 3:S0264-410X(24)00503-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1924. SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
    Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1925. MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
    Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
    Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1926. SEFAT KMSR, Kumar M, Kehl S, Kulkarni R, et al
    An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.
    Vaccine. 2024 May 3:S0264-410X(24)00482-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1927. BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
    Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
    Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1928. BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
    The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
    Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1929. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1930. MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
    Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
    Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1931. HU H, Ma F, Gong L, Wang Y, et al
    Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
    Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1932. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1933. ANGAITKAR P, Ram Janghel R, Prasad Sahu T
    An MCDM approach for Reverse vaccinology model to predict bacterial protective antigens.
    Vaccine. 2024 May 3:S0264-410X(24)00517-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1934. DHALARIA P, Kumar P, Verma A, Priyadarshini P, et al
    Exploring landscape of measles vaccination coverage: A step towards measles elimination goal in India.
    Vaccine. 2024 May 3:S0264-410X(24)00511-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1935. EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
    Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
    Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1936. MASTROLEO I
    Use of experimental vaccines is ethically permissible during public health emergencies.
    Vaccine. 2024 May 1:S0264-410X(24)00504-8. doi: 10.1016/j.vaccine.2024.
    >> Share

    April 2024
  1937. LV M, Du J, Xie MZ, Zhou Y, et al
    Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence.
    Vaccine. 2024;42:3091-3098.
    >> Share

  1938. WANG Z, Wang M, Wang F, Luo Y, et al
    Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models.
    Vaccine. 2024;42:3075-3083.
    >> Share

  1939. MAGALI P, Sophie M, Arnaud B, Pol L, et al
    Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings.
    Vaccine. 2024;42:3018-3023.
    >> Share

  1940. GRANT LR, Hanquet G, Sepulveda-Pachon IT, Theilacker C, et al
    Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.
    Vaccine. 2024;42:2983-2993.
    >> Share

  1941. JI W, Zhou H, Li J, Britto CD, et al
    Distributions of candidate vaccine Targets, virulence Factors, and resistance features of invasive group B Streptococcus using Whole-Genome Sequencing: A Multicenter, population-based surveillance study.
    Vaccine. 2024 Apr 30:S0264-410X(24)00498-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1942. FLEARY SA, Shahn Z, Teasdale CA
    Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
    Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1943. NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
    Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1944. GUDOORU K, Nguyen K, Le K, Sarabu V, et al
    Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
    Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1945. DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
    Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
    Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1946. PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
    A programmatic update on COVID-19 vaccination in rural communities in the United States.
    Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1947. LUO G, Zeng Y, Sheng R, Zhang Z, et al
    Wa-VP4* as a candidate rotavirus vaccine induced homologous and heterologous virus neutralizing antibody responses in mice, pigs, and cynomolgus monkeys.
    Vaccine. 2024 Apr 25:S0264-410X(24)00483-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1948. XIE Z, Stallings-Smith S, Patel S, Case S, et al
    COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
    Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1949. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1950. FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
    Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
    Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1951. SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
    Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
    Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1952. SWITALSKI J, Miazga W, Wnuk K, Tatara T, et al
    Analyzing the dynamics of meningococcal vaccinations initiatives by local government units in Poland (2017-2021) - Scope, challenges and recommendations.
    Vaccine. 2024 Apr 22:S0264-410X(24)00472-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1953. SONG S, Madewell ZJ, Liu M, Miao Y, et al
    A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
    Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1954. MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
    BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1955. WANG Y, Xu F, Yuan C, Zhang Y, et al
    Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein expressed by Escherichia coli and baculovirus-insect cells.
    Vaccine. 2024;42:2848-2857.
    >> Share

  1956. MOHANTY S, Done N, Liu Q, Song Y, et al
    Incidence of pneumococcal disease in children
    Vaccine. 2024;42:2758-2769.
    >> Share

  1957. LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
    Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
    Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1958. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1959. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1960. RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
    Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
    Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1961. ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
    COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
    Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1962. GAJEWSKA M, Lewtak K, Gorynski P, Piotrowicz M, et al
    Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
    Vaccine. 2024 Apr 18:S0264-410X(24)00433-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1963. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1964. BEITARI S, Yi S, Sharma S, Yung R, et al
    Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
    Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1965. MUTSAERTS EAML, van Cranenbroek B, Madhi SA, Simonetti E, et al
    Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones.
    Vaccine. 2024 Apr 17:S0264-410X(24)00448-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1966. MATUR RV, Thuluva S, Gunneri S, Yerroju V, et al
    Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1967. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1968. JI Y, Sui X, Miao W, Wang C, et al
    Erratum to "Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model" [Vaccine 42(6) (2024) 1292-1299].
    Vaccine. 2024 Apr 16:S0264-410X(24)00386-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1969. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  1970. GEE J, Shimabukuro TT, Su JR, Shay D, et al
    Overview of U.S. COVID-19 vaccine safety surveillance systems.
    Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1971. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1972. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1973. SHEFFER R, Bucris E, Amitai Z, Indenbaum V, et al
    Measles outbreak associated with a preschool setting among partially vaccinated children in the Tel Aviv District, Israel, October 2023.
    Vaccine. 2024 Apr 15:S0264-410X(24)00427-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1974. MELNIKOW J, Padovani A, Zhang J, Miller M, et al
    Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
    Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1975. WONG IOL, Wong C, Mak N, Dai A, et al
    Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
    Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1976. DAVIS BM, Blake I, Panicker G, Meites E, et al
    Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
    Vaccine. 2024 Apr 15:S0264-410X(24)00447-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1977. YAGI A, Ueda Y, Kimura T
    HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.
    Vaccine. 2024 Apr 13:S0264-410X(24)00407-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1978. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1979. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1980. NASKAR S, Harsukhbhai Chandpa H, Agarwal S, Meena J, et al
    Super epitope dengue vaccine instigated serotype independent immune protection in-silico.
    Vaccine. 2024 Apr 13:S0264-410X(24)00423-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1981. YONEKAWA M, Watanabe T, Kogawara O, Yoshii C, et al
    Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
    Vaccine. 2024 Apr 12:S0264-410X(24)00388-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1982. LEE JS, Choi H, Shin SH, Hwang MJ, et al
    Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
    Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  1983. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1984. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1985. AHERN S, Browne J, Murphy A, Teljeur C, et al
    An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00441-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  1986. OWUSU-EDUSEI K, Favre-Bulle A, Tsoumani E, Mutschler T, et al
    Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00431-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  1987. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  1988. HUSETH-ZOSEL AL, Fuller H, Hicks A, Carson PJ, et al
    Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust.
    Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1989. BLAKE JM, Thompson J, HogenEsch H, Ekenstedt KJ, et al
    Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.
    Vaccine. 2024 Apr 10:S0264-410X(24)00398-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1990. THAI H, Audet EC, Koestner R
    Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
    Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  1991. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  1992. EL BUSHRA HE, Haroun AAA, Dauod Altaf M, Gardiwal H, et al
    Early use of oral cholera vaccines as a prime control measure during outbreaks: Necessary but not sufficient.
    Vaccine. 2024 Apr 8:S0264-410X(24)00332-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  1993. KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
    A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
    Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  1994. WONODI C, Crowcroft N, Bose AS, Oteri J, et al
    Country ownership as a guiding principle for IA2030: A case study of the measles and rubella elimination programs in Nepal and Nigeria.
    Vaccine. 2024;42 Suppl 1:S107-S117.
    >> Share

  1995. PATEL MK, Scobie HM, Serhan F, Dahl B, et al
    A global comprehensive vaccine-preventable disease surveillance strategy for the immunization Agenda 2030.
    Vaccine. 2024;42 Suppl 1.
    >> Share

  1996. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    >> Share

  1997. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  1998. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  1999. CHONG CY, Kam KQ, Zhang J, Bertoletti A, et al
    Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
    Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2000. BINTE HOSSAIN F, Muscatello D, Jayasinghe S, Jonnagaddala J, et al
    Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13.
    Vaccine. 2024 Apr 6:S0264-410X(24)00426-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2001. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2002. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2003. STEFANIZZI P, Moscara L, Palmieri C, Martinelli A, et al
    Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Vaccine. 2024 Apr 5:S0264-410X(24)00311-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2004. NYBRU GLEDITSCH R, Skogset Ofitserova T, Aubrey White R, Karoline Raberg Kjollesdal M, et al
    Vaccine coverage among children born to immigrant parents in Norway, 2000-2020.
    Vaccine. 2024 Apr 5:S0264-410X(24)00395-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2005. NAKANO T, Hasegawa M, Endo M, Matsuda K, et al
    Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants >/= 2 and < 43 months of Age: A phase III, multicenter
    Vaccine. 2024 Apr 5:S0264-410X(24)00394-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  2006. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2007. ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
    Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
    Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2008. HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
    Identifying effective vaccine champions: Findings from a national survey of primary care professionals.
    Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2009. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2010. TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
    Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2011. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    >> Share

  2012. LIU J, Qi Q, Liu Y, Ni P, et al
    A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak and strengthen local immunization programs.
    Vaccine. 2024;42:2155-2160.
    >> Share

  2013. SU L, Zhou X, Peng W, Luo J, et al
    Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen.
    Vaccine. 2024;42:2448-2454.
    >> Share

  2014. HUBER A, Kovacs E, Horvath A, Sahin-Toth J, et al
    Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary.
    Vaccine. 2024;42:2271-2277.
    >> Share

  2015. KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
    Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
    Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
    >> Share

    March 2024
  2016. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2017. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2018. PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
    Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development.
    Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2019. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2020. FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al
    Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus.
    Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2021. BRUUN N, Laursen MF, Carmelo R, Christensen E, et al
    Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
    Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2022. PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al
    Reduced pertussis disease severity in infants following the introduction of pertussis vaccination of pregnant women in Spain, 2015-2019.
    Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2023. WEYANT C, Hooda Y, Munira SJ, Lo NC, et al
    Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
    Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2024. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2025. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2026. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  2027. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2028. PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al
    Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens.
    Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2029. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2030. STUREBORG R, Nichols J, Dhingra B, Yang J, et al
    Development and validation of VaxConcerns: A taxonomy of vaccine concerns and misinformation with Crowdsource-Viability.
    Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2031. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2032. COMES JDG, Doets K, Zegers T, Kessler M, et al
    Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
    Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2033. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2034. HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al
    Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series.
    Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2035. ZHANG Y, Wang Y, Li G, Zhao X, et al
    A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older.
    Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2036. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2037. ZHAO Z, Meng Q, Sun TZ, Zhu B, et al
    Mannose modified targeted immersion vaccine delivery system improves protective immunity against Infectious spleen and kidney necrosis virus in mandarin fish (Siniperca chuatsi).
    Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2038. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2039. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2040. BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al
    The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2041. CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al
    Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
    Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2042. ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al
    Subolesin knockdown in tick cells provides insights into vaccine protective mechanisms.
    Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2043. CHENG Y, Shen R, Liu F, Li Y, et al
    Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines.
    Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2044. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  2045. GEHRT L, Englund H, Laake I, Nieminen H, et al
    Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
    Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2046. ANWARI P, Burnett E, Chavers TP, Samsor A, et al
    Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
    Vaccine. 2024;42:2059-2064.
    >> Share

  2047. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    >> Share

  2048. SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al
    The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
    Vaccine. 2024;42:1966-1972.
    >> Share

  2049. KWON KW, Choi HG, Choi HH, Choi E, et al
    Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains.
    Vaccine. 2024;42:1941-1952.
    >> Share

  2050. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2051. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2052. WU J, Jiang L, Shao Q, Liu J, et al
    Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
    Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2053. MEDENI V, Altiner OT, Medeni I
    Measles vaccination coverage and immunization status of nurses: An interventional study in Turkiye.
    Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2054. DANGOR Z, Benson N, Berkley JA, Bielicki J, et al
    Vaccine value profile for Klebsiella pneumoniae.
    Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2055. OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al
    High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
    Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2056. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2057. FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al
    Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2058. HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al
    Lymphatic distribution considerations for subunit vaccine design and development.
    Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2059. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2060. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2061. JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al
    Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France.
    Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2062. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2063. MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al
    Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
    Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2064. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2065. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2066. SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al
    Varicella outbreak at nursery school under routine immunization in Japan in 2017 and 2018 and vaccine effectiveness.
    Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2067. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2068. SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al
    UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration.
    Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2069. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2070. MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al
    Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 201
    Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2071. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2072. SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al
    An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
    Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2073. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2074. HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al
    Current vaccine strategies and novel approaches to combatting Francisella infection.
    Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2075. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2076. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2077. BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al
    Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations.
    Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2078. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2079. GHASEMIFAR S, Chabak O, Piri-Gharaghie T, Doosti A, et al
    PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model.
    Vaccine. 2024 Mar 7:S0264-410X(24)00209-3. doi: 10.1016/j.vaccine.2024.
    >> Share


  2080. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    >> Share


  2081. Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020, Pages 830-839].
    Vaccine. 2024;42:1850.
    >> Share

  2082. DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al
    The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs.
    Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2083. SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al
    A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole.
    Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2084. GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al
    Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
    Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2085. MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al
    Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia.
    Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2086. ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al
    Probability of exposure to the wild measles virus in adult population - Estimation from seroepidemiology and historical data.
    Vaccine. 2024;42:1648-1655.
    >> Share

  2087. HYAMS C, Lahuerta M, Theilacker C, King J, et al
    Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
    Vaccine. 2024;42:1599-1607.
    >> Share

  2088. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2089. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2090. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2091. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2092. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2093. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2094. BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
    A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
    Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2095. DUAN X, Zhang L, Ding L, Zhang C, et al
    Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
    Vaccine. 2024 Mar 2:S0264-410X(24)00172-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2096. ZAMAN K, Schuind AE, Adjei S, Antony K, et al
    Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Vaccine. 2024 Mar 1:S0264-410X(24)00251-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2097. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    >> Share

    February 2024
  2098. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2099. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    >> Share

  2100. CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
    An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
    Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2101. LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
    Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents.
    Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2102. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2103. OMAR ALI S, Dessart C, Parikh R
    Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2104. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2105. ZHOU W, Guo X, Lu J, Lu X, et al
    Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.
    Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2106. JACKSON S, Kabir Z, Comiskey C
    Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
    Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
    >> Share

  2107. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2108. TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
    Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
    >> Share

  2109. GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
    Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
    Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
    >> Share

  2110. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    >> Share

  2111. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    >> Share

  2112. KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
    Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
    Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2113. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  2114. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    >> Share

  2115. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  2116. BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
    Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
    Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
    >> Share

  2117. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    >> Share

  2118. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    >> Share

  2119. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    >> Share

  2120. DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
    Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
    Vaccine. 2024;42:1094-1107.
    >> Share

  2121. PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
    What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
    Vaccine. 2024;42:1065-1070.
    >> Share

    November 2023
  2122. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    >> Share

  2123. FLANDES X, Hansen CA, Palani S, Abbas K, et al
    Vaccine value profile for Chikungunya.
    Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  2124. HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
    Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis.
    Vaccine. 2023;41 Suppl 2.
    >> Share

  2125. UGHASORO MD, Nnakenyi I, Echendu N, Akpeh JO, et al
    Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria.
    Vaccine. 2023;41:6820-6823.
    >> Share

  2126. DO LAH, Le NTN, Mahmud S, Mulholland K, et al
    Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Vaccine. 2023;41:6782-6790.
    >> Share

    October 2023
  2127. CORSTEN C, Vang ZM, Gold I, Goldenberg MJ, et al
    Understanding COVID-19 vaccine hesitancy in Canada.
    Vaccine. 2023 Oct 27:S0264-410X(23)01260-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  2128. LI J, Shi LW, Li K, Huang LR, et al
    Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.
    Vaccine. 2023;41:7212-9.
    >> Share

  2129. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016